<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148610</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1029-2330</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of drug targeting</Title>
                <ISOAbbreviation>J Drug Target</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Secure and effective gene delivery system of plasmid DNA coated by polynucleotide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Polynucleotides are anionic macromolecules which are expected to transfer into the targeted cells through specific uptake mechanisms. So, we developed polynucleotides coating complexes of plasmid DNA (pDNA) and polyethylenimine (PEI) for a secure and efficient gene delivery system and evaluated their usefulness. Polyadenylic acid (polyA), polyuridylic acid (polyU), polycytidylic acid (polyC), and polyguanylic acid (polyG) were examined as the coating materials. pDNA/PEI/polyA, pDNA/PEI/polyU, and pDNA/PEI/polyC complexes formed nanoparticles with a negative surface charge although pDNA/PEI/polyG was aggregated. The pDNA/PEI/polyC complex showed high transgene efficiency in B16-F10 cells although there was little efficiency in pDNA/PEI/polyA and pDNA/PEI/polyU complexes. An inhibition study strongly indicated the specific uptake mechanism of pDNA/PEI/polyC complex. Polynucleotide coating complexes had lower cytotoxicity than pDNA/PEI complex. The pDNA/PEI/polyC complex showed high gene expression selectively in the spleen after intravenous injection into mice. The pDNA/PEI/polyC complex showed no agglutination with erythrocytes and no acute toxicity although these were observed in pDNA/PEI complex. Thus, we developed polynucleotide coating complexes as novel vectors for clinical gene therapy, and the pDNA/PEI/polyC complex as a useful candidate for a gene delivery system.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kodama</LastName>
                    <ForeName>Yukinobu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Hospital Pharmacy, Nagasaki University Hospital , Nagasaki , Japan and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ohkubo</LastName>
                    <ForeName>Chikako</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Kurosaki</LastName>
                    <ForeName>Tomoaki</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Egashira</LastName>
                    <ForeName>Kanoko</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Sato</LastName>
                    <ForeName>Kayoko</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Fumoto</LastName>
                    <ForeName>Shintaro</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Nishida</LastName>
                    <ForeName>Koyo</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Higuchi</LastName>
                    <ForeName>Norihide</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Kitahara</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Nakamura</LastName>
                    <ForeName>Tadahiro</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Sasaki</LastName>
                    <ForeName>Hitoshi</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Drug Target</MedlineTA>
            <NlmUniqueID>9312476</NlmUniqueID>
            <ISSNLinking>1026-7158</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Gene delivery</Keyword>
            <Keyword MajorTopicYN="N">pDNA</Keyword>
            <Keyword MajorTopicYN="N">polyethylenimine</Keyword>
            <Keyword MajorTopicYN="N">polynucleotide</Keyword>
            <Keyword MajorTopicYN="N">ternary complex</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/1061186X.2014.950665</ArticleId>
            <ArticleId IdType="pubmed">25148610</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148541</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-0464</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Drug delivery</Title>
                <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Penetration depth, concentration and efficiency of transdermal ??-arbutin delivery after ultrasound treatment with albumin-shelled microbubbles in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-10</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Recently, the feasibility and effects of using microbubbles (MBs) as an ultrasound (US) contrast agent for enhancing the penetration in transdermal delivery in vivo have been demonstrated, but the mechanism and efficiency are unclear. This study demonstrates the penetration depth, concentration and efficiency of transdermal ??-arbutin delivery during 4 weeks after US treatment with MBs in mice. Experimental animals were randomly divided into the following four groups (n???=???5 animals per group): (1) penetrating ??-arbutin alone (C), (2) US combined with penetrating ??-arbutin, (3) US combined with MBs and penetrating ??-arbutin, and (4) US combined with diluted MBs and penetrating ??-arbutin (UBD). The penetration depths in agarose phantoms and pigskin were 47 and 84% greater for group UBD, respectively, than for group C. The in vitro skin penetration by 2% ??-arbutin after 3???h was 83% greater in group UBD than in group C. The degree of in vivo skin whitening (quantified as the luminosity index) in group UBD significantly increased by 25% after 1 week, 34% after 2 weeks, and then stabilized after 3 weeks at 37% in C57BL/6J mice over a 4-week experimental period. Our results indicate that combined treatment with optimal US and MBs can increase skin permeability so as to enhance ??-arbutin delivery to inhibit melanogenesis without damaging the skin in mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liao</LastName>
                    <ForeName>Ai-Ho</ForeName>
                    <Initials>AH</Initials>
                    <Affiliation>Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology , Taipei, Taiwan , ROC .</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Wan-Chun</ForeName>
                    <Initials>WC</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Chih-Hung</ForeName>
                    <Initials>CH</Initials>
                </Author>
                <Author>
                    <LastName>Yeh</LastName>
                    <ForeName>Ming-Kung</ForeName>
                    <Initials>MK</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Drug Deliv</MedlineTA>
            <NlmUniqueID>9417471</NlmUniqueID>
            <ISSNLinking>1071-7544</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">melanin</Keyword>
            <Keyword MajorTopicYN="N">microbubbles</Keyword>
            <Keyword MajorTopicYN="N">transdermal delivery</Keyword>
            <Keyword MajorTopicYN="N">ultrasound</Keyword>
            <Keyword MajorTopicYN="N">??-Arbutin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10717544.2014.951102</ArticleId>
            <ArticleId IdType="pubmed">25148541</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148519</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ProSAAS-Derived Peptides Are Differentially Processed and Sorted in Mouse Brain and AtT-20 Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104232</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0104232</ELocationID>
            <Abstract>
                <AbstractText>ProSAAS is the precursor for some of the most abundant peptides found in mouse brain and other tissues, including peptides named SAAS, PEN, and LEN. Both SAAS and LEN are found in big and little forms due to differential processing. Initial processing of proSAAS is mediated by furin (and/or furin-like enzymes) and carboxypeptidase D, while the smaller forms are generated by secretory granule prohormone convertases and carboxypeptidase E. In mouse hypothalamus, PEN and big LEN colocalize with neuropeptide Y. In the present study, little LEN and SAAS were detected in mouse hypothalamus but not in cell bodies of neuropeptide Y-expressing neurons. PEN and big LEN show substantial colocalization in hypothalamus, but big LEN and little LEN do not. An antiserum to SAAS that detects both big and little forms of this peptide did not show substantial colocalization with PEN or big LEN. To further study this, the AtT-20 cells mouse pituitary corticotrophic cell line was transfected with rat proSAAS and the distribution of peptides examined. As found in mouse hypothalamus, only some of the proSAAS-derived peptides colocalized with each other in AtT-20 cells. The two sites within proSAAS that are known to be efficiently cleaved by furin were altered by site-directed mutagenesis to convert the P4 Arg into Lys; this change converts the sequences from furin consensus sites into prohormone convertase consensus sites. Upon expression of the mutated form of proSAAS in AtT-20 cells, there was significantly more colocalization of proSAAS-derived peptides PEN and SAAS. Taken together, these results indicate that proSAAS is initially cleaved in the Golgi or trans-Golgi network by furin and/or furin-like enzymes and the resulting fragments are sorted into distinct vesicles and further processed by additional enzymes into the mature peptides.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wardman</LastName>
                    <ForeName>Jonathan H</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fricker</LastName>
                    <ForeName>Lloyd D</ForeName>
                    <Initials>LD</Initials>
                    <Affiliation>Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, United States of America; Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104232</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-15014</ArticleId>
            <ArticleId IdType="pubmed">25148519</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148516</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-4804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal chemistry</Title>
                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Orally Bioavailable 6-Chloro-7-methoxy-4(1H)-quinolones Efficacious against Multiple Stages of Plasmodium.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The continued proliferation of malaria throughout temperate and tropical regions of the world has promoted a push for more efficacious treatments to combat the disease. Unfortunately, more recent remedies such as artemisinin combination therapies (ACTs) have been rendered less effective due to developing parasite resistance and new drugs are required that target the parasite in the liver to support the disease elimination efforts. Research was initiated to revisit antimalarials developed in the 1940's and 1960's that were deemed unsuitable for use as therapeutic agents as a result of poor understanding of both physicochemical properties and parasitology. Structure activity studies (SAR) and structure property studies (SPR) were conducted to generate a set of compounds with the general 6-chloro-7-methoxy-2-methyl-4(1H)-quinolone scaffold which were substituted at the 3-position with a variety of phenyl moieties possessing various properties. Extensive physicochemical evaluation for the quinolone series was carried out to downselect the most promising 4(1H)-quinolones 7, 62, 66 and 67 which possessed low nanomolar EC50s against W2 and TM90-C2B as well as improved microsomal stability. Additionally, in vivo Thompson test results using P. berghei in mice showed that these 4(1H)-quinolones were efficacious for the reduction of parasitemia at &gt;99% after 6 days.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cross</LastName>
                    <ForeName>Richard Matthew</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author>
                    <LastName>Flanigan</LastName>
                    <ForeName>David L</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author>
                    <LastName>Monastyrskyi</LastName>
                    <ForeName>Andrii</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>LaCrue</LastName>
                    <ForeName>Alexis N</ForeName>
                    <Initials>AN</Initials>
                </Author>
                <Author>
                    <LastName>Saenz</LastName>
                    <ForeName>Fabian E</ForeName>
                    <Initials>FE</Initials>
                </Author>
                <Author>
                    <LastName>Maignan</LastName>
                    <ForeName>Jordany R</ForeName>
                    <Initials>JR</Initials>
                </Author>
                <Author>
                    <LastName>Mutka</LastName>
                    <ForeName>Tina S</ForeName>
                    <Initials>TS</Initials>
                </Author>
                <Author>
                    <LastName>White</LastName>
                    <ForeName>Karen L</ForeName>
                    <Initials>KL</Initials>
                </Author>
                <Author>
                    <LastName>Shackleford</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author>
                    <LastName>Bathurst</LastName>
                    <ForeName>Ian</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author>
                    <LastName>Fronczek</LastName>
                    <ForeName>Frank R</ForeName>
                    <Initials>FR</Initials>
                </Author>
                <Author>
                    <LastName>Wojtas</LastName>
                    <ForeName>Lukasz</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Guida</LastName>
                    <ForeName>Wayne Charles</ForeName>
                    <Initials>WC</Initials>
                </Author>
                <Author>
                    <LastName>Charman</LastName>
                    <ForeName>Susan A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author>
                    <LastName>Burrows</LastName>
                    <ForeName>Jeremy N</ForeName>
                    <Initials>JN</Initials>
                </Author>
                <Author>
                    <LastName>Kyle</LastName>
                    <ForeName>Dennis E</ForeName>
                    <Initials>DE</Initials>
                </Author>
                <Author>
                    <LastName>Manetsch</LastName>
                    <ForeName>Roman</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Med Chem</MedlineTA>
            <NlmUniqueID>9716531</NlmUniqueID>
            <ISSNLinking>0022-2623</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm500942v</ArticleId>
            <ArticleId IdType="pubmed">25148516</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148511</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clusterin/Apolipoprotein J Attenuates Angiotensin II-Induced Renal Fibrosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105635</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105635</ELocationID>
            <Abstract>
                <AbstractText>The blockade of angiotensin II (Ang II) is a major therapeutic strategy for diabetic nephropathy. The main roles of Ang II in renal disease are mediated via the Ang type 1 receptor (AT1R). Upregulation of clusterin/apolipoprotein J has been reported in nephropathy models, suggesting it has a protective role in nephropathogenesis. Here, we studied how clusterin acts against Ang II-induced renal fibrosis. Levels of AT1R and fibrotic markers in clusterin-/- mice and Ang II infused rats transfected with an adenovirus encoding clusterin were evaluated by immunoblot analysis, real time RT-PCR, and immunohistochemical staining. The effect of clusterin on renal fibrosis was evaluated in NRK-52E cells, a cultured renal tubular epithelial cell line, using immunoblot analysis and real time RT-PCR. Nuclear localization of NF-??B was evaluated using immunofluorecence and co-immunoprecipitation. Renal fibrosis and expression of AT1R was higher in the kidneys of clusterin-/- mice than in those of wild-type mice. Furthermore, loss of clusterin accelerated Ang II-stimulated renal fibrosis and AT1R expression. Overexpression of clusterin in proximal tubular epithelial cells decreased the levels of Ang II-stimulated fibrotic markers and AT1R. Moreover, intrarenal delivery of clusterin attenuated Ang II-mediated expression of fibrotic markers and AT1R in rats. Fluorescence microscopy and co-immunoprecipitation in conjunction with western blot revealed that clusterin inhibited Ang II-stimulated nuclear localization of p-NF-??B via a direct physical interaction and subsequently decreased the AT1R level in proximal tubular epithelial cells. These data suggest that clusterin attenuates Ang II-induced renal fibrosis by inhibition of NF-??B activation and subsequent downregulation of AT1R. This study raises the possibility that clusterin could be used as a therapeutic target for Ang II-induced renal diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Gwon-Soo</ForeName>
                    <Initials>GS</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeon</LastName>
                    <ForeName>Jae-Han</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Yun-A</ForeName>
                    <Initials>YA</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Yeon-Kyung</ForeName>
                    <Initials>YK</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Hye-Soon</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jung-Guk</ForeName>
                    <Initials>JG</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Keun-Gyu</ForeName>
                    <Initials>KG</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Mi-Kyung</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>In-Kyu</ForeName>
                    <Initials>IK</Initials>
                    <Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105635</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-00344</ArticleId>
            <ArticleId IdType="pubmed">25148511</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148457</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1944-9917</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular endocrinology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Mol. Endocrinol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hepatic SRC-1 Activity Orchestrates Transcriptional Circuitries of Amino Acid Pathways with Potential Relevance for Human Metabolic Pathogenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>me20141083</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Disturbances in amino acid metabolism are increasingly recognized as being associated with, and serving as prognostic markers for, chronic human diseases such as cancer or type 2 diabetes. In the current study, a quantitative metabolomics profiling strategy revealed global impairment in amino acid metabolism in mice deleted for the transcriptional coactivator SRC-1. Aberrations were hepatic in origin, since selective re-expression of SRC-1 in the liver of SRC-1 null mice largely restored amino acids concentrations to normal levels. Cistromic analysis of SRC-1 binding sites in hepatic tissues confirmed a prominent influence of this coregulator on transcriptional programs regulating amino acid metabolism. More specifically, SRC-1 markedly impacted tyrosine levels and was found to regulate the transcriptional activity of the tyrosine aminotransferase (TAT) gene, which encodes the rate-limiting enzyme of tyrosine catabolism. Consequently, SRC-1 null mice displayed low TAT expression and presented with hypertyrosinemia and corneal alterations, two clinical features observed in the human syndrome of TAT deficiency. A heterozygous missense variant of SRC-1 (p.P1272S) that is known to alter its coactivation potential, was found in patients harboring idiopathic tyrosinemia-like disorders and may therefore represent one risk factor for their clinical symptoms. Hence, we reinforce the concept that SRC-1 is a central factor in the fine orchestration of multiple pathways of intermediary metabolism, suggesting it as a potential therapeutic target that may be exploitable in human metabolic diseases and cancer.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tannour-Louet</LastName>
                    <ForeName>Mounia</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030;</Affiliation>
                </Author>
                <Author>
                    <LastName>York</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Ke</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Stashi</LastName>
                    <ForeName>Erin</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Bouguerra</LastName>
                    <ForeName>Hichem</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Suoling</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Wong</LastName>
                    <ForeName>Lee-Jun C</ForeName>
                    <Initials>LJ</Initials>
                </Author>
                <Author>
                    <LastName>Stevens</LastName>
                    <ForeName>Robert D</ForeName>
                    <Initials>RD</Initials>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Jianming</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Newgard</LastName>
                    <ForeName>Christopher B</ForeName>
                    <Initials>CB</Initials>
                </Author>
                <Author>
                    <LastName>O'Malley</LastName>
                    <ForeName>Bert W</ForeName>
                    <Initials>BW</Initials>
                </Author>
                <Author>
                    <LastName>Louet</LastName>
                    <ForeName>Jean-Francois</ForeName>
                    <Initials>JF</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Endocrinol</MedlineTA>
            <NlmUniqueID>8801431</NlmUniqueID>
            <ISSNLinking>0888-8809</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1210/me.2014-1083</ArticleId>
            <ArticleId IdType="pubmed">25148457</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148404</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modified Extracorporeal Photopheresis with Cells from a Healthy Donor for Acute Graft-versus-Host Disease in a Mouse Model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105896</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105896</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Graft-versus-host disease (GvHD) is a major challenge after hematopoietic stem cell transplantation but treatment options for patients are still limited. In many cases first-line treatment with glucocorticoids is not successful. Among second-line therapies the extracorporeal photopheresis (ECP) is frequently performed, due to induction of selective tolerance instead of general immunosuppression. However, for some patients with severe acute GvHD the leukapheresis step of the ECP procedure is physically exhausting and limits the number of ECP cycles.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We hypothesized that leukocytes from healthy cell donors could be used as a replacement for ECP leukocytes gained from the GvHD patient. For this purpose we used a well established mouse model of acute GvHD. The ECP therapy was based on cells with the genetic background of the initial donor of the stem cell transplantation. As a precondition we developed a protocol representing conventional ECP in mice equivalent to clinical used ECP setup.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We could demonstrate that conventional, clinically derived ECP setup is able to alleviate acute GvHD. By using leukocytes obtained from healthy mice with the bone marrow donor's genetic background we could not observe a statistically significant therapeutic effect.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Conventional human ECP setup is effective in the mouse model of severe acute GvHD. In addition we could not prove that ECP cells from healthy mice with bone marrow donor's genetic background are as effective as ECP cells derived from GvHD mice. Based on our findings, new questions arise for further studies, in which the cellular characteristics for ECP mediated immune tolerance are a matter of investigation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Budde</LastName>
                    <ForeName>Holger</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Transfusion Medicine, University Medical Center G??ttingen, G??ttingen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kolb</LastName>
                    <ForeName>Susanne</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Transfusion Medicine, University Medical Center G??ttingen, G??ttingen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salinas Tejedor</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Transfusion Medicine, University Medical Center G??ttingen, G??ttingen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wulf</LastName>
                    <ForeName>Gerald</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Hematology and Oncology, University Medical Center G??ttingen, G??ttingen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reichardt</LastName>
                    <ForeName>Holger M</ForeName>
                    <Initials>HM</Initials>
                    <Affiliation>Institute for Cellular and Molecular Immunology, University Medical Center G??ttingen, G??ttingen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riggert</LastName>
                    <ForeName>Joachim</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Transfusion Medicine, University Medical Center G??ttingen, G??ttingen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Legler</LastName>
                    <ForeName>Tobias J</ForeName>
                    <Initials>TJ</Initials>
                    <Affiliation>Department of Transfusion Medicine, University Medical Center G??ttingen, G??ttingen, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105896</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-15497</ArticleId>
            <ArticleId IdType="pubmed">25148404</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148388</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Crosstalk between Nitrite, Myoglobin and Reactive Oxygen Species to Regulate Vasodilation under Hypoxia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105951</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105951</ELocationID>
            <Abstract>
                <AbstractText>The systemic response to decreasing oxygen levels is hypoxic vasodilation. While this mechanism has been known for more than a century, the underlying cellular events have remained incompletely understood. Nitrite signaling is critically involved in vessel relaxation under hypoxia. This can be attributed to the presence of myoglobin in the vessel wall together with other potential nitrite reductases, which generate nitric oxide, one of the most potent vasodilatory signaling molecules. Questions remain relating to the precise concentration of nitrite and the exact dose-response relations between nitrite and myoglobin under hypoxia. It is furthermore unclear whether regulatory mechanisms exist which balance this interaction. Nitrite tissue levels were similar across all species investigated. We then investigated the exact fractional myoglobin desaturation in an ex vivo approach when gassing with 1% oxygen. Within a short time frame myoglobin desaturated to 58??12%. Given that myoglobin significantly contributes to nitrite reduction under hypoxia, dose-response experiments using physiological to pharmacological nitrite concentrations were conducted. Along all concentrations, abrogation of myoglobin in mice impaired vasodilation. As reactive oxygen species may counteract the vasodilatory response, we used superoxide dismutase and its mimic tempol as well as catalase and ebselen to reduce the levels of reactive oxygen species during hypoxic vasodilation. Incubation of tempol in conjunction with catalase alone and catalase/ebselen increased the vasodilatory response to nitrite. Our study shows that modest hypoxia leads to a significant nitrite-dependent vessel relaxation. This requires the presence of vascular myoglobin for both physiological and pharmacological nitrite levels. Reactive oxygen species, in turn, modulate this vasodilation response.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Totzeck</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Medical Faculty, University Hospital D??sseldorf, D??sseldorf, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hendgen-Cotta</LastName>
                    <ForeName>Ulrike B</ForeName>
                    <Initials>UB</Initials>
                    <Affiliation>Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Medical Faculty, University Hospital D??sseldorf, D??sseldorf, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelm</LastName>
                    <ForeName>Malte</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Medical Faculty, University Hospital D??sseldorf, D??sseldorf, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rassaf</LastName>
                    <ForeName>Tienush</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine, Medical Faculty, University Hospital D??sseldorf, D??sseldorf, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105951</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-24475</ArticleId>
            <ArticleId IdType="pubmed">25148388</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148369</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1614-0575</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Season>Spring</Season>
                    </PubDate>
                </JournalIssue>
                <Title>The review of diabetic studies : RDS</Title>
                <ISOAbbreviation>Rev Diabet Stud</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Profiling of embryonic stem cell differentiation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>102-14</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1900/RDS.2014.11.102</ELocationID>
            <Abstract>
                <AbstractText>Embryonic stem (ES) cells have been shown to recapitulate normal developmental stages. They are therefore a highly useful tool in the study of developmental biology. Profiling of ES cell-derived cells has yielded important information about the characteristics of differentiated cells, and allowed the identification of novel marker genes and pathways of differentiation. In this review, we focus on recent results from profiling studies of mouse embryos, human islets, and human ES cell-derived differentiated cells from several research groups. Global gene expression data from mouse embryos have been used to identify novel genes or pathways involved in the developmental process, and to search for transcription factors that regulate direct reprogramming. We introduce gene expression databases of human pancreas cells (Beta Cell Gene Atlas, EuroDia database), and summarize profiling studies of islet- or human ES cell-derived pancreatic cells, with a focus on gene expression, microRNAs, epigenetics, and protein expression. Then, we describe our gene expression profile analyses and our search for novel endoderm, or pancreatic, progenitor marker genes. We differentiated mouse ES cells into mesendoderm, definitive endoderm (DE), mesoderm, ectoderm, and Pdx1-expressing pancreatic lineages, and performed DNA microarray analyses. Genes specifically expressed in DE, and/or in Pdx1-expressing cells, were extracted and their expression patterns in normal embryonic development were studied by in situ hybridization. Out of 54 genes examined, 27 were expressed in the DE of E8.5 mouse embryos, and 15 genes were expressed in distinct domains in the pancreatic buds of E14.5 mouse embryos. Akr1c19, Aebp2, Pbxip1, and Creb3l1 were all novel, and none has been described as being expressed, either in the DE, or in the pancreas. By introducing the profiling results of ES cell-derived cells, the benefits of using ES cells to study early embryonic development will be discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shiraki</LastName>
                    <ForeName>Nobuaki</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Stem Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Honjo 2-2-1, Kumamoto 860-0811, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogaki</LastName>
                    <ForeName>Soichiro</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Stem Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Honjo 2-2-1, Kumamoto 860-0811, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kume</LastName>
                    <ForeName>Shoen</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Stem Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Honjo 2-2-1, Kumamoto 860-0811, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Rev Diabet Stud</MedlineTA>
            <NlmUniqueID>101227575</NlmUniqueID>
            <ISSNLinking>1613-6071</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1900/RDS.2014.11.102</ArticleId>
            <ArticleId IdType="pubmed">25148369</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148367</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1614-0575</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Season>Spring</Season>
                    </PubDate>
                </JournalIssue>
                <Title>The review of diabetic studies : RDS</Title>
                <ISOAbbreviation>Rev Diabet Stud</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sox9: a master regulator of the pancreatic program.</ArticleTitle>
            <Pagination>
                <MedlinePgn>51-83</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1900/RDS.2014.11.51</ELocationID>
            <Abstract>
                <AbstractText>Over the last decade, it has been discovered that the transcription factor Sox9 plays several critical roles in governing the development of the embryonic pancreas and the homeostasis of the mature organ. While analysis of pancreata from patients affected by the Sox9 haploinsufficiency syndrome campomelic dysplasia initially alluded to a functional role of Sox9 in pancreatic morphogenesis, transgenic mouse models have been instrumental in mechanistically dissecting such roles. Although initially defined as a marker and maintenance factor for pancreatic progenitors, Sox9 is now considered to fulfill additional indispensable functions during pancreogenesis and in the postnatal organ through its interactions with other transcription factors and signaling pathways such as Fgf and Notch. In addition to maintaining both multipotent and bipotent pancreatic progenitors, Sox9 is also required for initiating endocrine differentiation and maintaining pancreatic ductal identity, and it has recently been unveiled as a key player in the initiation of pancreatic cancer. These functions of Sox9 are discussed in this article, with special emphasis on the knowledge gained from various loss-of-function and lineage tracing mouse models. Also, current controversies regarding Sox9 function in healthy and injured adult pancreas and unanswered questions and avenues of future study are discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Seymour</LastName>
                    <ForeName>Philip A</ForeName>
                    <Initials>PA</Initials>
                    <Affiliation>The Danish Stem Cell Center (DanStem), University of Copenhagen, Panum Institute, Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Rev Diabet Stud</MedlineTA>
            <NlmUniqueID>101227575</NlmUniqueID>
            <ISSNLinking>1613-6071</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1900/RDS.2014.11.51</ArticleId>
            <ArticleId IdType="pubmed">25148367</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148366</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1614-0575</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Season>Spring</Season>
                    </PubDate>
                </JournalIssue>
                <Title>The review of diabetic studies : RDS</Title>
                <ISOAbbreviation>Rev Diabet Stud</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Colony-Forming Progenitor Cells in the Postnatal Mouse Liver and Pancreas Give Rise to Morphologically Distinct Insulin-Expressing Colonies in 3D Cultures.</ArticleTitle>
            <Pagination>
                <MedlinePgn>35-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1900/RDS.2014.11.35</ELocationID>
            <Abstract>
                <AbstractText>In our previous studies, colony-forming progenitor cells isolated from murine embryonic stem cell-derived cultures were differentiated into morphologically distinct insulin-expressing colonies. These colonies were small and not light-reflective when observed by phase-contrast microscopy (therefore termed &quot;Dark&quot; colonies). A single progenitor cell capable of giving rise to a Dark colony was termed a Dark colony-forming unit (CFU-Dark). The goal of the current study was to test whether endogenous pancreas, and its developmentally related liver, harbored CFU-Dark. Here we show that dissociated single cells from liver and pancreas of one-week-old mice give rise to Dark colonies in methylcellulose-based semisolid culture media containing either Matrigel or laminin hydrogel (an artificial extracellular matrix protein). CFU-Dark comprise approximately 0.1% and 0.03% of the postnatal hepatic and pancreatic cells, respectively. Adult liver also contains CFU-Dark, but at a much lower frequency (~0.003%). Microfluidic qRT-PCR, immunostaining, and electron microscopy analyses of individually handpicked colonies reveal the expression of insulin in many, but not all, Dark colonies. Most pancreatic insulin-positive Dark colonies also express glucagon, whereas liver colonies do not. Liver CFU-Dark require Matrigel, but not laminin hydrogel, to become insulin-positive. In contrast, laminin hydrogel is sufficient to support the development of pancreatic Dark colonies that express insulin. Postnatal liver CFU-Dark display a cell surface marker CD133+CD49flowCD107blow phenotype, while pancreatic CFU-Dark are CD133-. Together, these results demonstrate that specific progenitor cells in the postnatal liver and pancreas are capable of developing into insulin-expressing colonies, but they differ in frequency, marker expression, and matrix protein requirements for growth.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Liang</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chai</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghazalli</LastName>
                    <ForeName>Nadiah</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Dan</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zerda</LastName>
                    <ForeName>Ricardo</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Electron Microscopy Core, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhuo</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Electron Microscopy Core, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Jasper</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahdavi</LastName>
                    <ForeName>Alborz</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Bioengineering, California Institute of Technology, Pasadena, California 91125, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tirrell</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riggs</LastName>
                    <ForeName>Arthur D</ForeName>
                    <Initials>AD</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ku</LastName>
                    <ForeName>Hsun Teresa</ForeName>
                    <Initials>HT</Initials>
                    <Affiliation>Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California 91010, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Rev Diabet Stud</MedlineTA>
            <NlmUniqueID>101227575</NlmUniqueID>
            <ISSNLinking>1613-6071</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1900/RDS.2014.11.35</ArticleId>
            <ArticleId IdType="pubmed">25148366</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148360</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1097-4164</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>55</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cell</Title>
                <ISOAbbreviation>Mol. Cell</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hijacked by an oocyte: hierarchical molecular changes in somatic cell nuclear transfer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>507-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2014.08.008</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1097-2765(14)00641-8</ELocationID>
            <Abstract>
                <AbstractText>Xenopus oocytes can epigenetically reprogram mouse somatic cells toward totipotency. In this issue, Jullien et??al. (2014) now describe rapid, interdependent molecular events that facilitate this reprogramming.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Maza</LastName>
                    <ForeName>Itay</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanna</LastName>
                    <ForeName>Jacob H</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>The Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: jacob.hanna@weizmann.ac.il.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cell</MedlineTA>
            <NlmUniqueID>9802571</NlmUniqueID>
            <ISSNLinking>1097-2765</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1097-2765(14)00641-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.molcel.2014.08.008</ArticleId>
            <ArticleId IdType="pubmed">25148360</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148225</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1543-8392</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular pharmaceutics</Title>
                <ISOAbbreviation>Mol. Pharm.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development and Characterization of a Novel Mouse Line Humanized for the Intestinal Peptide Transporter PEPT1.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The proton-coupled oligopeptide transporter PEPT1 (SLC15A1) is abundantly expressed in the small intestine, but not colon, of mammals and found to mediate the uptake of di-/tri-peptides and peptide-like drugs from the intestinal lumen. However, species differences have been observed in both the expression (and localization) of PEPT1 and its substrate affinity. With this in mind, the objectives of this study were to develop a humanized PEPT1 mouse model (huPEPT1) and to characterize hPEPT1 expression and functional activity in the intestines. Thus, after generating huPEPT1 mice in animals previously nulled for mouse Pept1, phenotypic, PCR and immunoblot analyses were performed, along with in situ single-pass intestinal perfusion and in vivo oral pharmacokinetic studies with a model dipeptide, glycylsarcosine (GlySar). Overall, the huPEPT1 mice had normal survival rates, fertility, litter size, gender distribution and body weight. There was no obvious behavioral or pathological phenotype. The mRNA and protein profiles indicated that huPEPT1 mice had substantial PEPT1 expression in all regions of the small intestine (i.e., duodenum, jejunum and ileum) along with low but measurable expression in both proximal and distal segments of the colon. In agreement with PEPT1 expression, the in situ permeability of GlySar in huPEPT1 mice was similar to but lower than wildtype animals in small intestine, and greater than wildtype mice in colon. However, a species difference existed in the in situ transport kinetics of jejunal PEPT1, in which the maximal flux and Michaelis constant of GlySar were reduced 7-fold and 2- to 4-fold, respectively, in huPEPT1 compared to wildtype mice. Still, the in vivo function of intestinal PEPT1 appeared fully restored (compared to Pept1 knockout mice) as indicated by the nearly identical pharmacokinetics and plasma concentration-time profiles following a 5.0 nmol/g oral dose of GlySar to huPEPT1 and wildtype mice. This study reports, for the first time, the development and characterization of mice humanized for PEPT1. This novel transgenic huPEPT1 mouse model should prove useful in examining the role, relevance and regulation of PEPT1 in diet and disease, and in the drug discovery process.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Yongjun</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Yehua</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yuqing</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Xiaomei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>David E</ForeName>
                    <Initials>DE</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Pharm</MedlineTA>
            <NlmUniqueID>101197791</NlmUniqueID>
            <ISSNLinking>1543-8384</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp500497p</ArticleId>
            <ArticleId IdType="pubmed">25148225</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148222</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2044-5385</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Blood cancer journal</Title>
                <ISOAbbreviation>Blood Cancer J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e240</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/bcj.2014.53</ELocationID>
            <Abstract>
                <AbstractText>The spleen tyrosine kinase (SYK) was identified as an oncogenic driver in a broad spectrum of hematologic malignancies. The in vivo comparison of three SYK containing oncogenes, SYK(wt), TEL-SYK and IL-2-inducible T-cell kinase (ITK)-SYK revealed a general myeloexpansion and the establishment of three different hematologic (pre)diseases. SYK(wt) enhanced the myeloid and T-cell compartment, without leukemia/lymphoma development. ITK-SYK caused lethal T-cell lymphomas and the cytoplasmic TEL-SYK fusion induced an acute panmyelosis with myelofibrosis-type acute myeloid leukemia (AML) with up to 50% immature megakaryoblasts infiltrating bone marrow, spleen and liver, additional MPN features (myelofibrosis and granulocyte expansion) and MDS stigmata with megakaryocytic and erythroid dysplasia. LKS cells were reduced and all subsets (LT/ST/MPP) showed reduced proliferation rates. SYK inhibitor treatment (R788) of diseased TEL-SYK mice reduced leukocytosis, spleen and liver infiltration, enhanced the hematocrit and prolonged survival time, but could not significantly reduce myelofibrosis. Stat5 was identified as a major downstream mediator of TEL-SYK in vitro as well as in vivo. Consequently, targeted deletion of Stat5 in vivo completely abrogated TEL-SYK-induced AML and myelofibrosis development, proving Stat5 as a major driver of SYK-induced transformation. Our experiments highlight the important role of SYK in AML and myelofibrosis and prove SYK and STAT5 inhibitors as potent treatment options for those diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sprissler</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>1] Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany [2] University of Freiburg, Schaenzlestrasse 1, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belenki</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maurer</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aumann</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Pathology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pfeifer</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klein</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>M??ller</LastName>
                    <ForeName>T A</ForeName>
                    <Initials>TA</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kissel</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>H??lsd??nker</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alexandrovski</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brummer</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>1] Institut f??r Molekulare Medizin und Zellforschung, University of Freiburg, Stefan-Meier-Str. 17, Freiburg, Germany [2] Centre for Biological Signaling Studies BIOSS, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jumaa</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1] Department of Pathology, University Medical Center Freiburg, Freiburg, Germany [2] Institut f??r Molekulare Medizin und Zellforschung, University of Freiburg, Stefan-Meier-Str. 17, Freiburg, Germany [3] Centre for Biological Signaling Studies BIOSS, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duyster</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dierks</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>1] Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany [2] Centre for Biological Signaling Studies BIOSS, Freiburg, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Blood Cancer J</MedlineTA>
            <NlmUniqueID>101568469</NlmUniqueID>
            <ISSNLinking>2044-5385</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">bcj201453</ArticleId>
            <ArticleId IdType="doi">10.1038/bcj.2014.53</ArticleId>
            <ArticleId IdType="pubmed">25148222</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148209</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-4804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal chemistry</Title>
                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of (S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The SAR of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Jia</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Dai</LastName>
                    <ForeName>Guangxiu</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Weng</LastName>
                    <ForeName>Jianyang</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Zhulin</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Jiao</LastName>
                    <ForeName>Longxian</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Cui</LastName>
                    <ForeName>Yumin</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Ren</LastName>
                    <ForeName>Yongxin</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Shiming</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Jinghong</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Qing</LastName>
                    <ForeName>Weiguo</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Gu</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Sai</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Su</LastName>
                    <ForeName>Weiguo</ForeName>
                    <Initials>W</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Med Chem</MedlineTA>
            <NlmUniqueID>9716531</NlmUniqueID>
            <ISSNLinking>0022-2623</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm500510f</ArticleId>
            <ArticleId IdType="pubmed">25148209</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148207</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genome-Wide Analysis of miRNA Signature in the APPswe/PS1??E9 Mouse Model of Alzheimer's Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e101725</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0101725</ELocationID>
            <Abstract>
                <AbstractText>Alzheimer's disease (AD) is the most common cause of dementia. One of the pathological hallmarks of AD is amyloid ?? (A??) deposition. MicroRNAs (miRNAs) are small non-coding RNAs whose expression levels change significantly during neuronal pathogenesis and may be used as diagnostic markers. Some miRNAs are important in AD development by targeting genes responsible for A?? metabolism. However, a systematic assessment of the miRNA expression profile induced by A??-mediated neuronal pathogenesis is still lacking. In the present study, we examined miRNA expression profile by using the APPswe/PS1??E9 mouse model of AD. Two sibling pairs of mice were examined, showing 30 and 24 miRNAs with significantly altered expression levels from each paired control, respectively. Nine known miRNAs were common in both groups. Prediction of putative target genes and functional annotation implied that these altered miRNAs affect many target genes mainly involved in PI3K/Akt signaling pathway. This study provides a general profile of miRNAs regulated by A??-associated signal pathways, which is helpful to understand the mechanism of A??-induced neuronal dysfunction in AD development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Hongxue</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Qi</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Xiaoyang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiong</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Jinyong</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Junyu</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Diao</LastName>
                    <ForeName>Yarui</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Ludwig Institute for Cancer Research, La Jolla, California, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Duo</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, California, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Maosheng</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>GaoZhou people's Hospital, Gao Zhou, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Jinhua</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>GaoZhou people's Hospital, Gao Zhou, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miao</LastName>
                    <ForeName>Jianting</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an City, Shanxi Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wan</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong Province, China; Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0101725</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-02444</ArticleId>
            <ArticleId IdType="pubmed">25148207</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148130</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Contractile Force Is Enhanced in Aortas from Pendrin Null Mice Due to Stimulation of Angiotensin II-Dependent Signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105101</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi">10.1371/journal.pone.0105101</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Pendrin is a Cl-/HCO3- exchanger expressed in the apical regions of renal intercalated cells. Following pendrin gene ablation, blood pressure falls, in part, from reduced renal NaCl absorption. We asked if pendrin is expressed in vascular tissue and if the lower blood pressure observed in pendrin null mice is accompanied by reduced vascular reactivity. Thus, the contractile responses to KCl and phenylephrine (PE) were examined in isometrically mounted thoracic aortas from wild-type and pendrin null mice. Although pendrin expression was not detected in the aorta, pendrin gene ablation changed contractile protein abundance and increased the maximal contractile response to PE when normalized to cross sectional area (CSA). However, the contractile sensitivity to this agent was unchanged. The increase in contractile force/cross sectional area observed in pendrin null mice was due to reduced cross sectional area of the aorta and not from increased contractile force per vessel. The pendrin-dependent increase in maximal contractile response was endothelium- and nitric oxide-independent and did not occur from changes in Ca2+ sensitivity or chronic changes in catecholamine production. However, application of 100 nM angiotensin II increased force/CSA more in aortas from pendrin null than from wild type mice. Moreover, angiotensin type 1 receptor inhibitor (candesartan) treatment in vivo eliminated the pendrin-dependent changes contractile protein abundance and changes in the contractile force/cross sectional area in response to PE. In conclusion, pendrin gene ablation increases aorta contractile force per cross sectional area in response to angiotensin II and PE due to stimulation of angiotensin type 1 receptor-dependent signaling. The angiotensin type 1 receptor-dependent increase in vascular reactivity may mitigate the fall in blood pressure observed with pendrin gene ablation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sutliff</LastName>
                    <ForeName>Roy L</ForeName>
                    <Initials>RL</Initials>
                    <Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States of America; Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Walp</LastName>
                    <ForeName>Erik R</ForeName>
                    <Initials>ER</Initials>
                    <Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States of America; Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Young Hee</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Walker</LastName>
                    <ForeName>Lori A</ForeName>
                    <Initials>LA</Initials>
                    <Affiliation>Departments of Medicine and Cardiology, University of Colorado Health Sciences Center, Aurora, Colorado, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>El-Ali</LastName>
                    <ForeName>Alexander M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States of America; Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States of America; Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bonsall</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ramosevac</LastName>
                    <ForeName>Semra</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Physiology, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Eaton</LastName>
                    <ForeName>Douglas C</ForeName>
                    <Initials>DC</Initials>
                    <Affiliation>Department of Physiology, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Verlander</LastName>
                    <ForeName>Jill W</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Department of Medicine, University of Florida, Gainesville, Florida, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hansen</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gleason</LastName>
                    <ForeName>Rudolph L Jr</ForeName>
                    <Initials>RL</Initials>
                    <Affiliation>School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pham</LastName>
                    <ForeName>Truyen D</ForeName>
                    <Initials>TD</Initials>
                    <Affiliation>Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hong</LastName>
                    <ForeName>Seongun</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pech</LastName>
                    <ForeName>Vladimir</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Medicine, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wall</LastName>
                    <ForeName>Susan M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Medicine, Emory University, Atlanta, Georgia, United States of America; Department of Physiology, Emory University, Atlanta, Georgia, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105101</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-21364</ArticleId>
            <ArticleId IdType="pubmed">25148130</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25148100</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-4804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal chemistry</Title>
                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of Novel Highly Potent Hepatitis C Virus NS5A Inhibitor (AV4025).</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">A series of next in class small-molecule Hepatitis C Virus (HCV) NS5A inhibitors with picomolar potency containing 2-pyrrolidin-2-yl-5-{4-[4-(2-pyrrolidin-2-yl-1H-imidazol-5-yl)buta-1,3-diynyl]phenyl}-1H-imidazole cores was designed based on the SAR studies available for the reported NS5A inhibitors. Compound 13a (AV4025), with (S,S,S,S)-stereochemistry (EC50 = 3.4 ?? 0.2 pM, HCV replicon genotype 1b), was dramatically more active than were the compounds with two (S)- and two (R)-chiral centers. Human serum did not significantly reduce the antiviral activity (&lt; 4-fold). Relatively favorable pharmacokinetic features and good oral bioavailability were observed during animal studies. Compound 13a was well tolerated in rodents (in mice, LD50 = 2326 mg/kg or higher), providing a relatively high therapeutic index. During safety, pharmacology and sub-chronic toxicity studies in rats and dogs, it was not associated with any significant pathological or clinical findings. This compound is currently being evaluated in Phase I/II clinical trials for the treatment of HCV infection.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ivachtchenko</LastName>
                    <ForeName>Alexandre V</ForeName>
                    <Initials>AV</Initials>
                </Author>
                <Author>
                    <LastName>Mitkin</LastName>
                    <ForeName>Oleg D</ForeName>
                    <Initials>OD</Initials>
                </Author>
                <Author>
                    <LastName>Yamanushkin</LastName>
                    <ForeName>Pavel M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author>
                    <LastName>Kuznetsova</LastName>
                    <ForeName>Irina V</ForeName>
                    <Initials>IV</Initials>
                </Author>
                <Author>
                    <LastName>Bulanova</LastName>
                    <ForeName>Elena A</ForeName>
                    <Initials>EA</Initials>
                </Author>
                <Author>
                    <LastName>Shevkun</LastName>
                    <ForeName>Natalia A</ForeName>
                    <Initials>NA</Initials>
                </Author>
                <Author>
                    <LastName>Koryakova</LastName>
                    <ForeName>Angela G</ForeName>
                    <Initials>AG</Initials>
                </Author>
                <Author>
                    <LastName>Karapetian</LastName>
                    <ForeName>Ruben N</ForeName>
                    <Initials>RN</Initials>
                </Author>
                <Author>
                    <LastName>Bichko</LastName>
                    <ForeName>Vadim V</ForeName>
                    <Initials>VV</Initials>
                </Author>
                <Author>
                    <LastName>Trifelenkov</LastName>
                    <ForeName>Andrey S</ForeName>
                    <Initials>AS</Initials>
                </Author>
                <Author>
                    <LastName>Kravchenko</LastName>
                    <ForeName>Dmitry V</ForeName>
                    <Initials>DV</Initials>
                </Author>
                <Author>
                    <LastName>Vostokova</LastName>
                    <ForeName>Natalia V</ForeName>
                    <Initials>NV</Initials>
                </Author>
                <Author>
                    <LastName>Veselov</LastName>
                    <ForeName>Mark S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author>
                    <LastName>Chufarova</LastName>
                    <ForeName>Nina V</ForeName>
                    <Initials>NV</Initials>
                </Author>
                <Author>
                    <LastName>Ivanenkov</LastName>
                    <ForeName>Yan Andreevich</ForeName>
                    <Initials>YA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Med Chem</MedlineTA>
            <NlmUniqueID>9716531</NlmUniqueID>
            <ISSNLinking>0022-2623</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm500951r</ArticleId>
            <ArticleId IdType="pubmed">25148100</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148077</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Alternative Inactivated Poliovirus Vaccines Adjuvanted with Quillaja brasiliensis or Quil-A Saponins Are Equally Effective in Inducing Specific Immune Responses.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105374</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105374</ELocationID>
            <Abstract>
                <AbstractText>Inactivated polio vaccines (IPV) have an important role at the final stages of poliomyelitis eradication programs, reducing the risks associated with the use of attenuated polio vaccine (OPV). An affordable option to enhance vaccine immunogenicity and reduce costs of IPV may be the use of an effective and renewable adjuvant. In the present study, the adjuvant activity of aqueous extract (AE) and saponin fraction QB-90 from Quillaja brasiliensis using poliovirus antigen as model were analyzed and compared to a preparation adjuvanted with Quil-A, a well-known saponin-based commercial adjuvant. Experimental vaccines were prepared with viral antigen plus saline (control), Quil-A (50 ??g), AE (400 ??g) or QB-90 (50 ??g). Sera from inoculated mice were collected at days 0, 28, 42 and 56 post-inoculation of the first dose of vaccine. Serum levels of specific IgG, IgG1 and IgG2a were significantly enhanced by AE, QB-90 and Quil-A compared to control group on day 56. The magnitude of enhancement was statistically equivalent for QB-90 and Quil-A. The cellular response was evaluated through DTH and analysis of IFN-?? and IL-2 mRNA levels using in vitro reestimulated splenocytes. Results indicated that AE and QB-90 were capable of stimulating the generation of Th1 cells against the administered antigen to the same extent as Quil-A. Mucosal immune response was enhanced by the vaccine adjuvanted with QB-90 as demonstrated by increases of specific IgA titers in bile, feces and vaginal washings, yielding comparable or higher titers than Quil-A. The results obtained indicate that saponins from Q. brasiliensis are potent adjuvants of specific cellular and humoral immune responses and represent a viable option to Quil-A.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>de Costa</LastName>
                    <ForeName>Fernanda</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Plant Physiology Laboratory, Center for Biotechnology and Department of Botany, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Faculty of Pharmacy, UFRGS, Porto Alegre, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yendo</LastName>
                    <ForeName>Anna Carolina A</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>Plant Physiology Laboratory, Center for Biotechnology and Department of Botany, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Faculty of Pharmacy, UFRGS, Porto Alegre, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cibulski</LastName>
                    <ForeName>Samuel P</ForeName>
                    <Initials>SP</Initials>
                    <Affiliation>Fepagro Animal Health - Institute of Veterinary Research &quot;Desid??rio Finamor&quot; (IPVDF), Eldorado do Sul, Brazil, and Virology Laboratory, Microbiology Department, UFRGS, Porto Alegre, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fleck</LastName>
                    <ForeName>Juliane D</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Molecular Microbiology Laboratory, Feevale University, Novo Hamburgo, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roehe</LastName>
                    <ForeName>Paulo M</ForeName>
                    <Initials>PM</Initials>
                    <Affiliation>Fepagro Animal Health - Institute of Veterinary Research &quot;Desid??rio Finamor&quot; (IPVDF), Eldorado do Sul, Brazil, and Virology Laboratory, Microbiology Department, UFRGS, Porto Alegre, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spilki</LastName>
                    <ForeName>Fernando R</ForeName>
                    <Initials>FR</Initials>
                    <Affiliation>Molecular Microbiology Laboratory, Feevale University, Novo Hamburgo, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gosmann</LastName>
                    <ForeName>Grace</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Faculty of Pharmacy, UFRGS, Porto Alegre, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fett-Neto</LastName>
                    <ForeName>Arthur G</ForeName>
                    <Initials>AG</Initials>
                    <Affiliation>Plant Physiology Laboratory, Center for Biotechnology and Department of Botany, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105374</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-20334</ArticleId>
            <ArticleId IdType="pubmed">25148077</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148042</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Optogenetic recruitment of dorsal raphe serotonergic neurons acutely decreases mechanosensory responsivity in behaving mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105941</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105941</ELocationID>
            <Abstract>
                <AbstractText>The inhibition of sensory responsivity is considered a core serotonin function, yet this hypothesis lacks direct support due to methodological obstacles. We adapted an optogenetic approach to induce acute, robust and specific firing of dorsal raphe serotonergic neurons. In vitro, the responsiveness of individual dorsal raphe serotonergic neurons to trains of light pulses varied with frequency and intensity as well as between cells, and the photostimulation protocol was therefore adjusted to maximize their overall output rate. In vivo, the photoactivation of dorsal raphe serotonergic neurons gave rise to a prominent light-evoked field response that displayed some sensitivity to a 5-HT1A agonist, consistent with autoreceptor inhibition of raphe neurons. In behaving mice, the photostimulation of dorsal raphe serotonergic neurons produced a rapid and reversible decrease in the animals' responses to plantar stimulation, providing a new level of evidence that serotonin gates sensory-driven responses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dugu??</LastName>
                    <ForeName>Guillaume P</ForeName>
                    <Initials>GP</Initials>
                    <Affiliation>Champalimaud Neuroscience Programme, Champalimaud Center for the Unknown, Lisbon, Portugal; Institut de Biologie de l'Ecole Normale Sup??rieure, Centre National de la Recherche Scientifique (CNRS) UMR8197, Institut National de la Sant?? et de la Recherche M??dicale (INSERM) U1024, Paris, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>L??rincz</LastName>
                    <ForeName>Magor L</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>Champalimaud Neuroscience Programme, Champalimaud Center for the Unknown, Lisbon, Portugal; MTA-SZTE Research Group for Cortical Microcircuits, Department of Physiology, University of Szeged, Szeged, Hungary.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lottem</LastName>
                    <ForeName>Eran</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Champalimaud Neuroscience Programme, Champalimaud Center for the Unknown, Lisbon, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Audero</LastName>
                    <ForeName>Enrica</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Champalimaud Neuroscience Programme, Champalimaud Center for the Unknown, Lisbon, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matias</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Champalimaud Neuroscience Programme, Champalimaud Center for the Unknown, Lisbon, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Correia</LastName>
                    <ForeName>Patricia A</ForeName>
                    <Initials>PA</Initials>
                    <Affiliation>Champalimaud Neuroscience Programme, Champalimaud Center for the Unknown, Lisbon, Portugal.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>L??na</LastName>
                    <ForeName>Cl??ment</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institut de Biologie de l'Ecole Normale Sup??rieure, Centre National de la Recherche Scientifique (CNRS) UMR8197, Institut National de la Sant?? et de la Recherche M??dicale (INSERM) U1024, Paris, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mainen</LastName>
                    <ForeName>Zachary F</ForeName>
                    <Initials>ZF</Initials>
                    <Affiliation>Champalimaud Neuroscience Programme, Champalimaud Center for the Unknown, Lisbon, Portugal.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105941</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-11988</ArticleId>
            <ArticleId IdType="pubmed">25148042</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148024</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1097-4180</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>41</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Immunity</Title>
                <ISOAbbreviation>Immunity</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Transcription Factor T-bet Is Induced by IL-15 and Thymic Agonist Selection and Controls CD8????(+) Intraepithelial Lymphocyte Development.</ArticleTitle>
            <Pagination>
                <MedlinePgn>230-43</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.06.018</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00274-X</ELocationID>
            <Abstract>
                <AbstractText>CD8????(+) intraepithelial lymphocytes (IELs) are instrumental in maintaining the epithelial barrier in the intestine. Similar to natural killer cells and other innate lymphoid cells, CD8????(+) IELs constitutively express the T-box transcription factor T-bet. However, the precise role of T-bet for the differentiation or function of IELs is unknown. Here we show that mice genetically deficient for T-bet lacked both TCR????(+) and TCR????(+) CD8????(+) IELs and thus are more susceptible to chemically induced colitis. Although T-bet was induced in thymic IEL precursors (IELPs) as a result of agonist selection and interleukin-15 (IL-15) receptor signaling, it was dispensable for the generation of IELPs. Subsequently, T-bet was required for the??IL-15-dependent activation, differentiation, and expansion of IELPs in the periphery. Our study reveals a function of T-bet as a central transcriptional regulator linking agonist selection and IL-15 signaling with the emergence of CD8????(+) IELs.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Klose</LastName>
                    <ForeName>Christoph S N</ForeName>
                    <Initials>CS</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Department of Internal Medicine IV, University of Freiburg Medical Center, 79106 Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blatz</LastName>
                    <ForeName>Katharina</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Department of Internal Medicine IV, University of Freiburg Medical Center, 79106 Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>d'Hargues</LastName>
                    <ForeName>Yannick</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Department of Internal Medicine IV, University of Freiburg Medical Center, 79106 Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernandez</LastName>
                    <ForeName>Pedro P</ForeName>
                    <Initials>PP</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Institute of Medical Microbiology and Hygiene, University of Mainz Medical Center, 55131 Mainz, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kofoed-Nielsen</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Institute of Medical Microbiology and Hygiene, University of Mainz Medical Center, 55131 Mainz, Germany; International Max Planck Research School for Molecular and Cellular Biology, 79108 Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ripka</LastName>
                    <ForeName>Juliane F</ForeName>
                    <Initials>JF</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Department of Internal Medicine IV, University of Freiburg Medical Center, 79106 Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ebert</LastName>
                    <ForeName>Karolina</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Department of Internal Medicine IV, University of Freiburg Medical Center, 79106 Freiburg, Germany; Faculty of Biology, 79104 Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arnold</LastName>
                    <ForeName>Sebastian J</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Department of Internal Medicine IV, University of Freiburg Medical Center, 79106 Freiburg, Germany; BIOSS Center of Biological Signalling Studies, 79104 Freiburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Diefenbach</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Mainz Medical Center, 55131 Mainz, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palmer</LastName>
                    <ForeName>Ed</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Laboratory of Transplantation Immunology, Departments of Biomedicine and Nephrology, University Hospital Basel, 4031 Basel, Switzerland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanriver</LastName>
                    <ForeName>Yakup</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Center, 79104 Freiburg, Germany; Department of Internal Medicine IV, University of Freiburg Medical Center, 79106 Freiburg, Germany. Electronic address: yakup.tanriver@uniklinik-freiburg.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Immunity</MedlineTA>
            <NlmUniqueID>9432918</NlmUniqueID>
            <ISSNLinking>1074-7613</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1074-7613(14)00274-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.06.018</ArticleId>
            <ArticleId IdType="pubmed">25148024</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25148020</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1097-4180</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>41</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Immunity</Title>
                <ISOAbbreviation>Immunity</ISOAbbreviation>
            </Journal>
            <ArticleTitle>&quot;Nuts and bolts&quot; of disease tolerance.</ArticleTitle>
            <Pagination>
                <MedlinePgn>176-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.immuni.2014.07.011</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1074-7613(14)00269-6</ELocationID>
            <Abstract>
                <AbstractText>Disease tolerance describes the ability of an infected host to limit disease severity without negatively impacting the causative pathogen. Bessede et??al. (2014) show that the aryl hydrocarbon receptor is an essential component of disease tolerance during bacterial infection in mice.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Soares</LastName>
                    <ForeName>Miguel P</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>Instituto Gulbenkian de Ci??ncia, 2780-156 Oeiras, Portugal. Electronic address: mpsoares@igc.gulbenkian.pt.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Immunity</MedlineTA>
            <NlmUniqueID>9432918</NlmUniqueID>
            <ISSNLinking>1074-7613</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1074-7613(14)00269-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.07.011</ArticleId>
            <ArticleId IdType="pubmed">25148020</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147982</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1945-7170</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrinology</Title>
                <ISOAbbreviation>Endocrinology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Humanized Mouse Model of Hereditary 1,25-Dihydroxyvitamin D Resistant Rickets Without Alopecia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>en20141417</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The syndrome of hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR) is a genetic disease of altered mineral homeostasis due to mutations in the vitamin D receptor (VDR) gene. It is frequently, but not always, accompanied by the presence of alopecia. Mouse models that recapitulate this syndrome have been prepared through genetic deletion of the Vdr gene and are characterized by the presence of rickets and alopecia. Subsequent studies have revealed that VDR expression in hair follicle keratinocytes protects from alopecia and that this activity is independent of the protein's ability to bind 1,25(OH)2D3. In the present study, we introduced into VDR null mice an hVDR BAC minigene containing a mutation that converts leucine to serine at amino acid 233 in the hVDR protein that prevents 1,25(OH)2D3 binding. We then assessed whether this transgene recreated features of HVDRR syndrome without alopecia. RT-PCR and western blot analysis in one strain showed an appropriate level of mutant hVDR expression in all tissues examined including skin. The hVDR L233S mutant failed to rescue the aberrant systemic and skeletal phenotype characteristic of the VDR null mouse, and was due to the mutant receptor's inability to activate transcription following treatment with 1,25(OH)2D3. Importantly, however, neither alopecia nor the dermal cysts characteristic of VDR null mice was observed in the skin of these hVDR-L233S mutant mice. This study confirms that we have created a humanized mouse model of HVDRR without alopecia that will be useful in defining additional features of this syndrome and in identifying potential novel functions of the unoccupied VDR.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Seong Min</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706;</Affiliation>
                </Author>
                <Author>
                    <LastName>Goellner</LastName>
                    <ForeName>Joseph J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author>
                    <LastName>O'Brien</LastName>
                    <ForeName>Charles A</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author>
                    <LastName>Pike</LastName>
                    <ForeName>J Wesley</ForeName>
                    <Initials>JW</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Endocrinology</MedlineTA>
            <NlmUniqueID>0375040</NlmUniqueID>
            <ISSNLinking>0013-7227</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2014-1417</ArticleId>
            <ArticleId IdType="pubmed">25147982</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147981</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1945-7170</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrinology</Title>
                <ISOAbbreviation>Endocrinology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Estradiol prevents fat accumulation and overcomes leptin resistance in female high fat diet mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>en20141342</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In pre-menopausal and menopausal women in particular, suboptimal estrogens have been linked to the development of the metabolic syndrome as major contributors to fat accumulation. At the same time, estrogens have been described to have a role in regulating body metabolic status. We evaluated how endogenous or administered estrogens impact on the changes associated with high fat diet (HFD) consumption in two different paradigms; ovarian-intact and in ovariectomized (OVX) mice. When estradiol (E2) was cyclically administered to ovarian-intact HFD fed mice for twelve weeks, animals gained significantly less weight than ovarian-intact vehicle controls (p&lt;0.01). This difference was mainly due to a reduced caloric intake but not to an increase in energy expenditure (EE) or locomotor activity (LA). This E2 treatment regime to mice exposed to HFD was overall able to avoid the increase of visceral fat (VF) content to levels of those found in mice fed a regular chow diet. In the OVX model the main BW and fat content reducing action of E2 was not only through decreasing food intake, but also by increasing the whole body EE, LA and by inducing fat oxidation. Importantly, these animals became responsive to the anorexigenic effects of leptin in contrast to the vehicle treated and the pair fed control groups (p&lt;0.01). Further in vitro hypothalamic secretion experiments revealed that treatment of obese mice with E2 is able to modulate the secretion of appetite regulating neuropeptides; namely, E2 increased the secretion of the anorectic neuropeptide ??-MSH and decreased the secretion of the orexigenic neuropetides NPY and AgRP. In conclusion, differences in response to E2 treatment of HFD fed animals depend on their endogenous estrogenic status. Overall, E2 administration overcomes arcuate leptin resistance and partially prevents fat accumulation on these mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Litwak</LastName>
                    <ForeName>Sara A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Monash Obesity &amp; Diabetes Institute/Department of Physiology Monash University, Vic, Australia.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wilson</LastName>
                    <ForeName>Jenny L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Weiyi</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Garcia-Rudaz</LastName>
                    <ForeName>Cecilia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Khaksari</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Cowley</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author>
                    <LastName>Enriori</LastName>
                    <ForeName>Pablo J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Endocrinology</MedlineTA>
            <NlmUniqueID>0375040</NlmUniqueID>
            <ISSNLinking>0013-7227</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2014-1342</ArticleId>
            <ArticleId IdType="pubmed">25147981</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147978</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1945-7170</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrinology</Title>
                <ISOAbbreviation>Endocrinology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>KISS1R Signals Independently of G??q/11 and Triggers LH Secretion via the ??-Arrestin Pathway in the Male Mouse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>en20141304</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Hypothalamic GnRH is the master regulator of the neuroendocrine reproductive axis, and its secretion is regulated by many factors. Among these is kisspeptin (Kp), a potent trigger of GnRH secretion. Kp signals via the Kp receptor (KISS1R), a G??q/11-coupled 7-transmembrane-spanning receptor. Until this study, it was understood that KISS1R mediates GnRH secretion via the G??q/11-coupled pathway in an ERK1/2-dependent manner. We recently demonstrated that KISS1R also signals independently of G??q/11 via ??-arrestin and that this pathway also mediates ERK1/2 activation. Because GnRH secretion is ERK1/2-dependent, we hypothesized that KISS1R regulates GnRH secretion via both the G??q/11- and ??-arrestin-coupled pathways. To test this hypothesis, we measured LH secretion, a surrogate marker of GnRH secretion, in mice lacking either ??-arrestin-1 or ??-arrestin-2. Results revealed that Kp-dependent LH secretion was significantly diminished relative to wild-type mice (P &lt; .001), thus supporting that ??-arrestin mediates Kp-induced GnRH secretion. Based on this, we hypothesized that G??q/11-uncoupled KISS1R mutants, like L148S, will display G??q/11-independent signaling. To test this hypothesis, L148S was expressed in HEK 293 cells. and results confirmed that, although strongly uncoupled from G??q/11, L148S retained the ability to trigger significant Kp-dependent ERK1/2 phosphorylation (P &lt; .05). Furthermore, using mouse embryonic fibroblasts lacking ??-arrestin-1 and -2, we demonstrated that L148S-mediated ERK1/2 phosphorylation is ??-arrestin-dependent. Overall, we conclude that KISS1R signals via G??q/11 and ??-arrestin to regulate GnRH secretion. This novel and important finding could explain why patients bearing some types of G??q/11-uncoupled KISS1R mutants display partial gonadotropic deficiency and even a reversal of the condition, idiopathic hypogonadotropic hypogonadism.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ahow</LastName>
                    <ForeName>Maryse</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>The Children's Health Research Institute (M.A., M.P., A.V.B.), London, Ontario, Canada; Lawson Health Research Institute (M.A., M.P., A.V.B.), London, Ontario, Canada; Departments of Obstetrics and Gynaecology (M.P., A.V.B.), Physiology and Pharmacology (M.A., M.B., A.V.B.), and Oncology (M.B.), The University of Western Ontario, London, Ontario, Canada; Division of Endocrinology, Diabetes, and Hypertension (L.M., J.W., K.S., R.S.C., U.B.K.), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115; Department of Biomedical Sciences (C.N., S.A.T.), Colorado State University, Fort Collins, Colorado 80523; and Department of Reproductive Medicine (C.A.G.-K., P.L.M.), Center for Reproductive Science and Medicine, University of California, San Diego, La Jolla, California 92093.</Affiliation>
                </Author>
                <Author>
                    <LastName>Min</LastName>
                    <ForeName>Le</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Pampillo</LastName>
                    <ForeName>Macarena</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Nash</LastName>
                    <ForeName>Connor</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Wen</LastName>
                    <ForeName>Junping</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Soltis</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Carroll</LastName>
                    <ForeName>Rona S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author>
                    <LastName>Glidewell-Kenney</LastName>
                    <ForeName>Christine A</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author>
                    <LastName>Mellon</LastName>
                    <ForeName>Pamela L</ForeName>
                    <Initials>PL</Initials>
                </Author>
                <Author>
                    <LastName>Bhattacharya</LastName>
                    <ForeName>Moshmi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Tobet</LastName>
                    <ForeName>Stuart A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author>
                    <LastName>Kaiser</LastName>
                    <ForeName>Ursula B</ForeName>
                    <Initials>UB</Initials>
                </Author>
                <Author>
                    <LastName>Babwah</LastName>
                    <ForeName>Andy V</ForeName>
                    <Initials>AV</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Endocrinology</MedlineTA>
            <NlmUniqueID>0375040</NlmUniqueID>
            <ISSNLinking>0013-7227</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2014-1304</ArticleId>
            <ArticleId IdType="pubmed">25147978</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147951</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cartilage-specific ablation of site-1 protease in mice results in the endoplasmic reticulum entrapment of type IIb procollagen and down-regulation of cholesterol and lipid homeostasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105674</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105674</ELocationID>
            <Abstract>
                <AbstractText>The proprotein convertase site-1 protease (S1P) converts latent ER-membrane bound transcription factors SREBPs and ATF6 to their active forms. SREBPs are involved in cholesterol and fatty acid homeostasis whereas ATF6 is involved in unfolded protein response pathways (UPR). Cartilage-specific ablation of S1P in mice (S1Pcko) results in abnormal cartilage devoid of type II collagen protein (Col II). S1Pcko mice also lack endochondral bone development. To analyze S1Pcko cartilage we performed double-labeled immunofluorescence studies for matrix proteins that demonstrated that type IIB procollagen is trapped inside the ER in S1Pcko chondrocytes. This retention is specific to type IIB procollagen; other cartilage proteins such as type IIA procollagen, cartilage oligomeric matrix protein (COMP) and aggrecan are not affected. The S1Pcko cartilage thus exhibits COMP-, aggrecan-, and type IIA procollagen-derived matrices but is characterized by the absence of a type IIB procollagen-derived matrix. To understand the molecular reason behind S1Pcko phenotypes we performed genome-wide transcriptional profiling of cartilage isolated from S1Pcko and wild type littermates. While the UPR pathways are unaffected, the SREBPs-directed cholesterol and fatty acid pathways are significantly down-regulated in S1Pcko chondrocytes, with maximal down-regulation of the stearoyl-CoA desaturase-1 (Scd1) gene. However, mouse models that lack Scd1 or exhibit reduction in lipid homeostasis do not suffer from the ER retention of Col II or lack endochondral bone. These studies indicate an indispensable role for S1P in type IIB procollagen trafficking from the ER. This role appears not to be related to lipid pathways or other current known functions of S1P and is likely dependent on additional, yet unknown, S1P substrates in chondrocytes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Patra</LastName>
                    <ForeName>Debabrata</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeLassus</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Guosheng</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sandell</LastName>
                    <ForeName>Linda J</ForeName>
                    <Initials>LJ</Initials>
                    <Affiliation>Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105674</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-11290</ArticleId>
            <ArticleId IdType="pubmed">25147951</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147932</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Distribution of Non-AT1, Non-AT2 Binding of 125I-Sarcosine1, Isoleucine8 Angiotensin II in Neurolysin Knockout Mouse Brains.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105762</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105762</ELocationID>
            <Abstract>
                <AbstractText>The recent identification of a novel binding site for angiotensin (Ang) II as the peptidase neurolysin (E.C. 3.4.24.16) has implications for the renin-angiotensin system (RAS). This report describes the distribution of specific binding of 125I-Sarcosine1, Isoleucine8 Ang II (125I-SI Ang II) in neurolysin knockout mouse brains compared to wild-type mouse brains using quantitative receptor autoradiography. In the presence of p-chloromercuribenzoic acid (PCMB), which unmasks the novel binding site, widespread distribution of specific (3 ??M Ang II displaceable) 125I-SI Ang II binding in 32 mouse brain regions was observed. Highest levels of binding &gt;700 fmol/g initial wet weight were seen in hypothalamic, thalamic and septal regions, while the lowest level of binding &lt;300 fmol/g initial wet weight was in the mediolateral medulla. 125I-SI Ang II binding was substantially higher by an average of 85% in wild-type mouse brains compared to neurolysin knockout brains, suggesting the presence of an additional non-AT1, non-AT2, non-neurolysin Ang II binding site in the mouse brain. Binding of 125I-SI Ang II to neurolysin in the presence of PCMB was highest in hypothalamic and ventral cortical brain regions, but broadly distributed across all regions surveyed. Non-AT1, non-AT2, non-neurolysin binding was also highest in the hypothalamus but had a different distribution than neurolysin. There was a significant reduction in AT2 receptor binding in the neurolysin knockout brain and a trend towards decreased AT1 receptor binding. In the neurolysin knockout brains, the size of the lateral ventricles was increased by 56% and the size of the mid forebrain (-2.72 to +1.48 relative to Bregma) was increased by 12%. These results confirm the identity of neurolysin as a novel Ang II binding site, suggesting that neurolysin may play a significant role in opposing the pathophysiological actions of the brain RAS and influencing brain morphology.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Speth</LastName>
                    <ForeName>Robert C</ForeName>
                    <Initials>RC</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America; Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carrera</LastName>
                    <ForeName>Eduardo J</ForeName>
                    <Initials>EJ</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America; Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bret??n</LastName>
                    <ForeName>Catalina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America; Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Linares</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez-Reiley</LastName>
                    <ForeName>Luz</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swindle</LastName>
                    <ForeName>Jamala D</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santos</LastName>
                    <ForeName>Kira L</ForeName>
                    <Initials>KL</Initials>
                    <Affiliation>Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America; College of Dentistry, University of Florida, Gainesville, Florida, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schadock</LastName>
                    <ForeName>Ines</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Max-Delbr??ck-Center for Molecular Medicine, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bader</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Max-Delbr??ck-Center for Molecular Medicine, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karamyan</LastName>
                    <ForeName>Vardan T</ForeName>
                    <Initials>VT</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America; Center for Blood-Brain Barrier Research, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105762</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-16787</ArticleId>
            <ArticleId IdType="pubmed">25147932</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147917</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-2308</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Epigenetics : official journal of the DNA Methylation Society</Title>
                <ISOAbbreviation>Epigenetics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>DPPA3 prevents cytosine hydroxymethylation of the maternal pronucleus and is required for normal development in bovine embryos.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Dppa3 has been described in mice as an important maternal factor contributed by the oocyte that participates in protecting the maternal genome from oxidation of methylated cytosines (5mC) to hydroxymethylated cytosines (5hmC). Dppa3 is also required for normal mouse preimplantation development. This gene is poorly conserved across mammalian species, with less than 32% of protein sequence shared between mouse, cow and human. RNA-seq analysis of bovine oocytes and preimplantation embryos revealed that DPPA3 transcripts are some of the most highly abundant mRNAs in the oocyte, and their levels gradually decrease toward the time of embryonic genome activation (EGA). Knockdown of DPPA3 by injection of siRNA in germinal vesicle (GV) stage oocytes was used to assess its role in epigenetic remodeling and embryo development. DPPA3 knockdown resulted in increased intensity of 5hmC staining in the maternal pronucleus (PN), demonstrating a role for this factor in the asymmetric remodeling of the maternal and paternal PN in bovine zygotes. Also, DPPA3 knockdown decreased the developmental competence of parthenogenetic and in vitro fertilized embryos. Finally, DPPA3 knockdown embryos that reached the blastocyst stage had significantly fewer ICM cells as compared with control embryos. We conclude that DPPA3 is a maternal factor important for correct epigenetic remodeling and normal embryonic development in cattle, indicating that the role of DPPA3 during early development is conserved between species.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Bakhtari</LastName>
                    <ForeName>Azizollah</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Animal Science; University of California; Davis, CA USA; Department of Animal Science; Isfahan University of Technology; Isfahan, Iran.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ross</LastName>
                    <ForeName>Pablo J</ForeName>
                    <Initials>PJ</Initials>
                    <Affiliation>Department of Animal Science; University of California; Davis, CA USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Epigenetics</MedlineTA>
            <NlmUniqueID>101265293</NlmUniqueID>
            <ISSNLinking>1559-2294</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">5-hydroxymethylcytosine</Keyword>
            <Keyword MajorTopicYN="N">DPPA3</Keyword>
            <Keyword MajorTopicYN="N">TET</Keyword>
            <Keyword MajorTopicYN="N">epigenetic</Keyword>
            <Keyword MajorTopicYN="N">knockdown</Keyword>
            <Keyword MajorTopicYN="N">preimplantation</Keyword>
            <Keyword MajorTopicYN="N">reprogramming</Keyword>
            <Keyword MajorTopicYN="N">zygote</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">32087</ArticleId>
            <ArticleId IdType="pubmed">25147917</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147876</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1364-5528</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Analyst</Title>
                <ISOAbbreviation>Analyst</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Plasma-based ambient sampling/ionization/transmission integrated source for mass spectrometry.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Better sensitivity and interface of ambient sampling/ionization mass spectrometry remain a challenge. Herein, a novel, plasma-based, ambient sampling/ionization/transmission (PASIT) integrated source in a pin-to-funnel configuration was developed for the sensitive analysis of complex samples. With the funnel sleeve directly affected by direct-current discharge plasma, PASIT combines the ability to sample/ionize analyte molecules and then efficiently collect/transport charged mass species under atmospheric pressure and consequently shows an improved sensitivity. The integrated source enhances the signal intensity by more than 2 orders of magnitude compared with the previous pin-to-plate plasma source without significant background addition. A surface limit of detection (LOD) of 130 fmol mm-(2) (S/N = 3) has been achieved for clenbuterol on filter paper with an argon carrier gas. Demonstrated applications include the direct determination of active ingredients from drugs and symbolic compounds from natural plants and cholesterol from mouse brain tissue sections.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Yueming</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing National Laboratory for Molecular Sciences, Beijing 100190, China. znie@iccas.ac.cn.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Ning</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yafeng</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Xiong</LastName>
                    <ForeName>Caiqiao</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Suming</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Yongtai</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Nie</LastName>
                    <ForeName>Zongxiu</ForeName>
                    <Initials>Z</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Analyst</MedlineTA>
            <NlmUniqueID>0372652</NlmUniqueID>
            <ISSNLinking>0003-2654</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c4an00979g</ArticleId>
            <ArticleId IdType="pubmed">25147876</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147827</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Upregulation of Pluripotency Markers in Adipose Tissue-Derived Stem Cells by miR-302 and Leukemia Inhibitory Factor.</ArticleTitle>
            <Pagination>
                <MedlinePgn>941486</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/941486</ELocationID>
            <Abstract>
                <AbstractText>The expression pattern of pluripotency markers in adipose tissue-derived stem cells (ADSCs) is a subject of controversy. Moreover, there is no data about the signaling molecules that regulate these markers in ADSCs. In the present study, we studied the roles of leukemia inhibitory factor (LIF) and miR-302 in this regard. Freshly isolated mouse ADSCs expressed hematopoietic, mesenchymal, and pluripotency markers. One day after plating, ADSCs expressed OCT4 and Sox2 proteins. After three passages, the expression of hematopoietic and pluripotency markers decreased, while the expression of mesenchymal stem cell markers exhibited a striking rise. Both supplementation of culture media with LIF and transfection of the ADSCs with miR-302 family upregulated the expression levels of OCT4, Nanog, and Sox2 mRNAs. These findings showed that mouse adipose tissue contains a population of cells with molecular resemblance to embryonic stem cells, and LIF and miR-302 family positively affect the expression of pluripotency markers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Taha</LastName>
                    <ForeName>Masoumeh Fakhr</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Boulevard, P.O. Box 14965-161, Tehran 1417863171, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Javeri</LastName>
                    <ForeName>Arash</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Pajoohesh Boulevard, P.O. Box 14965-161, Tehran 1417863171, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rohban</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, P.O. Box 14115-154, Tehran, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mowla</LastName>
                    <ForeName>Seyed Javad</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, P.O. Box 14115-154, Tehran, Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/941486</ArticleId>
            <ArticleId IdType="pubmed">25147827</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147816</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>817613</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/817613</ELocationID>
            <Abstract>
                <AbstractText>Extensive accumulation of the glycosaminoglycan hyaluronan is found in pancreatic cancer. The role of hyaluronan synthases 2 and 3 (HAS2, 3) was investigated in pancreatic cancer growth and the tumor microenvironment. Overexpression of HAS3 increased hyaluronan synthesis in BxPC-3 pancreatic cancer cells. In vivo, overexpression of HAS3 led to faster growing xenograft tumors with abundant extracellular hyaluronan accumulation. Treatment with pegylated human recombinant hyaluronidase (PEGPH20) removed extracellular hyaluronan and dramatically decreased the growth rate of BxPC-3 HAS3 tumors compared to parental tumors. PEGPH20 had a weaker effect on HAS2-overexpressing tumors which grew more slowly and contained both extracellular and intracellular hyaluronan. Accumulation of hyaluronan was associated with loss of plasma membrane E-cadherin and accumulation of cytoplasmic ??-catenin, suggesting disruption of adherens junctions. PEGPH20 decreased the amount of nuclear hypoxia-related proteins and induced translocation of E-cadherin and ??-catenin to the plasma membrane. Translocation of E-cadherin was also seen in tumors from a transgenic mouse model of pancreatic cancer and in a human non-small cell lung cancer sample from a patient treated with PEGPH20. In conclusion, hyaluronan accumulation by HAS3 favors pancreatic cancer growth, at least in part by decreasing epithelial cell adhesion, and PEGPH20 inhibits these changes and suppresses tumor growth.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kultti</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0002-8600-3565</Identifier>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Chunmei</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singha</LastName>
                    <ForeName>Netai C</ForeName>
                    <Initials>NC</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zimmerman</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0003-4748-4631</Identifier>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osgood</LastName>
                    <ForeName>Ryan J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Symons</LastName>
                    <ForeName>Rebecca</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaoming</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Curtis B</ForeName>
                    <Initials>CB</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Infante</LastName>
                    <ForeName>Jeffrey R</ForeName>
                    <Initials>JR</Initials>
                    <Affiliation>Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Avenue North, Nashville, TN 37203, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobetz</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Labfinity, 8110 Cordova Road, Suite 119, Cordova, TN 38016, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuveson</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frost</LastName>
                    <ForeName>Gregory I</ForeName>
                    <Initials>GI</Initials>
                    <Affiliation>Intrexon Corporation, 6620 Mesa Ridge Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shepard</LastName>
                    <ForeName>H Michael</ForeName>
                    <Initials>HM</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Zhongdong</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA 92121, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/817613</ArticleId>
            <ArticleId IdType="pubmed">25147816</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147807</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The parameters of transcutaneous electrical nerve stimulation are critical to its regenerative effects when applied just after a sciatic crush lesion in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>572949</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/572949</ELocationID>
            <Abstract>
                <AbstractText>We investigated the effect of two frequencies of transcutaneous electrical nerve stimulation (TENS) applied immediately after lesion on peripheral nerve regeneration after a mouse sciatic crush injury. The animals were anesthetized and subjected to crushing of the right sciatic nerve and then separated into three groups: nontreated, Low-TENS (4???Hz), and High-TENS (100???Hz). The animals of Low- and High-TENS groups were stimulated for 2???h immediately after the surgical procedure, while the nontreated group was only positioned for the same period. After five weeks the animals were euthanized, and the nerves dissected bilaterally for histological and histomorphometric analysis. Histological assessment by light and electron microscopy showed that High-TENS and nontreated nerves had a similar profile, with extensive signs of degeneration. Conversely, Low-TENS led to increased regeneration, displaying histological aspects similar to control nerves. High-TENS also led to decreased density of fibers in the range of 6-12?????m diameter and decreased fiber diameter and myelin area in the range of 0-2?????m diameter. These findings suggest that High-TENS applied just after a peripheral nerve crush may be deleterious for regeneration, whereas Low-TENS may increase nerve regeneration capacity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cavalcante Miranda de Assis</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <Identifier Source="ORCID">0000-0001-8216-9755</Identifier>
                    <Affiliation>Post-Graduation Program in Medicine and Health, Faculty of Medicine, Federal University of Bahia, Rua Augusto Viana, Canela, 40110-060 Salvador, BA, Brazil ; Functional Electrostimulation Laboratory, Department of Biomorphology, Federal University of Bahia, Avenida Reitor Miguel Calmon, S/N, Vale do Canela, 40110-902 Salvador, BA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martins Lima</LastName>
                    <ForeName>Emyle</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Post-Graduation Program in Medicine and Health, Faculty of Medicine, Federal University of Bahia, Rua Augusto Viana, Canela, 40110-060 Salvador, BA, Brazil ; Functional Electrostimulation Laboratory, Department of Biomorphology, Federal University of Bahia, Avenida Reitor Miguel Calmon, S/N, Vale do Canela, 40110-902 Salvador, BA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teixeira Goes</LastName>
                    <ForeName>Bruno</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Gon??alo Moniz Research Center, Oswaldo Cruz Foundation (FIOCRUZ), Rua Waldemar Falc??o, Candea, INCT-INPeTAm/MCT-CNPq, 40296-710 Salvador, BA, Brazil ; Biotechnology and Bioprospection Nucleus (NBBio), Bahian School of Medicine and Human Health, Rua Frei Henrique, 8 Nazar??, 40.050-420 Salvador, BA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zugaib Cavalcanti</LastName>
                    <ForeName>Jo??o</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Physiology and Synaptic Plasticity Laboratory, Department of Physiology, Faculty of Medicine of Ribeir??o Preto, University of S??o Paulo, S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barbosa Paix??o</LastName>
                    <ForeName>Ala??</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0002-8396-8775</Identifier>
                    <Affiliation>Functional Electrostimulation Laboratory, Department of Biomorphology, Federal University of Bahia, Avenida Reitor Miguel Calmon, S/N, Vale do Canela, 40110-902 Salvador, BA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vannier-Santos</LastName>
                    <ForeName>Marcos Andr??</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Gon??alo Moniz Research Center, Oswaldo Cruz Foundation (FIOCRUZ), Rua Waldemar Falc??o, Candea, INCT-INPeTAm/MCT-CNPq, 40296-710 Salvador, BA, Brazil ; IBCCF, Cidade Universit??ria, Avenida Pedro Calmon, 21941-901 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martinez</LastName>
                    <ForeName>Ana Maria Blanco</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Neuroregeneration and Repair Laboratory, Federal University of Rio de Janeiro-UFRJ, Avenida Pedro Calmon, Cidade Universit??ria, 21941-901 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baptista</LastName>
                    <ForeName>Abrah??o Fontes</ForeName>
                    <Initials>AF</Initials>
                    <Affiliation>Post-Graduation Program in Medicine and Health, Faculty of Medicine, Federal University of Bahia, Rua Augusto Viana, Canela, 40110-060 Salvador, BA, Brazil ; Functional Electrostimulation Laboratory, Department of Biomorphology, Federal University of Bahia, Avenida Reitor Miguel Calmon, S/N, Vale do Canela, 40110-902 Salvador, BA, Brazil ; Gon??alo Moniz Research Center, Oswaldo Cruz Foundation (FIOCRUZ), Rua Waldemar Falc??o, Candea, INCT-INPeTAm/MCT-CNPq, 40296-710 Salvador, BA, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/572949</ArticleId>
            <ArticleId IdType="pubmed">25147807</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147799</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Emerging Use of In Vivo Optical Imaging in the Study of Neurodegenerative Diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>401306</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The detection and subsequent quantification of photons emitted from living tissues, using highly sensitive charged-couple device (CCD) cameras, have enabled investigators to noninvasively examine the intricate dynamics of molecular reactions in wide assortment of experimental animals under basal and pathophysiological conditions. Nevertheless, extrapolation of this in vivo optical imaging technology to the study of the mammalian brain and related neurodegenerative conditions is still in its infancy. In this review, we introduce the reader to the emerging use of in vivo optical imaging in the study of neurodegenerative diseases. We highlight the current instrumentation that is available and reporter molecules (fluorescent and bioluminescent) that are commonly used. Moreover, we examine how in vivo optical imaging using transgenic reporter mice has provided new insights into Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Prion disease, and neuronal damage arising from excitotoxicity and inflammation. Furthermore, we also touch upon studies that have utilized these technologies for the development of therapeutic strategies for neurodegenerative conditions that afflict humans.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Patterson</LastName>
                    <ForeName>Aileen P</ForeName>
                    <Initials>AP</Initials>
                    <Identifier Source="ORCID">0000-0002-3761-5573</Identifier>
                    <Affiliation>Molecular PathoBiology Unit, Public Health Agency of Canada, National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3R2.</Affiliation>
                </Author>
                <Author>
                    <LastName>Booth</LastName>
                    <ForeName>Stephanie A</ForeName>
                    <Initials>SA</Initials>
                    <Affiliation>Molecular PathoBiology Unit, Public Health Agency of Canada, National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3R2 ; Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, 730 William Avenue, Winnipeg, MB, Canada R3E 0W3.</Affiliation>
                </Author>
                <Author>
                    <LastName>Saba</LastName>
                    <ForeName>Reuben</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Molecular PathoBiology Unit, Public Health Agency of Canada, National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3R2.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/401306</ArticleId>
            <ArticleId IdType="pubmed">25147799</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147795</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>miRNA Transcriptome of Hypertrophic Skeletal Muscle with Overexpressed Myostatin Propeptide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>328935</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/328935</ELocationID>
            <Abstract>
                <AbstractText>MicroRNAs (miRNAs) play an imperative role in cell proliferation, differentiation, and cell metabolism through regulation of gene expression. Skeletal muscle hypertrophy that results from myostatin depression by its propeptide provides an interesting model to understand how miRNA transcriptome is involved in myostatin-based fiber hypertrophy. This study employed Solexa deep sequencing followed by Q-PCR methods to analyze miRNA transcriptome of skeletal muscle of myostatin propeptide transgenic mice in comparison with their littermate controls. A total of 461 mature known and 69 novel miRNAs were reported from this study. Fifty-seven miRNAs were expressed differentially between transgenic and littermate controls, of which most abundant miRNAs, miR-133a and 378a, were significantly differentially expressed. Expression profiling was validated on 8 known and 2 novel miRNAs. The miRNA targets prediction and pathway analysis showed that FST, SMAD3, TGFBR1, and AcvR1a genes play a vital role in skeletal muscle hypertrophy in the myostatin propeptide transgenic mice. It is predicted that miR-101 targeted to TGFBR1 and SMAD3, miR-425 to TGFBR2 and FST, and miR-199a to AcvR2a and TGF-?? genes. In conclusion, the study offers initial miRNA profiling and methodology of miRNA targets prediction for myostatin-based hypertrophy. These differentially expressed miRNAs are proposed as candidate miRNAs for skeletal muscle hypertrophy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Javed</LastName>
                    <ForeName>Ruheena</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">0000-0001-7914-7811</Identifier>
                    <Affiliation>Department of Animal Genetics &amp; Breeding, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei Province 430070, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jing</LastName>
                    <ForeName>Lu</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Animal Genetics &amp; Breeding, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei Province 430070, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jinzeng</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0002-2483-4734</Identifier>
                    <Affiliation>Department of Human Nutrition, Food and Animal Sciences, University of Hawaii at Manoa, Honolulu, HI 96822, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xinyun</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Animal Genetics &amp; Breeding, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei Province 430070, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Jianhua</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Animal Genetics &amp; Breeding, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei Province 430070, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Shuhong</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Animal Genetics &amp; Breeding, College of Animal Science and Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei Province 430070, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/328935</ArticleId>
            <ArticleId IdType="pubmed">25147795</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147782</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2296-2360</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in pediatrics</Title>
                <ISOAbbreviation>Front Pediatr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting Glutathione S-transferase M4 in Ewing sarcoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>83</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fped.2014.00083</ELocationID>
            <Abstract>
                <AbstractText>Ewing sarcoma is a malignant pediatric bone and soft tissue tumor. Although the 5-year survival rate of localized disease approaches 75%, the prognosis of metastatic and/or therapy-resistant disease remains dismal despite the wide use of aggressive therapeutic strategies. We previously reported that high expression of glutathione S-transferase M4 (GSTM4) in primary tumors correlates with poor patient outcomes. GSTM4 is required for oncogenic transformation and mediates resistance to chemotherapeutic drugs in Ewing sarcoma cells. Here, we performed RNA-sequencing analyses of Ewing sarcoma cells and combined our results with publicly available datasets to demonstrate that GSTM4 is a major GST specifically expressed in Ewing sarcoma. Pharmacological inhibition of GSTM4 activity using a pan GST inhibitor, 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol (NBDHEX), significantly limited cellular proliferation and oncogenic transformation of Ewing sarcoma cells. Moreover, combined use of NBDHEX and etoposide synergistically increased cytotoxicity, suggesting a role for GSTM4 as an inhibitor of apoptosis. Mechanistic studies revealed that GSTM4 limits apoptosis owing to its ability to interact with Apoptosis Signal-regulating Kinase 1 (ASK1) and inhibit signaling via the c-Jun N-terminal Kinase axis. To exploit our observation that GSTM4 expression is specifically up-regulated in Ewing sarcoma, we tested the effect of a GSTM4-activated anti-cancer agent, O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate or JS-K, on tumor growth and survival. We found that JS-K robustly decreased Ewing sarcoma cell viability and xenograft tumor growth and improved overall survival of xenograft mice. Our data suggest that GSTM4 is a novel therapeutic target for the treatment of high GSTM4-expressing Ewing sarcoma. Strategies that combine standard chemotherapy with agents that inhibit GSTM4, that are activated by GSTM4, or that block GSTM4/ASK1 interactions, can potentially be more specific and/or efficacious than standard therapeutic approaches.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhuo</LastName>
                    <ForeName>Rupeng</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kosak</LastName>
                    <ForeName>Kenneth M</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sankar</LastName>
                    <ForeName>Savita</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wiles</LastName>
                    <ForeName>Elizabeth T</ForeName>
                    <Initials>ET</Initials>
                    <Affiliation>Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Microarray and Genomic Analysis Core Facility, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jianxing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Medicinal Chemistry, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ayello</LastName>
                    <ForeName>Janet</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Pediatrics, New York Medical College , Valhalla, NY , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prestwich</LastName>
                    <ForeName>Glenn D</ForeName>
                    <Initials>GD</Initials>
                    <Affiliation>Department of Medicinal Chemistry, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shami</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                    <Affiliation>Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cairo</LastName>
                    <ForeName>Mitchell S</ForeName>
                    <Initials>MS</Initials>
                    <Affiliation>Department of Pediatrics, New York Medical College , Valhalla, NY , USA ; Department of Medicine, New York Medical College , Valhalla, NY , USA ; Department of Microbiology and Immunology, New York Medical College , Valhalla, NY , USA ; Department of Cell Biology and Anatomy, New York Medical College , Valhalla, NY , USA ; Department of Pathology, New York Medical College , Valhalla, NY , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lessnick</LastName>
                    <ForeName>Stephen L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA ; Division of Pediatric Hematology/Oncology, School of Medicine, University of Utah , Salt Lake City, UT , USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Pediatrics, New York Medical College , Valhalla, NY , USA ; Department of Pathology, New York Medical College , Valhalla, NY , USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Pediatr</MedlineTA>
            <NlmUniqueID>101615492</NlmUniqueID>
            <ISSNLinking>2296-2360</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ewing sarcoma</Keyword>
            <Keyword MajorTopicYN="N">GSTM4</Keyword>
            <Keyword MajorTopicYN="N">JS-K</Keyword>
            <Keyword MajorTopicYN="N">NBDHEX</Keyword>
            <Keyword MajorTopicYN="N">drug resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2014.00083</ArticleId>
            <ArticleId IdType="pubmed">25147782</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147717</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2008-3645</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Jundishapur journal of microbiology</Title>
                <ISOAbbreviation>Jundishapur J Microbiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of Polyvinyl Alcohol (PVA) Containing Artemether in Treatment of Cutaneous Leishmaniasis Caused by Leishmania major in BALB/c Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e9696</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5812/jjm.9696</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Polyvinyl alcohol (PVA) is one of the well-known polymers, which has been used in numerous biomedical applications because of its good biocompatibility.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Due to problems made by the therapeutics already used for leishmaniasis, the aim of this study was to evaluate the effect of PVA containing artemether in treating cutaneous leishmaniasis in BALB/c mice.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Aqueous solution of PVA was prepared by mixing with Double Distilled Water. After preparation of PVA, 4.33 mg of each drug (main drug artemether and control drug 14% glucantime) was added to 100 g of prepared PVA-honey solution. The solution was incubated at 37??C and the release of artemether was evaluated by measuring absorbance at 260 nm wave length. In this study for treatment of mice lesion, we used PVA containing artemether and glucantime and this method was compared with ointment treatment.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean diameters of lesions in mice treated with artemether were smaller than the control group and the differences were significant (P &lt; 0.05). The mean lesion size of mice treated with PVA containing artemether in comparison with the group treated with ointment of artemether were smaller and the differences were significant (P &lt; 0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PVA containing artemether is a new method for treatment of cutaneous leishmaniasis and according to the obtained results, artemether is an appropriate and effective drug, especially when used with PVA as a lesion dressing; thus we suggest that this method can be applied for the treatment of cutaneous leishmaniasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ebrahimisadr</LastName>
                    <ForeName>Parisa</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Parasitology, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghaffarifar</LastName>
                    <ForeName>Fatemeh</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Parasitology, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassan</LastName>
                    <ForeName>Zuhir Mohammad</ForeName>
                    <Initials>ZM</Initials>
                    <Affiliation>Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sirousazar</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Faculty of Chemical Engineering, Urmia University of Technology, Urmia, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohammadnejad</LastName>
                    <ForeName>Fatemeh</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Parasitology, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Jundishapur J Microbiol</MedlineTA>
            <NlmUniqueID>101515122</NlmUniqueID>
            <ISSNLinking>2008-3645</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Artemether</Keyword>
            <Keyword MajorTopicYN="N">Leishmania major</Keyword>
            <Keyword MajorTopicYN="N">Polyvinyl alcohol</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.5812/jjm.9696</ArticleId>
            <ArticleId IdType="pubmed">25147717</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147706</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2008-3645</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Jundishapur journal of microbiology</Title>
                <ISOAbbreviation>Jundishapur J Microbiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Electrophoretic Patterns of Toxoplasma gondii Excreted/Secreted Antigens and Their Role in Induction of the Humoral Immune Response.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e9525</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5812/jjm.9525</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Toxoplasma gondii is an obligatory intracellular protozoan parasite on which studies are pending regarding production of vaccine. To date, the production of human vaccine has not been successful where approximately one third of the world's population is thought to be infected with T. gondii.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The present study was designed to compare the electrophoretic patterns of T. gondii excreted/secreted antigens (ESAs) and determine their role in the stimulation of the humoral immune response.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">T. gondii ESAs were prepared from cell cultures (albino rat fibroblast) and cell-free mediums (RPMI-1640). Next, the SDS-PAGE technique was used for comparing molecular weights of the antigens. Forty C57BL/6 mice were divided randomly into four groups (n = 10). Immunization was performed subcutaneously at an interval of 2 weeks in two groups by injecting 100 ??g of each of the above-mentioned antigens. Two groups, as negative control, also received fibroblast lysate proteins or adjuvant separately. All of the groups were then challenged with the T. gondii RH strain. Serum samples were collected from all mice and measured by immunoblotting technique for detection of immunogenic antigens.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The electrophoretic mobility of the prepared antigens/proteins from cell culture, cell-free media, Fibroblast Lysate Proteins and Toxoplasma Lysate Antigens (TLA) showed 13, 12, 8 and 8 bands, respectively. The case groups, in challenge with T. gondii (RH strain), showed more survival prolongation than the control groups. Furthermore, the survival period was identical for both case groups with a tendency for slightly higher survival of mice receiving ESA from cell-free medium. Analysis of sera by immunoblotting also revealed one band of 65 KDa in sera from both case groups.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We suggest that this band be extracted and its amino acids sequence determined to produce Synthetic Polypeptide for immunization studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Daryani</LastName>
                    <ForeName>Ahmad</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharif</LastName>
                    <ForeName>Mehdi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalani</LastName>
                    <ForeName>Hamed</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rafiei</LastName>
                    <ForeName>Alireza</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalani</LastName>
                    <ForeName>Farzad</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahmadpour</LastName>
                    <ForeName>Ehsan</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, IR Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Jundishapur J Microbiol</MedlineTA>
            <NlmUniqueID>101515122</NlmUniqueID>
            <ISSNLinking>2008-3645</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Immunization</Keyword>
            <Keyword MajorTopicYN="N">Immunoblotting</Keyword>
            <Keyword MajorTopicYN="N">Toxoplasma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.5812/jjm.9525</ArticleId>
            <ArticleId IdType="pubmed">25147706</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147703</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2008-3645</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Jundishapur journal of microbiology</Title>
                <ISOAbbreviation>Jundishapur J Microbiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Therapeutic Effect of Hedera helix Alcoholic Extract Against Cutaneous Leishmaniasis Caused by Leishmania major in Balb/c Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e9432</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5812/jjm.9432</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cutaneous leishmaniasis (CL) is common and endemic in many areas of Iran, caused by species of a protozoan parasite belonging to the genus Leishmania. There is not any effective vaccine against leishmaniasis; so, therapy is important for prevention and separation of disease. Herbal extract for treatment of CL is cost-effective, applicable topically to lesions, and can avoid the development of drug resistance.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the in vivo activity of an alcoholic extract of Hedera helix (a native Iranian plant) on the experimental ulcer of zoonotic CL in Balb/c mice.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">At least 5x l0(6) promastigotes of Leishmania major (MHOM/64/IR/ER75) were inoculated subcutaneously in the tail base of Balb/c mice. Fifty six infected mice were distributed in four groups, two groups (16 mice for 20% alcoholic extract of H. helix and 13 for 70% extract) were used as experimental groups, one (15 mice) as placebo control (Control A), and one (12 mice) as negative control. Treatment effects of two concentrations were determined by comparison of placebo and nontreated groups via measuring the size of skin lesions and the number of parasitologically positive and negative mice after the therapy period.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">This study showed that the main lesion size did not decrease significantly, or the small lesions did not completely disappear after treatment by H. helix alcoholic extract. Amastigotes counts (mean ?? SD) of the skin lesions decreased in control A and 20% concentration groups, but in negative control and 70% concentration groups the number of parasites did not reduce.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study did not support the in vivo antileishmanial effect of H. helix extract. We recommend further studies using major components of H. helix, especially hederasaponin (saponin K10), to investigate the antileishmanial effect of this plant on L. major.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hooshyar</LastName>
                    <ForeName>Hossein</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, IR Iran ; Anatomical Science Research Center, Kashan University of Medical Sciences, Kashan, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Talari</LastName>
                    <ForeName>Safarali</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feyzi</LastName>
                    <ForeName>Fatemeh</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Parasitology, School of Medicine, Kashan University of Medical Sciences, Kashan, IR Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Jundishapur J Microbiol</MedlineTA>
            <NlmUniqueID>101515122</NlmUniqueID>
            <ISSNLinking>2008-3645</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Hedera</Keyword>
            <Keyword MajorTopicYN="N">Leishmania</Keyword>
            <Keyword MajorTopicYN="N">Plants</Keyword>
            <Keyword MajorTopicYN="N">Therapeutics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.5812/jjm.9432</ArticleId>
            <ArticleId IdType="pubmed">25147703</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147682</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2008-3645</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Jundishapur journal of microbiology</Title>
                <ISOAbbreviation>Jundishapur J Microbiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bactericidal Effect of Silver Nanoparticles on Intramacrophage Brucella abortus 544.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e9039</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5812/jjm.9039</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brucellosis is an infectious disease that is caused by Brucella spp. As Brucella spp. are intramacrophage pathogens, the treatment of this infection is very difficult. On the other hand, due to the side effects of the brucellosis treatment regime, it is necessary to find new antimicrobial agents against it.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to investigate the antimicrobial effect of silver nanoparticles against Brucella abortus 544 in the intramacrophage condition.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The antimicrobial effect of silver nanoparticles was determined by an agar well diffusion method. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against B. abortus 544 were determined by a broth macrodilution method. The effect of time on the antimicrobial activity of silver nanoparticles was analyzed. The effect of silver nanoparticles on the intramacrophage survival of B. abortus 544 was studied on mice peritoneal macrophages.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The well diffusion agar study showed that silver nanoparticles have an antimicrobial effect on B. abortus 544. The MIC and MBC of silver nanoparticles against B. abortus 544 were; 6 ppm and 8 ppm, respectively. The silver nanoparticles showed antibacterial effects within 40 minutes. The results of the macrophage culture indicated that silver nanoparticles have antibacterial activity against intramacrophage B. abortus 544, and the highest efficiency was observed at a concentration of 8-10 ppm of silver nanoparticles.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results showed that silver nanoparticles have an antimicrobial effect against intramacrophage B. abortus 544.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alizadeh</LastName>
                    <ForeName>Hamed</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Young Researchers and Elite Club, Zanjan Branch, Islamic Azad University, Zanjan, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salouti</LastName>
                    <ForeName>Mojtaba</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Biology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shapouri</LastName>
                    <ForeName>Reza</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Biology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, IR Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Jundishapur J Microbiol</MedlineTA>
            <NlmUniqueID>101515122</NlmUniqueID>
            <ISSNLinking>2008-3645</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antimicrobial</Keyword>
            <Keyword MajorTopicYN="N">Brucella abortus</Keyword>
            <Keyword MajorTopicYN="N">Macrophage</Keyword>
            <Keyword MajorTopicYN="N">Nanoparticles</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.5812/jjm.9039</ArticleId>
            <ArticleId IdType="pubmed">25147682</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147675</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">2008-3645</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Jundishapur journal of microbiology</Title>
                <ISOAbbreviation>Jundishapur J Microbiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e8974</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.5812/jjm.8974</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Thiol-specific antioxidant (TSA) is an antigen of Leishmania major which is believed to be the most promising molecule as a vaccine candidate against leishmaniasis.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In this study, we investigated the protective efficacy of TSA-based DNA vaccine against L. major infection.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Recombinant plasmid construction TSA (pcTSA) was prepared and transfected into eukaryotic cells and expression was confirmed with western blot and RT-PCR. The mice were assigned to six different groups and DNA immunization was performed with 100 ??g intramuscular recombinant plasmid with a two-week interval. Cytokines and lymphocyte proliferation assay, antibody responses and determination of parasite burden were performed following immunization and the challenging infection with L. major.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The antibody and IFN-?? titers were higher in pcTSA + AlPO4 group the immunized mice with pcTSA alone, but there was no statistically significant difference between the two groups. Additionally the IL-4 titer was not statistically different between the groups following immunization and challenge. After infection with L. major promastigotes, the immunized mice with pcTSA and the one immunized with both pcTSA + AlPO4 presented a considerable reduction in diameter of lesion but there was no statistical difference between the two groups. The immunized mice had significantly lower parasite loads. No significant differences were observed between the two vaccinated groups. However the highest reduction in parasite burden was observed in the group immunized with pcDNA + AlPO4. No significant differences were observed in survival rate of the immunized mice after the challenge with L. major.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, TSA-based DNA vaccine induced Th1 platform immune response and aluminum phosphate could improve the efficacy of these vaccines with induction of humoral and cellular immune responses against L. major infection. There were no significant differences observed between pcTSA and pcTSA + AlPO4 groups.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tabatabaie</LastName>
                    <ForeName>Fatemeh</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mahdavi</LastName>
                    <ForeName>Mehdi</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Virology, Pasteur Institute of Iran, Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Faezi</LastName>
                    <ForeName>Sobhan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Bacteriology, Pasteur Institute of Iran, Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dalimi</LastName>
                    <ForeName>Abdolhossein</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharifi</LastName>
                    <ForeName>Zohreh</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akhlaghi</LastName>
                    <ForeName>Lame</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, IR Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghaffarifar</LastName>
                    <ForeName>Fatemeh</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>02</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Jundishapur J Microbiol</MedlineTA>
            <NlmUniqueID>101515122</NlmUniqueID>
            <ISSNLinking>2008-3645</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Aluminum Phosphate</Keyword>
            <Keyword MajorTopicYN="N">DNA vaccine</Keyword>
            <Keyword MajorTopicYN="N">Leishmania major</Keyword>
            <Keyword MajorTopicYN="N">Thiol-S Antioxidant</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>2</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.5812/jjm.8974</ArticleId>
            <ArticleId IdType="pubmed">25147675</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147647</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2001-3078</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of extracellular vesicles</Title>
                <ISOAbbreviation>J Extracell Vesicles</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3402/jev.v3.24015</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Outer membrane vesicles (OMVs) from Gram-negative bacteria are gaining increasing attention as vaccine platform for their built-in adjuvanticity and for their potential use as carriers of heterologous antigens. These 2 properties offer the opportunity to make highly effective, easy to produce multi-valent vaccines. OMVs can be loaded with foreign antigens by targeting protein expression either to the outer membrane or to the periplasm of the OMV-producing strain. Periplasmic expression is simple and relatively efficient but leads to the accumulation of recombinant antigens in the lumen of OMVs and the ability of OMVs carrying internalized antigens to induce antigen-specific antibody responses has been only marginally investigated and is considered to be sub-optimal.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We have systematically analyzed in qualitative and quantitative terms antibody responses induced by OMVs carrying different heterologous antigens in their lumen. Group A Streptococcus (GAS) Slo, SpyCEP, Spy0269 and Group B Streptococcus (GBS) SAM_1372 were fused to the OmpA leader sequence for secretion and expressed in Escherichia coli. OMVs from the recombinant strains were purified and tested for immunogenicity and protective activity.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All proteins were incorporated into the OMVs lumen in their native conformation. Upon mice immunization, OMVs induced high functional antibody titers against the recombinant proteins. Furthermore, immunization with Slo-OMVs and SpyCEP-OMVs protected mice against GAS lethal challenge.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The efficiency of antigen delivery to the vesicular lumen via periplasmic expression, and the surprisingly high immunogenicity and protective activity of OMVs carrying internalized recombinant antigens further strengthens the potential of OMVs as vaccine platform.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fantappi??</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Centre for Integrative Biology, University of Trento, Trento, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Santis</LastName>
                    <ForeName>Micaela</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Centre for Integrative Biology, University of Trento, Trento, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiarot</LastName>
                    <ForeName>Emiliano</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Novartis Vaccines and Diagnostics, Siena, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carboni</LastName>
                    <ForeName>Filippo</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Novartis Vaccines and Diagnostics, Siena, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bensi</LastName>
                    <ForeName>Giuliano</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Novartis Vaccines and Diagnostics, Siena, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jousson</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Centre for Integrative Biology, University of Trento, Trento, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Margarit</LastName>
                    <ForeName>Immaculada</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Novartis Vaccines and Diagnostics, Siena, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grandi</LastName>
                    <ForeName>Guido</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Centre for Integrative Biology, University of Trento, Trento, Italy ; Novartis Vaccines and Diagnostics, Siena, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Sweden</Country>
            <MedlineTA>J Extracell Vesicles</MedlineTA>
            <NlmUniqueID>101610479</NlmUniqueID>
            <ISSNLinking>2001-3078</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Group A Streptococcus</Keyword>
            <Keyword MajorTopicYN="N">Group B Streptococcus</Keyword>
            <Keyword MajorTopicYN="N">heterologous antigens</Keyword>
            <Keyword MajorTopicYN="N">outer membrane vesicles</Keyword>
            <Keyword MajorTopicYN="N">periplasmic expression</Keyword>
            <Keyword MajorTopicYN="N">vaccines</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3402/jev.v3.24015</ArticleId>
            <ArticleId IdType="pii">24015</ArticleId>
            <ArticleId IdType="pubmed">25147647</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147645</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2001-0001</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Pathobiology of aging &amp; age related diseases</Title>
                <ISOAbbreviation>Pathobiol Aging Age Relat Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An immunohistochemical approach for monitoring effects of exercise on tumor stromal cells in old mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3402/pba.v4.24824</ELocationID>
            <Abstract>
                <AbstractText>Epidemiological evidence supports a protective effect of physical activity for breast cancer in older women, but the mechanisms are not well understood. We used 18-month-old BALB/c mice injected in the mammary fat pad with syngeneic 4T1 tumor cells as a model of invasive breast cancer. During the tumor progression phase, there was a significant decrease in labeling for F4/80, a marker for mouse macrophages, and CD34, a marker for vascular endothelial cells, in primary tumors from mice that ran higher average distances compared to mice that ran lower average distances (p???0.05). These observations suggest that immunohistochemistry can be used to monitor stromal cell populations in tumors from old mice under exercise conditions.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pettan-Brewer</LastName>
                    <ForeName>Christina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Comparative Medicine, University of Washington, Seattle WA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goh</LastName>
                    <ForeName>Jorming</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Comparative Medicine, University of Washington, Seattle WA, USA ; Interdisciplinary Program in Nutritional Sciences, University of Washington, Seattle WA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ladiges</LastName>
                    <ForeName>Warren C</ForeName>
                    <Initials>WC</Initials>
                    <Affiliation>Department of Comparative Medicine, University of Washington, Seattle WA, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Sweden</Country>
            <MedlineTA>Pathobiol Aging Age Relat Dis</MedlineTA>
            <NlmUniqueID>101575310</NlmUniqueID>
            <ISSNLinking>2001-0001</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">aging</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">exercise</Keyword>
            <Keyword MajorTopicYN="N">immunohistochemistry</Keyword>
            <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
            <Keyword MajorTopicYN="N">tumor stromal cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3402/pba.v4.24824</ArticleId>
            <ArticleId IdType="pii">24824</ArticleId>
            <ArticleId IdType="pubmed">25147645</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147610</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1948-5875</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>ACS medicinal chemistry letters</Title>
                <ISOAbbreviation>ACS Med Chem Lett</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.</ArticleTitle>
            <Pagination>
                <MedlinePgn>894-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/ml500142b</ELocationID>
            <Abstract>
                <AbstractText>Continued optimization of the N-substituent in the piperidinone series provided potent piperidinone-pyridine inhibitors 6, 7, 14, and 15 with improved pharmacokinetic properties in rats. Reducing structure complexity of the N-alkyl substituent led to the discovery of 23, a potent and simplified inhibitor of MDM2. Compound 23 exhibits excellent pharmacokinetic properties and substantial in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft mouse model.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yingcai</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Jiang</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartberger</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Canon</LastName>
                    <ForeName>Jude</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ada</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chow</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eksterowicz</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fox</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Jiasheng</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gribble</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Therapeutic Discovery, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zhihong</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jiwen Jim</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lo</LastName>
                    <ForeName>Mei-Chu</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McMinn</LastName>
                    <ForeName>Dustin</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oliner</LastName>
                    <ForeName>Jonathan D</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osgood</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rew</LastName>
                    <ForeName>Yosup</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saiki</LastName>
                    <ForeName>Anne Y</ForeName>
                    <Initials>AY</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaffer</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Therapeutic Discovery, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Xuelei</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Qiuping</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Dongyin</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Oncology Research, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Xiaoning</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olson</LastName>
                    <ForeName>Steven H</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Medina</LastName>
                    <ForeName>Julio C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Daqing</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Departments of Therapeutic Discovery and Pharmacokinetics and Drug Metabolism, Amgen Inc. , 1120 Veterans Boulevard, South San Francisco, California 94080, United States.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>ACS Med Chem Lett</MedlineTA>
            <NlmUniqueID>101521073</NlmUniqueID>
            <ISSNLinking>1948-5875</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MDM2</Keyword>
            <Keyword MajorTopicYN="N">p53</Keyword>
            <Keyword MajorTopicYN="N">piperidinone</Keyword>
            <Keyword MajorTopicYN="N">protein???protein interaction</Keyword>
            <Keyword MajorTopicYN="N">pyridine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ml500142b</ArticleId>
            <ArticleId IdType="pubmed">25147610</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147608</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1948-5875</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>ACS medicinal chemistry letters</Title>
                <ISOAbbreviation>ACS Med Chem Lett</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Optimization of Rutaecarpine as ABCA1 Up-Regulator for Treating Atherosclerosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>884-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/ml500131a</ELocationID>
            <Abstract>
                <AbstractText>ATP-binding cassette transporter A1 (ABCA1) is a key transporter and receptor in promoting cholesterol efflux, and increasing the expression level of ABCA1 is antiatherogenic. In our previous study, rutaecarpine (RUT) was found to protect ApoE(-/-) mice from developing atherosclerosis through preferentially up-regulating ABCA1 expression. In the present work, a series of RUT derivatives were synthesized and examined as ABCA1 expression up-regulators. Compounds CD1, CD6, and BCD1-2 were found to possess the most potential activity as antiatherosclerotic agents among all compounds tested.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yongzhen</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Tingting</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Chang</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xiao</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Dongsheng</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Ni</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Minghua</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Yanni</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Si</LastName>
                    <ForeName>Shuyi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College , Tiantanxili No. 1, Beijing 100050, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>ACS Med Chem Lett</MedlineTA>
            <NlmUniqueID>101521073</NlmUniqueID>
            <ISSNLinking>1948-5875</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ABCA1</Keyword>
            <Keyword MajorTopicYN="N">RCT</Keyword>
            <Keyword MajorTopicYN="N">Rutaecarpine</Keyword>
            <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ml500131a</ArticleId>
            <ArticleId IdType="pubmed">25147608</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147596</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1942-0994</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Oxidative medicine and cellular longevity</Title>
                <ISOAbbreviation>Oxid Med Cell Longev</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Subanesthetic Isoflurane Reduces Zymosan-Induced Inflammation in Murine Kupffer Cells by Inhibiting ROS-Activated p38 MAPK/NF-??B Signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>851692</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/851692</ELocationID>
            <Abstract>
                <AbstractText>Volatile anesthetic isoflurane (ISO) has immunomodulatory effects. The fungal component zymosan (ZY) induces inflammation through toll-like receptor 2 or dectin-1 signaling. We investigated the molecular actions of subanesthetic (0.7%) ISO against ZY-induced inflammatory activation in murine Kupffer cells (KCs), which are known as the resident macrophages within the liver. We observed that ISO reduced ZY-induced cyclooxygenase 2 upregulation and prostaglandin E2 release, as determined by western blot and radioimmunoassay, respectively. ISO also reduced the production of tumor necrosis factor-??, interleukin-1??, IL-6, high-mobility group box-1, macrophage inflammatory protein-1??, macrophage inflammatory protein-2, and monocyte chemoattractant protein-1 as assessed by enzyme-linked immunosorbent assays. ISO blocked the ZY-induced nuclear translocation and DNA-binding activity of nuclear factor- (NF)-??B p65. Moreover, ISO attenuated ZY-induced p38 mitogen-activated protein kinase (MAPK) activation partly by scavenging reactive oxygen species (ROS); the interregulation that ROS activated p38 MAPK followed by NF-??B activation was crucial for the ZY-induced inflammatory responses in KCs. An in vivo study by peritoneal injection of ZY into BALB/C mice confirmed the anti-inflammatory properties of 0.7% ISO against ZY in KCs. These results suggest that ISO ameliorates ZY-induced inflammatory responses in murine KCs by inhibiting the interconnected ROS/p38 MAPK/NF-??B signaling pathways.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Nan-Lin</ForeName>
                    <Initials>NL</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jun-Tang</ForeName>
                    <Initials>JT</Initials>
                    <Affiliation>Institute of Anal-Colorectal Surgery, No. 150 Central Hospital of PLA, Luoyang, Henan 451000, China ; State Key Laboratory of Cancer Biology, Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Centre of Material and Drug Supply, No. 150 Central Hospital of PLA, Luoyang, Henan 451000, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Ya-Li</ForeName>
                    <Initials>YL</Initials>
                    <Affiliation>Centre of Material and Drug Supply, No. 150 Central Hospital of PLA, Luoyang, Henan 451000, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Anesthesiology, No. 150 Central Hospital of PLA, Luoyang, Henan 451000, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yi</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bian</LastName>
                    <ForeName>Jie-Fang</ForeName>
                    <Initials>JF</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jiang-Hao</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Shi-Fang</ForeName>
                    <Initials>SF</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Ting</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lv</LastName>
                    <ForeName>Yong-Gang</ForeName>
                    <Initials>YG</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ning-Ning</ForeName>
                    <Initials>NN</Initials>
                    <Affiliation>Institute of Anal-Colorectal Surgery, No. 150 Central Hospital of PLA, Luoyang, Henan 451000, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Xiao-Shan</ForeName>
                    <Initials>XS</Initials>
                    <Affiliation>Institute of Anal-Colorectal Surgery, No. 150 Central Hospital of PLA, Luoyang, Henan 451000, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ling</LastName>
                    <ForeName>Rui</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yun</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, Shaanxi 710032, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oxid Med Cell Longev</MedlineTA>
            <NlmUniqueID>101479826</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/851692</ArticleId>
            <ArticleId IdType="pubmed">25147596</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147583</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1866-1947</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neurodevelopmental disorders</Title>
                <ISOAbbreviation>J Neurodev Disord</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI).</ArticleTitle>
            <Pagination>
                <MedlinePgn>26</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1866-1955-6-26</ELocationID>
            <Abstract>
                <AbstractText>Fragile X-associated primary ovarian insufficiency (FXPOI) is among the family of disorders caused by the expansion of a CGG repeat sequence in the 5' untranslated region of the X-linked gene FMR1. About 20% of women who carry the premutation allele (55 to 200 unmethylated CGG repeats) develop hypergonadotropic hypogonadism and cease menstruating before age 40. Some proportion of those who are still cycling show hormonal profiles indicative of ovarian dysfunction. FXPOI leads to subfertility and an increased risk of medical conditions associated with early estrogen deficiency. Little progress has been made in understanding the etiology of this clinically significant disorder. Understanding the molecular mechanisms of FXPOI requires a detailed knowledge of ovarian FMR1 mRNA and FMRP's function. In humans, non-invasive methods to discriminate the mechanisms of the premutation on ovarian function are not available, thus necessitating the development of model systems. Vertebrate (mouse and rat) and invertebrate (Drosophila melanogaster) animal studies for the FMR1 premutation and ovarian function exist and have been instrumental in advancing our understanding of the disease phenotype. For example, rodent models have shown that FMRP is highly expressed in oocytes where it is important for folliculogenesis. The two premutation mouse models studied to date show evidence of ovarian dysfunction and, together, suggest that the long repeat in the transcript itself may have some pathological effect quite apart from any effect of the toxic protein. Further, ovarian morphology in young animals appears normal and the primordial follicle pool size does not differ from that of wild-type animals. However, there is a progressive premature decline in the levels of most follicle classes. Observations also include granulosa cell abnormalities and altered gene expression patterns. Further comparisons of these models are now needed to gain insight into the etiology of the ovarian dysfunction. Premutation model systems in non-human primates and those based on induced pluripotent stem cells show particular promise and will complement current models. Here, we review the characterization of the current models and describe the development and potential of the new models. Finally, we will discuss some of the molecular mechanisms that might be responsible for FXPOI.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sherman</LastName>
                    <ForeName>Stephanie L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Department of Human Genetics, Emory University, 615 Michael St, Emory University, Atlanta, GA 30322, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curnow</LastName>
                    <ForeName>Eliza C</ForeName>
                    <Initials>EC</Initials>
                    <Affiliation>Washington National Primate Center, University of Washington, Seattle, WA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Easley</LastName>
                    <ForeName>Charles A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Laboratory of Translational Cell Biology, Department of Cell Biology, Emory University, Atlanta, GA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Human Genetics, Emory University, 615 Michael St, Emory University, Atlanta, GA 30322, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hukema</LastName>
                    <ForeName>Renate K</ForeName>
                    <Initials>RK</Initials>
                    <Affiliation>Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tejada</LastName>
                    <ForeName>Maria Isabel</ForeName>
                    <Initials>MI</Initials>
                    <Affiliation>Molecular Genetics Laboratory, Genetics Service, BioCruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Biscay, Spain.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Willemsen</LastName>
                    <ForeName>Rob</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Usdin</LastName>
                    <ForeName>Karen</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Laboratory of Molecular and Cellular Biology, NIDDK, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Neurodev Disord</MedlineTA>
            <NlmUniqueID>101483832</NlmUniqueID>
            <ISSNLinking>1866-1947</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CGG repeat</Keyword>
            <Keyword MajorTopicYN="N">Fertility</Keyword>
            <Keyword MajorTopicYN="N">Fragile X syndrome</Keyword>
            <Keyword MajorTopicYN="N">Premature ovarian failure</Keyword>
            <Keyword MajorTopicYN="N">Primary ovarian insufficiency</Keyword>
            <Keyword MajorTopicYN="N">Repeat expansion disorder</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1866-1955-6-26</ArticleId>
            <ArticleId IdType="pii">1866-1955-6-26</ArticleId>
            <ArticleId IdType="pubmed">25147583</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147582</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1758-5996</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetology &amp; metabolic syndrome</Title>
                <ISOAbbreviation>Diabetol Metab Syndr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Metabolic profile response to administration of epigallocatechin-3-gallate in high-fat-fed mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>84</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1758-5996-6-84</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Obesity is associated with increased adipose tissue and glucose intolerance. High-fat diets (HFDs) are known to induce obesity and increase proinflammatory adipokines. The consumption of green tea may improve the health of obese individuals because it contains a potent antioxidant that has effects on body weight, energy expenditure and serum cholesterol concentrations.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We examined the effects of epigallocatechin-3-gallate (EGCG) (50??mg/kg body weight per day) or saline after 30 or 60??days of treatment. Mice were distributed into four groups: 1) NS: normolipidic diet receiving saline; 2) NE: normolipidic diet receiving EGCG; 3) HFS: high-fat diet receiving saline; 4) HFE: high-fat diet receiving EGCG.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed that administration of a HFD plus EGCG treatment for 60??days reduced delta weight, the relative weights of the mesenteric adipose tissue (MES), retroperitonial adipose tissue (RET), epididymal adipose tissue (EPI), the sum of the adipose tissues (SAT), reduced triacylglycerol (TG) and improved both high-density lipoprotein (HDL) cholesterol levels and the adiponectin/STA ratio when compared with HFS.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest that the chronic administration of EGCG (60??days) promoted a significant improvement in glucose tolerance, decreased adipose tissue deposits, weight mass, TG and HDL-C only when associated with high-fat diet treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moreno</LastName>
                    <ForeName>Mayara Franzoi</ForeName>
                    <Initials>MF</Initials>
                    <Affiliation>Departamento de Fisiologia, Universidade Federal de S??o Paulo-EPM, S??o Paulo, SP Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Laquila</LastName>
                    <ForeName>Rachel</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Departamento de Fisiologia, Universidade Federal de S??o Paulo-EPM, S??o Paulo, SP Brasil ; Faculdades Integradas Cora????o de Jesus - FAINC, Santo Andr??, SP Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okuda</LastName>
                    <ForeName>Marcos Hiromu</ForeName>
                    <Initials>MH</Initials>
                    <Affiliation>Departamento de Fisiologia, Universidade Federal de S??o Paulo-EPM, S??o Paulo, SP Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lira</LastName>
                    <ForeName>F??bio Santos</ForeName>
                    <Initials>FS</Initials>
                    <Affiliation>Immunometabolism Research Group, Department of Physical Education, Universidade Estadual Paulista, UNESP, Presidente Prudente, SP Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Souza</LastName>
                    <ForeName>Gabriel In??cio de Morais Honorato</ForeName>
                    <Initials>GI</Initials>
                    <Affiliation>Departamento de Fisiologia, Universidade Federal de S??o Paulo-EPM, S??o Paulo, SP Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Souza</LastName>
                    <ForeName>Cl??udio Teodoro</ForeName>
                    <Initials>CT</Initials>
                    <Affiliation>Laboratory of Exercise Biochemistry and Physiology, Health Sciences Unit, University of Southern Santa Catarina, Crici??ma, SC Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Telles</LastName>
                    <ForeName>Monica Marques</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Departamento de Ci??ncias Biol??gicas, Universidade Federal de S??o Paulo-Campus Diadema, Diadema, SP Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ribeiro</LastName>
                    <ForeName>Eliane Beraldi</ForeName>
                    <Initials>EB</Initials>
                    <Affiliation>Departamento de Fisiologia, Universidade Federal de S??o Paulo-EPM, S??o Paulo, SP Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>do Nascimento</LastName>
                    <ForeName>Claudia Maria Oller</ForeName>
                    <Initials>CM</Initials>
                    <Affiliation>Departamento de Fisiologia, Universidade Federal de S??o Paulo-EPM, S??o Paulo, SP Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oyama</LastName>
                    <ForeName>Lila Missae</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>Departamento de Fisiologia, Universidade Federal de S??o Paulo-EPM, S??o Paulo, SP Brasil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Diabetol Metab Syndr</MedlineTA>
            <NlmUniqueID>101488958</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adipokines</Keyword>
            <Keyword MajorTopicYN="N">Adipose tissue</Keyword>
            <Keyword MajorTopicYN="N">High-fat diet</Keyword>
            <Keyword MajorTopicYN="N">Inflammation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-5996-6-84</ArticleId>
            <ArticleId IdType="pii">350</ArticleId>
            <ArticleId IdType="pubmed">25147582</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25147578</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1748-6718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Computational and mathematical methods in medicine</Title>
                <ISOAbbreviation>Comput Math Methods Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Computerized neuropsychological assessment in aging: testing efficacy and clinical ecology of different interfaces.</ArticleTitle>
            <Pagination>
                <MedlinePgn>804723</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/804723</ELocationID>
            <Abstract>
                <AbstractText>Digital technologies have opened new opportunities for psychological testing, allowing new computerized testing tools to be developed and/or paper and pencil testing tools to be translated to new computerized devices. The question that rises is whether these implementations may introduce some technology-specific effects to be considered in neuropsychological evaluations. Two core aspects have been investigated in this work: the efficacy of tests and the clinical ecology of their administration (the ability to measure real-world test performance), specifically (1) the testing efficacy of a computerized test when response to stimuli is measured using a touch-screen compared to a conventional mouse-control response device; (2) the testing efficacy of a computerized test with respect to different input modalities (visual versus verbal); and (3) the ecology of two computerized assessment modalities (touch-screen and mouse-control), including preference measurements of participants. Our results suggest that (1) touch-screen devices are suitable for administering experimental tasks requiring precise timings for detection, (2) intrinsic nature of neuropsychological tests should always be respected in terms of stimuli presentation when translated to new digitalized environment, and (3) touch-screen devices result in ecological instruments being proposed for the computerized administration of neuropsychological tests with a high level of preference from elderly people.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Canini</LastName>
                    <ForeName>Matteo</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0002-9601-1534</Identifier>
                    <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, 20090 Milan, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Battista</LastName>
                    <ForeName>Petronilla</ForeName>
                    <Initials>P</Initials>
                    <Identifier Source="ORCID">0000-0002-3120-1214</Identifier>
                    <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, 20090 Milan, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Della Rosa</LastName>
                    <ForeName>Pasquale Anthony</ForeName>
                    <Initials>PA</Initials>
                    <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, 20090 Milan, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Catrical??</LastName>
                    <ForeName>Eleonora</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Laboratory of Neuropsychology, The Foundation of the Carlo Besta Neurological Institute, IRCSS, 20133 Milan, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salvatore</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">0000-0001-9312-4675</Identifier>
                    <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, 20090 Milan, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilardi</LastName>
                    <ForeName>Maria Carla</ForeName>
                    <Initials>MC</Initials>
                    <Identifier Source="ORCID">0000-0002-7392-471X</Identifier>
                    <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, 20090 Milan, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castiglioni</LastName>
                    <ForeName>Isabella</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Segrate, 20090 Milan, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Comput Math Methods Med</MedlineTA>
            <NlmUniqueID>101277751</NlmUniqueID>
            <ISSNLinking>1748-670X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/804723</ArticleId>
            <ArticleId IdType="pubmed">25147578</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147569</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1687-918X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of microbiology</Title>
                <ISOAbbreviation>Int J Microbiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The TIR Domain Containing Locus of Enterococcus faecalis Is Predominant among Urinary Tract Infection Isolates and Downregulates Host Inflammatory Response.</ArticleTitle>
            <Pagination>
                <MedlinePgn>918143</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/918143</ELocationID>
            <Abstract>
                <AbstractText>Based on Toll/interleukin-1 receptor (TIR) domain structure homology, we detected a previously uncharacterized gene encoding for a TIR domain containing protein (Tcp) in the genome of Enterococcus faecalis. We assigned this gene the name tcpF (as in Tcp of E. faecalis). Screening of E. faecalis samples revealed that tcpF is more common in isolates from urinary tract infections (UTIs) than in human faecal flora. tcpF alleles showed moderate single nucleotide polymorphism (SNP) among UTI isolates. Infection of mouse RAW264.7 macrophages with a tcpF knock-out mutant led to elevated cytokine response compared to the isogenic wild type E. faecalis strain. In silico analysis predicted significant tertiary structure homology to the TIR domain of human TLR1 (TLR1-TIR). When transiently expressed in cultured eukaryotic cells, TcpF caused suppression of TLR2-dependent NF-??B activation suggesting for TcpF a role as a factor in E. faecalis that benefits colonization by modulating the host's immune responses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kraemer</LastName>
                    <ForeName>Thomas Daniel</ForeName>
                    <Initials>TD</Initials>
                    <Affiliation>Institute of Medical Microbiology, Justus Liebig University, Schubertstra??e 81, 35392 Giessen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quintanar Haro</LastName>
                    <ForeName>Orlando Daniel</ForeName>
                    <Initials>OD</Initials>
                    <Affiliation>Institute of Medical Microbiology, Justus Liebig University, Schubertstra??e 81, 35392 Giessen, Germany ; Iztacala Superior Studies Faculty, National Autonomous University of Mexico, Avenida de los Barrios 1, Los Reyes Iztacala, 54090 Tlalnepantla, MEX, Mexico.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Domann</LastName>
                    <ForeName>Eugen</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Institute of Medical Microbiology, Justus Liebig University, Schubertstra??e 81, 35392 Giessen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chakraborty</LastName>
                    <ForeName>Trinad</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Institute of Medical Microbiology, Justus Liebig University, Schubertstra??e 81, 35392 Giessen, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tchatalbachev</LastName>
                    <ForeName>Svetlin</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Institute of Medical Microbiology, Justus Liebig University, Schubertstra??e 81, 35392 Giessen, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Egypt</Country>
            <MedlineTA>Int J Microbiol</MedlineTA>
            <NlmUniqueID>101516125</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/918143</ArticleId>
            <ArticleId IdType="pubmed">25147569</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147566</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1687-8337</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of endocrinology</Title>
                <ISOAbbreviation>Int J Endocrinol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Baicalein Protects against Type 2 Diabetes via Promoting Islet ??-Cell Function in Obese Diabetic Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>846742</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/846742</ELocationID>
            <Abstract>
                <AbstractText>In both type 1 (T1D) and type 2 diabetes (T2D), the deterioration of glycemic control over time is primarily caused by an inadequate mass and progressive dysfunction of ??-cell, leading to the impaired insulin secretion. Here, we show that dietary supplementation of baicalein, a flavone isolated from the roots of Chinese herb Scutellaria baicalensis, improved glucose tolerance and enhanced glucose-stimulated insulin secretion (GSIS) in high-fat diet (HFD-) induced middle-aged obese mice. Baicalein had no effect on food intake, body weight gain, circulating lipid profile, and insulin sensitivity in obese mice. Using another mouse model of type 2 diabetes generated by high-fat diet (HFD) feeding and low doses of streptozotocin injection, we found that baicalein treatment significantly improved hyperglycemia, glucose tolerance, and blood insulin levels in these middle-aged obese diabetic mice, which are associated with the improved islet ??-cell survival and mass. In the in vitro studies, baicalein significantly augmented GSIS and promoted viability of insulin-secreting cells and human islets cultured either in the basal medium or under chronic hyperlipidemic condition. These results demonstrate that baicalein may be a naturally occurring antidiabetic agent by directly modulating pancreatic ??-cell function.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Human Nutrition, Foods &amp; Exercises, College of Agriculture and Life Sciences, Virginia Tech, 1981 Kraft Drive, Corporate Research Center, Blacksburg, VA 24061, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0002-3211-4331</Identifier>
                    <Affiliation>Department of Human Nutrition, Foods &amp; Exercises, College of Agriculture and Life Sciences, Virginia Tech, 1981 Kraft Drive, Corporate Research Center, Blacksburg, VA 24061, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Zhenquan</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Biology, The University of North Carolina at Greensboro, Greensboro, NC 27412, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhen</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Human Nutrition, Foods &amp; Exercises, College of Agriculture and Life Sciences, Virginia Tech, 1981 Kraft Drive, Corporate Research Center, Blacksburg, VA 24061, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Kequan</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Nutrition and Food Science, Wayne State University, Detroit , MI 48202, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilbert</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Human Nutrition, Foods &amp; Exercises, College of Agriculture and Life Sciences, Virginia Tech, 1981 Kraft Drive, Corporate Research Center, Blacksburg, VA 24061, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Dongmin</ForeName>
                    <Initials>D</Initials>
                    <Identifier Source="ORCID">0000-0002-3877-8198</Identifier>
                    <Affiliation>Department of Human Nutrition, Foods &amp; Exercises, College of Agriculture and Life Sciences, Virginia Tech, 1981 Kraft Drive, Corporate Research Center, Blacksburg, VA 24061, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Egypt</Country>
            <MedlineTA>Int J Endocrinol</MedlineTA>
            <NlmUniqueID>101516376</NlmUniqueID>
            <ISSNLinking>1687-8337</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/846742</ArticleId>
            <ArticleId IdType="pubmed">25147566</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147554</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1664-8021</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in genetics</Title>
                <ISOAbbreviation>Front Genet</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genomic factors that shape craniofacial outcome and neural crest vulnerability in FASD.</ArticleTitle>
            <Pagination>
                <MedlinePgn>224</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fgene.2014.00224</ELocationID>
            <Abstract>
                <AbstractText>Prenatal alcohol exposure (PAE) causes distinctive facial characteristics in some pregnancies and not others; genetic factors may contribute to this differential vulnerability. Ethanol disrupts multiple events of neural crest development, including induction, survival, migration, and differentiation. Animal models and genomic approaches have substantially advanced our understanding of the mechanisms underlying these facial changes. PAE during gastrulation produces craniofacial changes corresponding with human fetal alcohol syndrome. These result because PAE reduces prechordal plate extension and suppresses sonic hedgehog, leading to holoprosencephaly and malpositioned facial primordia. Haploinsufficiency in sonic hedgehog signaling increases vulnerability to facial deficits and may influence some PAE pregnancies. In contrast, PAE during early neurogenesis produces facial hypoplasia, preceded by neural crest reductions due to significant apoptosis. Factors mediating this apoptosis include intracellular calcium mobilization, elevated reactive oxygen species, and loss of trophic support from ??-catenin/calcium, sonic hedgehog, and mTOR signaling. Genome-wide SNP analysis links PDGFRA with facial outcomes in human PAE. Multiple genomic-level comparisons of ethanol-sensitive and - resistant early embryos, in both mouse and chick, independently identify common candidate genes that may potentially modify craniofacial vulnerability, including ribosomal proteins, proteosome, RNA splicing, and focal adhesion. In summary, research using animal models with genome-level differences in ethanol vulnerability, as well as targeted loss-and gain-of-function mutants, has clarified the mechanisms mediating craniofacial change in PAE. The findings additionally suggest that craniofacial deficits may represent a gene-ethanol interaction for some affected individuals. Genetic-level changes may prime individuals toward greater sensitivity or resistance to ethanol's neurotoxicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Susan M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Nutritional Sciences, University of Wisconsin-Madison Madison, WI, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garic</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Nutritional Sciences, University of Wisconsin-Madison Madison, WI, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berres</LastName>
                    <ForeName>Mark E</ForeName>
                    <Initials>ME</Initials>
                    <Affiliation>Department of Animal Sciences, University of Wisconsin-Madison Madison, WI, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Flentke</LastName>
                    <ForeName>George R</ForeName>
                    <Initials>GR</Initials>
                    <Affiliation>Department of Nutritional Sciences, University of Wisconsin-Madison Madison, WI, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Genet</MedlineTA>
            <NlmUniqueID>101560621</NlmUniqueID>
            <ISSNLinking>1664-8021</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CaMKII</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">fetal alcohol spectrum disorders</Keyword>
            <Keyword MajorTopicYN="N">neural crest</Keyword>
            <Keyword MajorTopicYN="N">ribosome biogenesis</Keyword>
            <Keyword MajorTopicYN="N">sonic hedgehog</Keyword>
            <Keyword MajorTopicYN="N">??-catenin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fgene.2014.00224</ArticleId>
            <ArticleId IdType="pubmed">25147554</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147515</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1662-5153</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in behavioral neuroscience</Title>
                <ISOAbbreviation>Front Behav Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>GAD65 haplodeficiency conveys resilience in animal models of stress-induced psychopathology.</ArticleTitle>
            <Pagination>
                <MedlinePgn>265</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fnbeh.2014.00265</ELocationID>
            <Abstract>
                <AbstractText>GABAergic mechanisms are critically involved in the control of fear and anxiety, but their role in the development of stress-induced psychopathologies, including post-traumatic stress disorder (PTSD) and mood disorders is not sufficiently understood. We studied these functions in two established mouse models of risk factors for stress-induced psychopathologies employing variable juvenile stress and/or social isolation. A battery of emotional tests in adulthood revealed the induction of contextually generalized fear, anxiety, hyperarousal and depression-like symptoms in these paradigms. These reflect the multitude and complexity of stress effects in human PTSD patients. With factor analysis we were able to identify parameters that reflect these different behavioral domains in stressed animals and thus provide a basis for an integrated scoring of affectedness more closely resembling the clinical situation than isolated parameters. To test the applicability of these models to genetic approaches we further tested the role of GABA using heterozygous mice with targeted mutation of the GABA synthesizing enzyme GAD65 [GAD65(+/-) mice], which show a delayed postnatal increase in tissue GABA content in limbic and cortical brain areas. Unexpectedly, GAD65(+/-) mice did not show changes in exploratory activity regardless of the stressor type and were after the variable juvenile stress procedure protected from the development of contextual generalization in an auditory fear conditioning experiment. Our data demonstrate the complex nature of behavioral alterations in rodent models of stress-related psychopathologies and suggest that GAD65 haplodeficiency, likely through its effect on the postnatal maturation of GABAergic transmission, conveys resilience to some of these stress-induced effects.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>M??ller</LastName>
                    <ForeName>Iris</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Genetics and Molecular Neurobiology, Institute of Biology, Otto-von-Guericke University Magdeburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Obata</LastName>
                    <ForeName>Kunihiko</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>National Institute for Physiological Sciences Okazaki, Aichi, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richter-Levin</LastName>
                    <ForeName>Gal</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Neurobiology and Ethology and Department of Psychology, Institute for the Study of Affective Neuroscience, University of Haifa Haifa, Israel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stork</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Genetics and Molecular Neurobiology, Institute of Biology, Otto-von-Guericke University Magdeburg, Germany ; Center for Behavioural Brain Sciences Magdeburg, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Behav Neurosci</MedlineTA>
            <NlmUniqueID>101477952</NlmUniqueID>
            <ISSNLinking>1662-5153</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">glutamate decarboxylase</Keyword>
            <Keyword MajorTopicYN="N">juvenile trauma</Keyword>
            <Keyword MajorTopicYN="N">mutant mouse</Keyword>
            <Keyword MajorTopicYN="N">posttraumatic stress disorder</Keyword>
            <Keyword MajorTopicYN="N">social isolation</Keyword>
            <Keyword MajorTopicYN="N">stress resilience</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnbeh.2014.00265</ArticleId>
            <ArticleId IdType="pubmed">25147515</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25147512</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1662-5153</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in behavioral neuroscience</Title>
                <ISOAbbreviation>Front Behav Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mixed housing with DBA/2 mice induces stress in C57BL/6 mice: implications for interventions based on social enrichment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>257</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fnbeh.2014.00257</ELocationID>
            <Abstract>
                <AbstractText>Several behavioral interventions, based on social enrichment and observational learning are applied in treatment of neuropsychiatric disorders. However, the mechanism of such modulatory effect and the safety of applied methods on individuals involved in social support need further investigation. We took advantage of known differences between inbred mouse strains to reveal the effect of social enrichment on behavior and neurobiology of animals with different behavioral phenotypes. C57BL/6 and DBA/2 female mice displaying multiple differences in cognitive, social, and emotional behavior were group-housed either in same-strain or in mixed-strain conditions. Comprehensive behavioral phenotyping and analysis of expression of several plasticity- and stress-related genes were done to measure the reciprocal effects of social interaction between the strains. Contrary to our expectation, mixed housing did not change the behavior of DBA/2 mice. Nevertheless, the level of serum corticosterone and the expression of glucocorticoid receptor Nr3c1 in the brain were increased in mixed housed DBA/2 as compared with those of separately housed DBA/2 mice. In contrast, socially active C57BL/6 animals were more sensitive to the mixed housing, displaying several signs of stress: alterations in learning, social, and anxiety-like behavior and anhedonia. These behavioral impairments were accompanied by the elevated serum corticosterone and the reduced expression of Nr3c1, as well as the elevated Bdnf levels in the cortex and hippocampus. Our results demonstrate the importance of social factors in modulation of both behavior and the underlying neurobiological mechanisms in stress response, and draw attention to the potential negative impact of social interventions for individuals involved in social support.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kulesskaya</LastName>
                    <ForeName>Natalia</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Neuroscience Center, University of Helsinki Helsinki, Finland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karpova</LastName>
                    <ForeName>Nina N</ForeName>
                    <Initials>NN</Initials>
                    <Affiliation>Neuroscience Center, University of Helsinki Helsinki, Finland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Neuroscience Center, University of Helsinki Helsinki, Finland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tian</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Neuroscience Center, University of Helsinki Helsinki, Finland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Voikar</LastName>
                    <ForeName>Vootele</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Neuroscience Center, University of Helsinki Helsinki, Finland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Behav Neurosci</MedlineTA>
            <NlmUniqueID>101477952</NlmUniqueID>
            <ISSNLinking>1662-5153</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">animal model</Keyword>
            <Keyword MajorTopicYN="N">behavioral interventions</Keyword>
            <Keyword MajorTopicYN="N">mixed housing</Keyword>
            <Keyword MajorTopicYN="N">social enrichment</Keyword>
            <Keyword MajorTopicYN="N">social learning</Keyword>
            <Keyword MajorTopicYN="N">stress</Keyword>
            <Keyword MajorTopicYN="N">stress-related genes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnbeh.2014.00257</ArticleId>
            <ArticleId IdType="pubmed">25147512</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147477</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1879-2871</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>766-767</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>8</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Mutation research. Fundamental and molecular mechanisms of mutagenesis</Title>
                <ISOAbbreviation>Mutat Res Fundam Mol Mech Mutagen</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Deletion of BRCA2 exon 27 causes defects in response to both stalled and collapsed replication forks.</ArticleTitle>
            <Pagination>
                <MedlinePgn>66-72</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">BRCA2 is a tumor suppressor that maintains genomic integrity through double strand break (DSB) repair and replication fork protection. The BRC motifs and an exon 27-encoded domain (Ex27) of BRCA2 interact with the recombinase RAD51 to respectively facilitate the formation and stability of a RAD51 filament on single strand DNA. The BRC-RAD51 associations enable DSB repair while the Ex27-RAD51 association protects the nascent replication strand from MRE11-mediated degradation. MRE11 is a nuclease that facilitates the generation of 3' overhangs needed for homologous recombination (HR)-mediated DSB repair. Here we report the dynamics of replication fork maintenance in mouse embryonic stem (ES) cells deleted for Ex27 (brca2(lex1/lex2) ) after exposure to hydroxyurea (HU) that depletes nucleotides. HU conditions were varied from mild to severe. Mild conditions induce an ATR-response to replication fork stalling while severe conditions induce a DNA-PKCS-response to replication fork collapse and a DSB. These responses were differentiated by replication protein A (RPA) phosphorylation. We found that Ex27 deletion reduced MRE11 localization to stalled, but not collapsed, replication forks and that Ex27-deletion caused a proportionately more severe phenotype with HU dose. Therefore, the BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Tae Moon</ForeName>
                    <Initials>TM</Initials>
                    <Affiliation>Department of Molecular Medicine/Institute of Biotechnology, The Barshop Center of Aging, The University of Texas Health Science Center at San Antonio, 15355 Lambda Drive, San Antonio, Texas 78245-3207, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Son</LastName>
                    <ForeName>Mi Young</ForeName>
                    <Initials>MY</Initials>
                    <Affiliation>Department of Molecular Medicine/Institute of Biotechnology, The Barshop Center of Aging, The University of Texas Health Science Center at San Antonio, 15355 Lambda Drive, San Antonio, Texas 78245-3207, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dodds</LastName>
                    <ForeName>Sherry</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Molecular Medicine/Institute of Biotechnology, The Barshop Center of Aging, The University of Texas Health Science Center at San Antonio, 15355 Lambda Drive, San Antonio, Texas 78245-3207, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Lingchuan</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Molecular Medicine/Institute of Biotechnology, The Barshop Center of Aging, The University of Texas Health Science Center at San Antonio, 15355 Lambda Drive, San Antonio, Texas 78245-3207, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hasty</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Molecular Medicine/Institute of Biotechnology, The Barshop Center of Aging, The University of Texas Health Science Center at San Antonio, 15355 Lambda Drive, San Antonio, Texas 78245-3207, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mutat Res Fundam Mol Mech Mutagen</MedlineTA>
            <NlmUniqueID>101632178</NlmUniqueID>
            <ISSNLinking>1386-1964</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA2</Keyword>
            <Keyword MajorTopicYN="N">RAD51</Keyword>
            <Keyword MajorTopicYN="N">chromosomal instability</Keyword>
            <Keyword MajorTopicYN="N">double strand break</Keyword>
            <Keyword MajorTopicYN="N">replication fork stalling</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mrfmmm.2014.06.003</ArticleId>
            <ArticleId IdType="pubmed">25147477</ArticleId>
        </ArticleIdList>
        <?nihms?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147439</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1466-1861</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Mediators of inflammation</Title>
                <ISOAbbreviation>Mediators Inflamm.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Palmitoleic Acid (N-7) Attenuates the Immunometabolic Disturbances Caused by a High-Fat Diet Independently of PPAR ??.</ArticleTitle>
            <Pagination>
                <MedlinePgn>582197</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/582197</ELocationID>
            <Abstract>
                <AbstractText>Palmitoleic acid (PMA) has anti-inflammatory and antidiabetic activities. Here we tested whether these effects of PMA on glucose homeostasis and liver inflammation, in mice fed with high-fat diet (HFD), are PPAR-?? dependent. C57BL6 wild-type (WT) and PPAR-??-knockout (KO) mice fed with a standard diet (SD) or HFD for 12 weeks were treated after the 10th week with oleic acid (OLA, 300???mg/kg of b.w.) or PMA 300???mg/kg of b.w. Steatosis induced by HFD was associated with liver inflammation only in the KO mice, as shown by the increased hepatic levels of IL1-beta, IL-12, and TNF-??; however, the HFD increased the expression of TLR4 and decreased the expression of IL1-Ra in both genotypes. Treatment with palmitoleate markedly attenuated the insulin resistance induced by the HFD, increased glucose uptake and incorporation into muscle in vitro, reduced the serum levels of AST in WT mice, decreased the hepatic levels of IL1-beta and IL-12 in KO mice, reduced the expression of TLR-4 and increased the expression of IL-1Ra in WT mice, and reduced the phosphorylation of NF ????B (p65) in the livers of KO mice. We conclude that palmitoleate attenuates diet-induced insulin resistance, liver inflammation, and damage through mechanisms that do not depend on PPAR-??.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Souza</LastName>
                    <ForeName>Camila O</ForeName>
                    <Initials>CO</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, University of S??o Paulo, Avenida Lineu Prestes 1524, 05508-000 S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teixeira</LastName>
                    <ForeName>Alexandre A S</ForeName>
                    <Initials>AA</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, University of S??o Paulo, Avenida Lineu Prestes 1524, 05508-000 S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lima</LastName>
                    <ForeName>Edson A</ForeName>
                    <Initials>EA</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, University of S??o Paulo, Avenida Lineu Prestes 1524, 05508-000 S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Batatinha</LastName>
                    <ForeName>Helena A P</ForeName>
                    <Initials>HA</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, University of S??o Paulo, Avenida Lineu Prestes 1524, 05508-000 S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gomes</LastName>
                    <ForeName>Lara M</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>Bioenergetic Laboratory, Extremo Sul Catarinense University, 88806-000 Criciuma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carvalho-Silva</LastName>
                    <ForeName>Milena</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Bioenergetic Laboratory, Extremo Sul Catarinense University, 88806-000 Criciuma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mota</LastName>
                    <ForeName>Isabella T</ForeName>
                    <Initials>IT</Initials>
                    <Affiliation>Bioenergetic Laboratory, Extremo Sul Catarinense University, 88806-000 Criciuma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Streck</LastName>
                    <ForeName>Emilio L</ForeName>
                    <Initials>EL</Initials>
                    <Affiliation>Bioenergetic Laboratory, Extremo Sul Catarinense University, 88806-000 Criciuma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirabara</LastName>
                    <ForeName>Sandro M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Institute of Physical Activity Sciences and Sports, Cruzeiro do Sul University, 01506-000 S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neto</LastName>
                    <ForeName>Jos?? C Rosa</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, University of S??o Paulo, Avenida Lineu Prestes 1524, 05508-000 S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mediators Inflamm</MedlineTA>
            <NlmUniqueID>9209001</NlmUniqueID>
            <ISSNLinking>0962-9351</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/582197</ArticleId>
            <ArticleId IdType="pubmed">25147439</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147435</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1466-1861</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Mediators of inflammation</Title>
                <ISOAbbreviation>Mediators Inflamm.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Red Ginseng Extract Ameliorates Autoimmune Arthritis via Regulation of STAT3 Pathway, Th17/Treg Balance, and Osteoclastogenesis in Mice and Human.</ArticleTitle>
            <Pagination>
                <MedlinePgn>351856</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/351856</ELocationID>
            <Abstract>
                <AbstractText>Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic joint inflammation. Red ginseng is a steamed and dried Panax ginseng C.A. Meyer, which has been used as alternative medicine for thousands of years. This study was undertaken to investigate the effects of red ginseng extracts (RGE) on autoimmune arthritis in mice and humans and to delineate the underlying mechanism. RGE was orally administered three times a week to mice with arthritis. Oral administration of RGE markedly ameliorated clinical arthritis score and histologically assessed joint inflammation in mice with CIA. A significant reduction in STAT3 phosphorylation and a decrease in the number of Th17 cells were observed with RGE treatment. There was also a marked reduction in RANKL-induced osteoclastogenesis with treatment of RGE. The inhibitory effect of RGE on Th17 differentiation and osteoclastogenesis observed in mice was also confirmed in the subsequent experiments performed using human peripheral blood mononuclear cells. Our findings provide the first evidence that RGE can regulate Th17 and reciprocally promote Treg cells by inhibiting the phosphorylation of STAT3. Therefore, RGE can ameliorate arthritis in mice with CIA by targeting pathogenic Th17 and osteoclast differentiation, suggesting a novel therapy for treatment of RA.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jhun</LastName>
                    <ForeName>JooYeon</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Byun</LastName>
                    <ForeName>Jae-Kyeong</ForeName>
                    <Initials>JK</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Eun-Kyung</ForeName>
                    <Initials>EK</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Woo</LastName>
                    <ForeName>Jung-Won</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jae-Ho</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwok</LastName>
                    <ForeName>Seung-Ki</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ju</LastName>
                    <ForeName>Ji-Hyeon</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Kyung-Su</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ho-Youn</ForeName>
                    <Initials>HY</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Sung Hwan</ForeName>
                    <Initials>SH</Initials>
                    <Identifier Source="ORCID">0000-0003-1711-2060</Identifier>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Mi-La</ForeName>
                    <Initials>ML</Initials>
                    <Affiliation>The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea ; Divison of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Republic of Korea ; Conversant Research Consortium in Immunologic Disease, College of Medicine, The Catholic University of Korea, Korea 505 Banpo-Dong, Seocho-Ku, Seoul 137-040, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mediators Inflamm</MedlineTA>
            <NlmUniqueID>9209001</NlmUniqueID>
            <ISSNLinking>0962-9351</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/351856</ArticleId>
            <ArticleId IdType="pubmed">25147435</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147341</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4636</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
                <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gestational Loss and Growth Restriction by Angiogenic Defects in Placental Growth Factor Transgenic Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ATVBAHA.114.303693</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Angiogenesis is an important biological process during development, reproduction, and in immune responses. Placental growth factor (PlGF) is a member of vascular endothelial growth factor that is critical for angiogenesis and vasculogenesis. We generated transgenic mice overexpressing PlGF in specifically T cells using the human CD2-promoter to investigate the effects of PlGF overexpression.</AbstractText>
                <AbstractText Label="APPROACH AND RESULTS" NlmCategory="UNASSIGNED">Transgenic mice were difficult to obtain owing to high lethality; for this reason, we investigated why gestational loss occurred in these transgenic mice. Here, we report that placenta detachment and inhibition of angiogenesis occurred in PlGF transgenic mice during the gestational period. Moreover, even when transgenic mice were born, their growth was restricted.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Conclusively, PlGF overexpression prevents angiogenesis by inhibiting Braf, extracellular signal-regulated kinase activation, and downregulation of HIF-1?? in the mouse placenta. Furthermore, it affected regulatory T cells, which are important for maintenance of pregnancy.</AbstractText>
                <CopyrightInformation>?? 2014 American Heart Association, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kang</LastName>
                    <ForeName>Min-Cheol</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Seo Jin</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Hei Jung</ForeName>
                    <Initials>HJ</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Jinhee</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Dong Hoon</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Bae</LastName>
                    <ForeName>Ki Beom</ForeName>
                    <Initials>KB</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Ji</LastName>
                    <ForeName>Young Rae</ForeName>
                    <Initials>YR</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Si Jun</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Jeong</LastName>
                    <ForeName>Jain</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Jang</LastName>
                    <ForeName>Woo Young</ForeName>
                    <Initials>WY</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Jung-Hak</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Choi</LastName>
                    <ForeName>Myung-Sook</ForeName>
                    <Initials>MS</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Dong-Seok</ForeName>
                    <Initials>DS</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Hyun-Shik</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Sanggyu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Sung Hyun</ForeName>
                    <Initials>SH</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Myoung Ok</ForeName>
                    <Initials>MO</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Gyeongsin</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Choo</LastName>
                    <ForeName>Yeon Sik</ForeName>
                    <Initials>YS</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Je-Yoel</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Ryoo</LastName>
                    <ForeName>Zae Young</ForeName>
                    <Initials>ZY</Initials>
                    <Affiliation>From the School of Life Sciences and Biotechnology (M.-c. K., S.J.P., H.J.K., J.L., D.H.Y., K.B.B., Y.R.J., S.J.P., J.J., W.Y.J., J.-H.K., M.S.C., D.-S.L., H.-S.L., S.L., S.H.K., M.O.K., Z.Y.R.) and School of Biology (Y.S.C.), Kyungpook National University, Daegu, Korea; Department of Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea (G.P.); and Department of Biochemistry, College of Veterinary Medicine, Seoul National University, Seoul, Korea (J.-Y.C.). jaewoong64@hanmail.net.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
            <NlmUniqueID>9505803</NlmUniqueID>
            <ISSNLinking>1079-5642</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">placenta growth factor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ATVBAHA.114.303693</ArticleId>
            <ArticleId IdType="doi">10.1161/ATVBAHA.114.303693</ArticleId>
            <ArticleId IdType="pubmed">25147341</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147340</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4636</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
                <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Canonical Wnt Signaling Induces Vascular Endothelial Dysfunction via p66Shc-Regulated Reactive Oxygen Species.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ATVBAHA.114.304338</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Reactive oxygen species regulate canonical Wnt signaling. However, the role of the redox regulatory protein p66(Shc) in the canonical Wnt pathway is not known. We investigated whether p66(Shc) is essential for canonical Wnt signaling in the endothelium and determined whether the canonical Wnt pathway induces vascular endothelial dysfunction via p66(Shc)-mediated oxidative stress.</AbstractText>
                <AbstractText Label="APPROACH AND RESULTS" NlmCategory="UNASSIGNED">The canonical Wnt ligand Wnt3a induced phosphorylation (activation) of p66(Shc) in endothelial cells. Wnt3a-stimulated dephosphorylation of ??-catenin, and ??-catenin-dependent transcription, was inhibited by knockdown of p66(Shc). Exogenous H2O2-induced ??-catenin dephosphorylation was also mediated by p66(Shc). Moreover, p66(Shc) overexpression dephosphorylated ??-catenin and increased ??-catenin-dependent transcription, independent of Wnt3a ligand. P66(Shc)-induced ??-catenin dephosphorylation was inhibited by antioxidants N-acetyl cysteine and catalase. Wnt3a upregulated endothelial NADPH oxidase-4, and ??-catenin dephosphorylation was suppressed by knocking down NADPH oxidase-4 and by antioxidants. Wnt3a increased H2O2 levels in endothelial cells and impaired endothelium-dependent vasorelaxation in mouse aortas, both of which were rescued by p66(Shc) knockdown. P66(Shc) knockdown also inhibited adhesion of monocytes to Wnt3a-stimulated endothelial cells. Furthermore, constitutively active ??-catenin expression in the endothelium increased vascular reactive oxygen species and impaired endothelium-dependent vasorelaxation. In vivo, high-fat diet feeding-induced endothelial dysfunction in mice was associated with increased endothelial Wnt3a, dephosphorylated ??-catenin, and phosphorylated p66(Shc). High-fat diet-induced dephosphorylation of endothelial ??-catenin was diminished in mice in which p66(Shc) was knocked down.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">p66(Shc) plays a vital part in canonical Wnt signaling in the endothelium and mediates Wnt3a-stimulated endothelial oxidative stress and dysfunction.</AbstractText>
                <CopyrightInformation>?? 2014 American Heart Association, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Vikram</LastName>
                    <ForeName>Ajit</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.). ajit-vikram@uiowa.edu kaikobad-irani@uiowa.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Young-Rae</ForeName>
                    <Initials>YR</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kumar</LastName>
                    <ForeName>Santosh</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Naqvi</LastName>
                    <ForeName>Asma</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Hoffman</LastName>
                    <ForeName>Timothy A</ForeName>
                    <Initials>TA</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kumar</LastName>
                    <ForeName>Ajay</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Miller</LastName>
                    <ForeName>Francis J</ForeName>
                    <Initials>FJ</Initials>
                    <Suffix>Jr</Suffix>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Cuk-Seong</ForeName>
                    <Initials>CS</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Irani</LastName>
                    <ForeName>Kaikobad</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>From the Cardiovascular Division, Department of Internal Medicine, University of Iowa Carver College of Medicine (A.V., Y.-R.K., S.K., F.J.M., K.I.); Cardiovascular Institute, University of Pittsburgh, PA (A.N., A.K.); University of Louisville, KY (T.A.H.); and Department of Physiology, Chungnam National University, Daejeon, Korea (C.-S.K.). ajit-vikram@uiowa.edu kaikobad-irani@uiowa.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
            <NlmUniqueID>9505803</NlmUniqueID>
            <ISSNLinking>1079-5642</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">endothelial cells</Keyword>
            <Keyword MajorTopicYN="N">oxidation???reduction</Keyword>
            <Keyword MajorTopicYN="N">reactive oxygen species</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ATVBAHA.114.304338</ArticleId>
            <ArticleId IdType="doi">10.1161/ATVBAHA.114.304338</ArticleId>
            <ArticleId IdType="pubmed">25147340</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147339</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4636</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
                <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neutrophils in Atherosclerosis: From Mice to Man.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ATVBAHA.114.303564</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Infiltration of leukocyte subsets is a driving force of atherosclerotic lesion growth, and during the past decade, neutrophils have received growing attention in chronic inflammatory processes, such as atherosclerosis. Equipped with various ready to be released mediators, evolved to fight invading pathogens, neutrophils may also hold key functions in affecting sterile inflammation, such as in atherosclerosis. Many of their secretion products might instruct or activate other immune cells (particularly monocytes) to, for example, enter atherosclerotic lesions or release proinflammatory mediators. Despite the emerging evidence for the mechanistic contribution of neutrophils to early atherosclerosis in mice, their role in human atherogenesis, atheroprogression, and atherosclerotic plaque destabilization is still poorly understood. This brief review will summarize latest findings on the role of neutrophils in atherosclerosis and will pay special attention to studies describing a translation approach by combining measurements in mouse and human.</AbstractText>
                <CopyrightInformation>?? 2014 American Heart Association, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>D??ring</LastName>
                    <ForeName>Yvonne</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., M.D., O.S., C.W.); Department of Pathology, Academic Medical Center, Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (O.S., C.W.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Drechsler</LastName>
                    <ForeName>Maik</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., M.D., O.S., C.W.); Department of Pathology, Academic Medical Center, Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (O.S., C.W.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Soehnlein</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., M.D., O.S., C.W.); Department of Pathology, Academic Medical Center, Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (O.S., C.W.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Weber</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., M.D., O.S., C.W.); Department of Pathology, Academic Medical Center, Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (O.S., C.W.). chweber@med.lmu.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
            <NlmUniqueID>9505803</NlmUniqueID>
            <ISSNLinking>1079-5642</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">atherosclerosis</Keyword>
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">leukocyte</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ATVBAHA.114.303564</ArticleId>
            <ArticleId IdType="doi">10.1161/ATVBAHA.114.303564</ArticleId>
            <ArticleId IdType="pubmed">25147339</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147336</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4636</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
                <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nucleoside Diphosphate Kinase B Regulates Angiogenesis Through Modulation of Vascular Endothelial Growth Factor Receptor Type 2 and Endothelial Adherens Junction Proteins.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ATVBAHA.114.304239</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Nucleoside diphosphate kinase B (NDPKB) participates in the activation of heterotrimeric and monomeric G proteins, which are pivotal mediators in angiogenic signaling. The role of NDPKB in angiogenesis has to date not been defined. Therefore, we analyzed the contribution of NDPKB to angiogenesis and its underlying mechanisms in well-characterized in vivo and in vitro models.</AbstractText>
                <AbstractText Label="APPROACH AND RESULTS" NlmCategory="UNASSIGNED">Zebrafish embryos were depleted of NDPKB by morpholino-mediated knockdown. These larvae displayed severe malformations specifically in vessels formed by angiogenesis. NDPKB-deficient (NDPKB(-/-)) mice were subjected to oxygen-induced retinopathy. In this model, the number of preretinal neovascularizations in NDPKB(-/-) mice was strongly reduced in comparison with wild-type littermates. In accordance, a delayed blood flow recovery was detected in the NDPKB(-/-) mice after hindlimb ligation. In in vitro studies, a small interfering RNA-mediated knockdown of NDPKB was performed in human umbilical endothelial cells. NDPKB depletion impaired vascular endothelial growth factor (VEGF)-induced sprouting and hampered the VEGF-induced spatial redistributions of the VEGF receptor type 2 and VE-cadherin at the plasma membrane. Concomitantly, NDPKB depletion increased the permeability of the human umbilical endothelial cell monolayer.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first report to show that NDPKB is required for VEGF-induced angiogenesis and contributes to the correct localization of VEGF receptor type 2 and VE-cadherin at the endothelial adherens junctions. Therefore, our data identify NDPKB as a novel molecular target to modulate VEGF-dependent angiogenesis.</AbstractText>
                <CopyrightInformation>?? 2014 American Heart Association, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Feng</LastName>
                    <ForeName>Yuxi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Gross</LastName>
                    <ForeName>Shalini</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Wolf</LastName>
                    <ForeName>Nadine M</ForeName>
                    <Initials>NM</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Butensch??n</LastName>
                    <ForeName>Vicki M</ForeName>
                    <Initials>VM</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Qiu</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Devraj</LastName>
                    <ForeName>Kavi</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Liebner</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Kroll</LastName>
                    <ForeName>Jens</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Skolnik</LastName>
                    <ForeName>Edward Y</ForeName>
                    <Initials>EY</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Hammes</LastName>
                    <ForeName>Hans-Peter</ForeName>
                    <Initials>HP</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Wieland</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>From the Institute of Experimental and Clinical Pharmacology and Toxicology (Y.F., S.G., N.M.W., V.M.B., Y.Q., T.W.), Department of Vascular Biology and Tumor Angiogenesis (J.K.), and the Fifth Medical Clinic (H.-P.H.), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt, Germany, (K.D., S.L.); and Division of Nephrology, New York University Langone Medical Center, New York (E.Y.S.). thomas.wieland@medma.uni-heidelberg.de.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
            <NlmUniqueID>9505803</NlmUniqueID>
            <ISSNLinking>1079-5642</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">nucleoside-diphosphate kinase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ATVBAHA.114.304239</ArticleId>
            <ArticleId IdType="doi">10.1161/ATVBAHA.114.304239</ArticleId>
            <ArticleId IdType="pubmed">25147336</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147334</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4636</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Arteriosclerosis, thrombosis, and vascular biology</Title>
                <ISOAbbreviation>Arterioscler. Thromb. Vasc. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>RUC-4: A Novel ??IIb??3 Antagonist for Prehospital Therapy of Myocardial Infarction.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ATVBAHA.114.303724</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Treatment of myocardial infarction within the first 1 to 2 hours with a thrombolytic agent, percutaneous coronary intervention, or an ??IIb??3 antagonist decreases mortality and the later development of heart failure. We previously reported on a novel small molecule ??IIb??3 antagonist, RUC-2, that has a unique mechanism of action. We have now developed a more potent and more soluble congener of RUC-2, RUC-4, designed to be easily administered intramuscularly by autoinjector to facilitate its use in the prehospital setting. Here, we report the properties of RUC-4 and the antiplatelet and antithrombotic effects of RUC-2 and RUC-4 in animal models.</AbstractText>
                <AbstractText Label="APPROACH AND RESULTS" NlmCategory="UNASSIGNED">RUC-4 was ???20% more potent than RUC-2 in inhibiting human ADP-induced platelet aggregation and much more soluble in aqueous solutions (60-80 mg/mL). It shared RUC-2's specificity for ??IIb??3 versus ??V??3, did not prime the receptor to bind fibrinogen, or induce changes in ??3 identified by a conformation-specific monoclonal antibody. Both RUC-2 and RUC-4 prevented FeCl3-induced thrombotic occlusion of the carotid artery in mice and decreased microvascular thrombi in response to laser injury produced by human platelets infused into transgenic mice containing a mutated von Willebrand factor that reacts with human but not mouse platelets. Intramuscular injection of RUC-4 in nonhuman primates at 1.9 and 3.85 mg/kg led to complete inhibition of platelet aggregation within 15 minutes, with dose-dependent return of platelet aggregation after 4.5 to 24 hours.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">RUC-4 has favorable biochemical, pharmacokinetic, pharmacodynamic, antithrombotic, and solubility properties as a prehospital therapy of myocardial infarction, but the possibility of increased bleeding with therapeutic doses remains to be evaluated.</AbstractText>
                <CopyrightInformation>?? 2014 American Heart Association, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Jihong</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Vootukuri</LastName>
                    <ForeName>Spandana</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Shang</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Negri</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Jian-Kang</ForeName>
                    <Initials>JK</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Nedelman</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Diacovo</LastName>
                    <ForeName>Thomas G</ForeName>
                    <Initials>TG</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Filizola</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Thomas</LastName>
                    <ForeName>Craig J</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.).</Affiliation>
                </Author>
                <Author>
                    <LastName>Coller</LastName>
                    <ForeName>Barry S</ForeName>
                    <Initials>BS</Initials>
                    <Affiliation>From the Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY (J.L., S.V., B.S.C.); Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY (Y.S., A.N., M.F.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD (J.-k.J., C.J.T.); Ekam Imaging, Boston, MA (M.N.); and Departments of Pediatrics and Pathology, Columbia University Medical Center, New York, NY (T.G.D.). collerb@rockefeller.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA>
            <NlmUniqueID>9505803</NlmUniqueID>
            <ISSNLinking>1079-5642</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">blood platelets</Keyword>
            <Keyword MajorTopicYN="N">myocardial infarction</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ATVBAHA.114.303724</ArticleId>
            <ArticleId IdType="doi">10.1161/ATVBAHA.114.303724</ArticleId>
            <ArticleId IdType="pubmed">25147334</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147298</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1754-8411</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Disease models &amp; mechanisms</Title>
                <ISOAbbreviation>Dis Model Mech</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-?? deficiency.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1083-91</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1242/dmm.014878</ELocationID>
            <Abstract>
                <AbstractText>Glycogen storage disease type 1a (GSD-1a) is caused by a deficiency in glucose-6-phosphatase-?? (G6Pase-??), and is characterized by impaired glucose homeostasis and a high risk of developing hepatocellular adenomas (HCAs). A globally G6Pase-??-deficient (G6pc(-/-)) mouse model that shows pathological features similar to those of humans with GSD-1a has been developed. These mice show a very severe phenotype of disturbed glucose homeostasis and rarely live beyond weaning. We generated liver-specific G6Pase-??-deficient (LS???G6pc(-/-)) mice as an alternative animal model for studying the long-term pathophysiology of the liver and the potential treatment strategies, such as cell therapy. LS???G6pc(-/-) mice were viable and exhibited normal glucose profiles in the fed state, but showed significantly lower blood glucose levels than their control littermates after 6 hours of fasting. LS???G6pc(-/-) mice developed hepatomegaly with glycogen accumulation and hepatic steatosis, and progressive hepatic degeneration. Ninety percent of the mice analyzed developed amyloidosis by 12 months of age. Finally, 25% of the mice sacrificed at age 10-20 months showed the presence of multiple HCAs and in one case late development of hepatocellular carcinoma (HCC). In conclusion, LS???G6pc(-/-) mice manifest hepatic symptoms similar to those of human GSD-1a and, therefore, represent a valid model to evaluate long-term liver pathogenesis of GSD-1a.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Resaz</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Laboratory of Molecular Biology, Istituto Gannina Gaslini, 16147 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vanni</LastName>
                    <ForeName>Cristina</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laboratory of Molecular Biology, Istituto Gannina Gaslini, 16147 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Segalerba</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Laboratory of Molecular Biology, Istituto Gannina Gaslini, 16147 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sementa</LastName>
                    <ForeName>Angela R</ForeName>
                    <Initials>AR</Initials>
                    <Affiliation>Department of Pediatric Pathology, Istituto Gannina Gaslini, 16147 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mastracci</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Surgical and Diagnostic Sciences (DISC), Anatomic Pathology Unit, University of Genova, 16132 Genova, Italy IRCCS AOU San Martino-IST, National Cancer Research Institute, 16132 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grillo</LastName>
                    <ForeName>Federica</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Surgical and Diagnostic Sciences (DISC), Anatomic Pathology Unit, University of Genova, 16132 Genova, Italy IRCCS AOU San Martino-IST, National Cancer Research Institute, 16132 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murgia</LastName>
                    <ForeName>Daniele</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Pediatric Pathology, Istituto Gannina Gaslini, 16147 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bosco</LastName>
                    <ForeName>Maria Carla</ForeName>
                    <Initials>MC</Initials>
                    <Affiliation>Laboratory of Molecular Biology, Istituto Gannina Gaslini, 16147 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chou</LastName>
                    <ForeName>Janice Y</ForeName>
                    <Initials>JY</Initials>
                    <Affiliation>Section on Cellular Differentiation, Program on Developmental Endocrinology and Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1830, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barbieri</LastName>
                    <ForeName>Ottavia</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>IRCCS AOU San Martino-IST, National Cancer Research Institute, 16132 Genova, Italy Department of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varesio</LastName>
                    <ForeName>Luigi</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Laboratory of Molecular Biology, Istituto Gannina Gaslini, 16147 Genova, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eva</LastName>
                    <ForeName>Alessandra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Laboratory of Molecular Biology, Istituto Gannina Gaslini, 16147 Genova, Italy alessandraeva@ospedale-gaslini.ge.it.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Dis Model Mech</MedlineTA>
            <NlmUniqueID>101483332</NlmUniqueID>
            <ISSNLinking>1754-8403</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Animal model</Keyword>
            <Keyword MajorTopicYN="N">Glucose-6-phosphatase-??</Keyword>
            <Keyword MajorTopicYN="N">Glycogen storage disease type 1a</Keyword>
            <Keyword MajorTopicYN="N">Hepatic steatosis</Keyword>
            <Keyword MajorTopicYN="N">Hepatocellular adenoma</Keyword>
            <Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
            <Keyword MajorTopicYN="N">Hepatomegaly</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">7/9/1083</ArticleId>
            <ArticleId IdType="doi">10.1242/dmm.014878</ArticleId>
            <ArticleId IdType="pubmed">25147298</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147297</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1754-8411</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Disease models &amp; mechanisms</Title>
                <ISOAbbreviation>Dis Model Mech</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1047-55</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1242/dmm.016030</ELocationID>
            <Abstract>
                <AbstractText>Reduced levels of brain-derived neurotrophic factor (BDNF) are thought to contribute to the pathophysiology of Rett syndrome (RTT), a severe neurodevelopmental disorder caused by loss-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2). In Mecp2 mutant mice, BDNF deficits have been associated with breathing abnormalities, a core feature of RTT, as well as with synaptic hyperexcitability within the brainstem respiratory network. Application of BDNF can reverse hyperexcitability in acute brainstem slices from Mecp2-null mice, suggesting that therapies targeting BDNF or its receptor, TrkB, could be effective at acute reversal of respiratory abnormalities in RTT. Therefore, we examined the ability of LM22A-4, a small-molecule BDNF loop-domain mimetic and TrkB partial agonist, to modulate synaptic excitability within respiratory cell groups in the brainstem nucleus tractus solitarius (nTS) and to acutely reverse abnormalities in breathing at rest and during behavioral arousal in Mecp2 mutants. Patch-clamp recordings in Mecp2-null brainstem slices demonstrated that LM22A-4 decreases excitability at primary afferent synapses in the nTS by reducing the amplitude of evoked excitatory postsynaptic currents and the frequency of spontaneous and miniature excitatory postsynaptic currents. In vivo, acute treatment of Mecp2-null and -heterozygous mutants with LM22A-4 completely eliminated spontaneous apneas in resting animals, without sedation. Moreover, we demonstrate that respiratory dysregulation during behavioral arousal, a feature of human RTT, is also reversed in Mecp2 mutants by acute treatment with LM22A-4. Together, these data support the hypothesis that reduced BDNF signaling and respiratory dysfunction in RTT are linked, and establish the proof-of-concept that treatment with a small-molecule structural mimetic of a BDNF loop domain and a TrkB partial agonist can acutely reverse abnormal breathing at rest and in response to behavioral arousal in symptomatic RTT mice.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kron</LastName>
                    <ForeName>Miriam</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lang</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adams</LastName>
                    <ForeName>Ian T</ForeName>
                    <Initials>IT</Initials>
                    <Affiliation>Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sceniak</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Longo</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Katz</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                    <Affiliation>Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA david.katz@case.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Dis Model Mech</MedlineTA>
            <NlmUniqueID>101483332</NlmUniqueID>
            <ISSNLinking>1754-8403</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Arousal</Keyword>
            <Keyword MajorTopicYN="N">Brain-derived neurotrophic factor (BDNF)</Keyword>
            <Keyword MajorTopicYN="N">Brainstem</Keyword>
            <Keyword MajorTopicYN="N">Mecp2</Keyword>
            <Keyword MajorTopicYN="N">Respiration</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">7/9/1047</ArticleId>
            <ArticleId IdType="doi">10.1242/dmm.016030</ArticleId>
            <ArticleId IdType="pubmed">25147297</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147296</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1754-8411</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Disease models &amp; mechanisms</Title>
                <ISOAbbreviation>Dis Model Mech</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1033-1046</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Systemic lupus erythematosus (SLE) represents a challenging autoimmune disease from a clinical perspective because of its varied forms of presentation. Although broad-spectrum steroids remain the standard treatment for SLE, they have many side effects and only provide temporary relief from the symptoms of the disease. Thus, gaining a deeper understanding of the genetic traits and biological pathways that confer susceptibility to SLE will help in the design of more targeted and effective therapeutics. Both human genome-wide association studies (GWAS) and investigations using a variety of mouse models of SLE have been valuable for the identification of the genes and pathways involved in pathogenesis. In this Review, we link human susceptibility genes for SLE with biological pathways characterized in mouse models of lupus, and discuss how the mechanistic insights gained could advance drug discovery for the disease.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Crampton</LastName>
                    <ForeName>Steve P</ForeName>
                    <Initials>SP</Initials>
                    <Affiliation>Laboratory of Immunogenetics, National Institute of Allergic and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morawski</LastName>
                    <ForeName>Peter A</ForeName>
                    <Initials>PA</Initials>
                    <Affiliation>Laboratory of Immunogenetics, National Institute of Allergic and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bolland</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Laboratory of Immunogenetics, National Institute of Allergic and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA sbolland@niaid.nih.gov.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>REVIEW</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Dis Model Mech</MedlineTA>
            <NlmUniqueID>101483332</NlmUniqueID>
            <ISSNLinking>1754-8403</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Human genetics</Keyword>
            <Keyword MajorTopicYN="N">Lupus</Keyword>
            <Keyword MajorTopicYN="N">Mouse models</Keyword>
            <Keyword MajorTopicYN="N">SLE</Keyword>
            <Keyword MajorTopicYN="N">Susceptibility genes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">7/9/1033</ArticleId>
            <ArticleId IdType="doi">10.1242/dmm.016451</ArticleId>
            <ArticleId IdType="pubmed">25147296</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147295</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2083</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The severity of retinal pathology in homozygous Crb1rd8/rd8 mice is dependent on additional genetic factors.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ddu424</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Understanding phenotype-genotype correlations in retinal degeneration is a major challenge. Mutations in CRB1 lead to a spectrum of autosomal recessive retinal dystrophies with variable phenotypes suggesting the influence of modifying factors. To establish the contribution of the genetic background to phenotypic variability associated with the Crb1(rd8/rd8) mutation, we compared the retinal pathology of Crb1(rd8/rd8)/J inbred mice with that of two Crb1(rd8/rd8) lines backcrossed with C57BL/6JOlaHsd mice. TEFI and SLO fundus images of all three Crb1(rd8/rd8) lines showed a significant increase in the number of inferior retinal lesions that was strikingly variable between the lines. OCT, semithin, ultrastructural morphology and assessment of inflammatory and vascular marker by immunohistochemistry and quantitative RT-PCR revealed that the lesions were associated with photoreceptor death, M??ller- and microglia activation and telangiectasia-like vascular remodelling - features that were stable in the inbred, variable in the second, but virtually absent in the third Crb1(rd8/rd8) line, even at 12 months of age. This suggests that the Crb1(rd8/rd8) mutation is necessary, but not sufficient for the development of these degenerative features. By whole-genome SNP analysis of the genotype-phenotype correlation, a candidate region on chromosome 15 was identified. This may carry one or more genetic modifiers for the manifestation of the retinal pathology associated with mutations in Crb1. This study also provides insight into the nature of the retinal vascular lesions that likely represent a clinical correlate for the formation of retinal telangiectasia or Coats' like vasculopathy in patients with CRB1 mutations that are thought to depend on such genetic modifiers.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Luhmann</LastName>
                    <ForeName>Ulrich F</ForeName>
                    <Initials>UF</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom u.luhmann@ucl.ac.uk.</Affiliation>
                </Author>
                <Author>
                    <LastName>Carvalho</LastName>
                    <ForeName>Livia S</ForeName>
                    <Initials>LS</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kleine Holthaus</LastName>
                    <ForeName>Sophia-Martha</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom MRC Laboratory for Molecular Cell Biology, University College London, London WC1E 6BT, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cowing</LastName>
                    <ForeName>Jill A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Greenaway</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Imaging Unit, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chu</LastName>
                    <ForeName>Colin J</ForeName>
                    <Initials>CJ</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Herrmann</LastName>
                    <ForeName>Philipp</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>Alexander J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Munro</LastName>
                    <ForeName>Peter M G</ForeName>
                    <Initials>PM</Initials>
                    <Affiliation>Imaging Unit, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Potter</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Mammalian Genetics Unit, MRC Harwell, Oxfordshire OX11 ORD, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bainbridge</LastName>
                    <ForeName>James W B</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ali</LastName>
                    <ForeName>Robin R</ForeName>
                    <Initials>RR</Initials>
                    <Affiliation>Department of Genetics, UCL Institute of Ophthalmology, London EC1V 9EL, United Kingdom NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, United Kingdom.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ddu424</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/ddu424</ArticleId>
            <ArticleId IdType="pubmed">25147295</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147279</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1095-9203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Science (New York, N.Y.)</Title>
                <ISOAbbreviation>Science</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aging-induced type I interferon response at the choroid plexus negatively affects brain function.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">1252945</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Aging-associated cognitive decline is affected by factors produced inside and outside the brain. Using multi-organ genome-wide analysis of aged mice, we found that the choroid plexus, an interface between the brain and the circulation, shows a type I interferon (IFN-I)-dependent gene expression profile, which was also found in aged human brains. In aged mice, this response was induced by brain-derived signals, present in the cerebrospinal fluid. Blocking IFN-I signaling within the aged brain, partially restored cognitive function and hippocampal neurogenesis, and re-established IFN-II-dependent choroid plexus activity, lost in aging. Our data identify a chronic aging-induced IFN-I signature, often associated with anti-viral response, at the brain's choroid plexus, and demonstrate its negative influence on brain function, thereby suggesting a target for ameliorating cognitive decline in aging.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for the Advancement of Science.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Baruch</LastName>
                    <ForeName>Kuti</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Deczkowska</LastName>
                    <ForeName>Aleksandra</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>David</LastName>
                    <ForeName>Eyal</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Castellano</LastName>
                    <ForeName>Joseph M</ForeName>
                    <Initials>JM</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Miller</LastName>
                    <ForeName>Omer</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kertser</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Berkutzki</LastName>
                    <ForeName>Tamara</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Barnett-Itzhaki</LastName>
                    <ForeName>Zohar</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bezalel</LastName>
                    <ForeName>Dana</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wyss-Coray</LastName>
                    <ForeName>Tony</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Amit</LastName>
                    <ForeName>Ido</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schwartz</LastName>
                    <ForeName>Michal</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Science</MedlineTA>
            <NlmUniqueID>0404511</NlmUniqueID>
            <ISSNLinking>0036-8075</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">science.1252945</ArticleId>
            <ArticleId IdType="doi">10.1126/science.1252945</ArticleId>
            <ArticleId IdType="pubmed">25147279</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147274</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-009X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Drug metabolism and disposition: the biological fate of chemicals</Title>
                <ISOAbbreviation>Drug Metab. Dispos.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adaptive Hepatic and Intestinal Alterations in Mice after Deletion of NADPH-Cytochrome P450 Oxidoreductase (Cpr) in Hepatocytes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">dmd.114.060053</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cytochrome P450 enzymes (Cyps) play important roles in first-pass metabolism in both the intestine and liver. NADPH-cytochrome P450 oxidoreductase (Cpr) is an essential electron transfer protein required for microsomal CYP activity. Mice with conditional knockout of Cpr in hepatocytes develop normally and survive even with complete loss of liver microsomal CYP activity. The current studies were performed to determine whether alternative drug-metabolizing pathways increase in an attempt to maintain whole-body homeostasis. In addition to liver, Cpr is mainly expressed in tissues such as lung, kidney, and gastrointestinal tract. In livers of H-Cpr-null mice, there is a marked increase in mRNA expression of phase-I enzymes (Aldh1a1, 1a7, 3a2; Ces1b2, 2a6, and 2a12), antioxidant enzymes (Ho-1, Nqo1, and epoxide hydrolase), phase-II enzymes (Ugt1a9; Gsta1/2, m3, m4, m6, t1, and t3; and Sult1a1 and 1d1), and drug transporters (Oatp1a4, Oct3, Mate1, Mdr1a, and Mrp3 and 4). In addition, glucuronide-conjugated bilirubin concentrations are doubled in serum of H-Cpr-null mice. Both CAR and Nrf2 protein in nuclei are higher in livers of H-Cpr-null mice, indicating that CAR and Nrf2 are activated. In the small intestine of H-Cpr-null mice, mRNA expression of Cyp3a11 and Mdr1a, two genes critical for intestinal first-pass metabolism, are markedly up-regulated. In addition, nutrient (Pept1) and cholesterol (Npc1l1) transporters are induced in the small intestine of H-Cpr-null mice. In conclusion, in H-Cpr-null mice, adaptive regulation of alternative detoxification genes in liver and small intestine appear to partially compensate for the loss of microsomal Cyp function in liver.</AbstractText>
                <CopyrightInformation>The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>Xingguo</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>St. John's University;</Affiliation>
                </Author>
                <Author>
                    <LastName>Gu</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Wadsworth Center;</Affiliation>
                </Author>
                <Author>
                    <LastName>Klaassen</LastName>
                    <ForeName>Curtis D</ForeName>
                    <Initials>CD</Initials>
                    <Affiliation>University of Kansas Medical Center cdkcorvette@gmail.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Drug Metab Dispos</MedlineTA>
            <NlmUniqueID>9421550</NlmUniqueID>
            <ISSNLinking>0090-9556</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">NADPH cytochrome P450 reductase</Keyword>
            <Keyword MajorTopicYN="N">cytochrome P450</Keyword>
            <Keyword MajorTopicYN="N">enzyme induction</Keyword>
            <Keyword MajorTopicYN="N">nuclear receptors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dmd.114.060053</ArticleId>
            <ArticleId IdType="doi">10.1124/dmd.114.060053</ArticleId>
            <ArticleId IdType="pubmed">25147274</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147246</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1477-9145</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of experimental biology</Title>
                <ISOAbbreviation>J. Exp. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Titin force is enhanced in actively stretched skeletal muscle.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jeb.105361</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The sliding filament theory of muscle contraction is widely accepted as the means by which muscles generate force during activation. Within the constraints of this theory, isometric, steady-state force produced during muscle activation is proportional to the amount of filament overlap. Previous studies from our laboratory demonstrated enhanced titin-based force in myofibrils that were actively stretched to lengths which exceeded filament overlap. This observation cannot be explained by the sliding filament theory. The aim of the present study was to further investigate the enhanced state of titin during active stretch. Specifically, we confirm that this enhanced state of force is observed in a mouse model and quantify the contribution of calcium to this force. Titin-based force was increased by up to four times that of passive force during active stretch of isolated myofibrils. Enhanced titin-based force has now been demonstrated in two distinct animal models, suggesting that modulation of titin-based force during active stretch is an inherent property of skeletal muscle. Our results also demonstrated that 15% of titin's enhanced state can be attributed to direct calcium effects on the protein, presumably a stiffening of the protein upon calcium binding to the E-rich region of the PEVK segment and selected Ig domain segments. We suggest that the remaining unexplained 85% of this extra force results from titin binding to the thin filament. With this enhanced force confirmed in the mouse model, future studies will aim to elucidate the proposed titin-thin filament interaction in actively stretched sarcomeres.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Powers</LastName>
                    <ForeName>Krysta</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>University of Calgary, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Schappacher-Tilp</LastName>
                    <ForeName>Gudrun</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Karl-Franzens-University Graz, Austria;</Affiliation>
                </Author>
                <Author>
                    <LastName>Jinha</LastName>
                    <ForeName>Azim</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University of Calgary, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Leonard</LastName>
                    <ForeName>Tim</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>University of Calgary, Canada;</Affiliation>
                </Author>
                <Author>
                    <LastName>Nishikawa</LastName>
                    <ForeName>Kiisa</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Northern Arizona University, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Herzog</LastName>
                    <ForeName>Walter</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>University of Calgary, Canada; wherzog@ucalgary.ca.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Exp Biol</MedlineTA>
            <NlmUniqueID>0243705</NlmUniqueID>
            <ISSNLinking>0022-0949</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jeb.105361</ArticleId>
            <ArticleId IdType="doi">10.1242/jeb.105361</ArticleId>
            <ArticleId IdType="pubmed">25147246</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147245</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1477-9145</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of experimental biology</Title>
                <ISOAbbreviation>J. Exp. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The relationship between cardiopulmonary size and aerobic performance in adult deer mice at high altitude.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jeb.103713</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Deer mice (Peromyscus maniculatus sonoriensis) populations in the White Mountains of Eastern California are found across a substantial range of partial pressures of oxygen (pO2). Reduction in pO2 at high altitude can have a negative impact on aerobic performance. We studied plastic changes in organ mass and volume involved in aerobic respiration in response to acclimation to high altitude, and how those changes are matched with aerobic performance measured by VO2 max. Adult deer mice born and raised at 340 m were acclimated at either 340 m or 3800 m for a period of nine weeks. Lung volume increased by 9% in mice acclimated to high altitude. VO2 max was also significantly higher under hypoxic conditions after high altitude acclimation compared to controls. Body mass corrected residuals of VO2 max were significantly correlated with an index of cardiopulmonary size (summed standardized residuals of lung volume and heart mass) under both hypoxic and normoxic conditions. These data show that phenotypic plasticity in lung volume and heart mass plays an important role in maintaining aerobic performance under hypoxic conditions, and account for up to 55% of the variance in aerobic performance.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Shirkey</LastName>
                    <ForeName>Nicholas J</ForeName>
                    <Initials>NJ</Initials>
                    <Affiliation>University of California Riverside, United States nshir001@ucr.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hammond</LastName>
                    <ForeName>Kimberly A</ForeName>
                    <Initials>KA</Initials>
                    <Affiliation>University of California Riverside, United States.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Exp Biol</MedlineTA>
            <NlmUniqueID>0243705</NlmUniqueID>
            <ISSNLinking>0022-0949</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jeb.103713</ArticleId>
            <ArticleId IdType="doi">10.1242/jeb.103713</ArticleId>
            <ArticleId IdType="pubmed">25147245</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147239</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1469-9001</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>RNA (New York, N.Y.)</Title>
                <ISOAbbreviation>RNA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Detecting translational regulation by change point analysis of ribosome profiling data sets.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Ribo-Seq maps the location of translating ribosomes on mature mRNA transcripts. While during normal translation, ribosome density is constant along the length of the mRNA coding region, this can be altered in response to translational regulatory events. In the present study, we developed a method to detect translational regulation of individual mRNAs from their ribosome profiles, utilizing changes in ribosome density. We used mathematical modeling to show that changes in ribosome density should occur along the mRNA at the point of regulation. We analyzed a Ribo-Seq data set obtained for mouse embryonic stem cells and showed that normalization by corresponding RNA-Seq can be used to improve the Ribo-Seq quality by removing bias introduced by deep-sequencing and alignment artifacts. After normalization, we applied a change point algorithm to detect changes in ribosome density present in individual mRNA ribosome profiles. Additional sequence and gene isoform information obtained from the UCSC Genome Browser allowed us to further categorize the detected changes into different mechanisms of regulation. In particular, we detected several mRNAs with known post-transcriptional regulation, e.g., premature termination for selenoprotein mRNAs and translational control of Atf4, but also several more mRNAs with hitherto unknown translational regulation. Additionally, our approach proved useful for identification of new transcript isoforms.</AbstractText>
                <CopyrightInformation>?? 2014 Zupanic et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zupanic</LastName>
                    <ForeName>Anze</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Centre for Integrated Systems Biology of Ageing and Nutrition, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, NE4 5PL, United Kingdom Department of Environmental Toxicology, Eawag: Swiss Federal Institute of Aquatic Science and Technology, 8600 D??bendorf, Switzerland daryl.shanley@ncl.ac.uk anze.zupanic@eawag.ch.</Affiliation>
                </Author>
                <Author>
                    <LastName>Meplan</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Institute for Cell and Molecular Biosciences and Human Nutrition Research Centre, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Grellscheid</LastName>
                    <ForeName>Sushma N</ForeName>
                    <Initials>SN</Initials>
                    <Affiliation>School of Biological and Biomedical Sciences, Durham University, Durham DH1 3LE, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mathers</LastName>
                    <ForeName>John C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Centre for Integrated Systems Biology of Ageing and Nutrition, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, NE4 5PL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kirkwood</LastName>
                    <ForeName>Tom B L</ForeName>
                    <Initials>TB</Initials>
                    <Affiliation>Centre for Integrated Systems Biology of Ageing and Nutrition, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, NE4 5PL, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hesketh</LastName>
                    <ForeName>John E</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Institute for Cell and Molecular Biosciences and Human Nutrition Research Centre, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, United Kingdom.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shanley</LastName>
                    <ForeName>Daryl P</ForeName>
                    <Initials>DP</Initials>
                    <Affiliation>Centre for Integrated Systems Biology of Ageing and Nutrition, Institute for Ageing and Health, Newcastle University, Newcastle-upon-Tyne, NE4 5PL, United Kingdom daryl.shanley@ncl.ac.uk anze.zupanic@eawag.ch.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>RNA</MedlineTA>
            <NlmUniqueID>9509184</NlmUniqueID>
            <ISSNLinking>1355-8382</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">change point analysis</Keyword>
            <Keyword MajorTopicYN="N">mathematical modeling</Keyword>
            <Keyword MajorTopicYN="N">ribosome profiling</Keyword>
            <Keyword MajorTopicYN="N">translation regulation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">rna.045286.114</ArticleId>
            <ArticleId IdType="doi">10.1261/rna.045286.114</ArticleId>
            <ArticleId IdType="pubmed">25147239</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147234</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1547</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Gastrointestinal and liver physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Gastrointest. Liver Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Oxytocin regulates gastrointestinal motility, inflammation, macromolecular permeability, and mucosal maintenance in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajpgi.00176.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Enteric neurons express oxytocin (OT); moreover, enteric neurons and enterocytes express developmentally regulated oxytocin receptors (OTRs). Although OT (with secretin) opposes intestinal inflammation, physiological roles played by enteric OT/OTR signaling have not previously been determined. We tested hypotheses that OT/OTR signaling contributes to enteric nervous system (ENS)-related gastrointestinal (GI) physiology. GI functions and OT effects were compared in OTR-deleted (OTRKO) and wild-type (WT) mice. Stool mass and water content were greater in OTRKO mice than in WT. GI transit time in OTRKO animals was faster than in WT; OT inhibited in vitro generation of ENS-dependent colonic migrating motor complexes in WT but not in OTRKO mice. Myenteric neurons were hyperplastic in OTRKO animals and mucosal exposure to cholera toxin (CTX) in vitro activated Fos in more myenteric neurons in OTRKO than in WT mice; OT inhibited the CTX response in WT but not in OTRKO mice. Villi and crypts were shorter in OTRKO than in WT mice and transit amplifying cell proliferation in OTRKO crypts was deficient. Macromolecular intestinal permeability in OTRKO &gt; WT mice and experimental colitis was more severe in OTRKO mice; moreover, OT protected WT animals from colitis. Observations suggest that OT/OTR signaling acts as a brake on intestinal motility, decreases mucosal activation of enteric neurons, and promotes enteric neuronal development and/or survival. It also regulates proliferation of crypt cells and mucosal permeability; moreover OT/OTR signaling is protective against inflammation. Oxytocinergic signaling may play an important role in multiple GI functions that are subject to neuronal regulation.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology- Gastrointestinal and Liver Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Welch</LastName>
                    <ForeName>Martha G</ForeName>
                    <Initials>MG</Initials>
                    <Affiliation>Columbia University mgw13@cumc.columbia.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Margolis</LastName>
                    <ForeName>Kara G</ForeName>
                    <Initials>KG</Initials>
                    <Affiliation>Columbia University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Zhishan</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Columbia University.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gershon</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <Affiliation>Columbia University.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Gastrointest Liver Physiol</MedlineTA>
            <NlmUniqueID>100901227</NlmUniqueID>
            <ISSNLinking>0193-1857</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">colitis</Keyword>
            <Keyword MajorTopicYN="N">enteric nervous system</Keyword>
            <Keyword MajorTopicYN="N">nurture</Keyword>
            <Keyword MajorTopicYN="N">oxytocin receptor knockout</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajpgi.00176.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpgi.00176.2014</ArticleId>
            <ArticleId IdType="pubmed">25147234</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147230</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1547</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Gastrointestinal and liver physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Gastrointest. Liver Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hepatic entrapment of esterified cholesterol drives continual expansion of whole-body sterol pool in lysosomal acid lipase-deficient mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">ajpgi.00243.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Cholesteryl ester storage disease (CESD) results from loss-of-function mutations in LIPA, the gene that encodes lysosomal acid lipase (LAL). Hepatomegaly and deposition of esterified cholesterol (EC) in multiple organs ensue. The present studies quantitated rates of synthesis, absorption, and disposition of cholesterol, and whole-body cholesterol pool size in a mouse model of CESD. In 50-day old lal(-/-) and matching lal(+/+) mice fed a low-cholesterol diet, whole-animal cholesterol content equalled 210 and 50 mg, respectively, indicating that since birth the lal(-/-) mice sequestered cholesterol at an average rate of 3.2 mg/day/animal. The proportion of the body sterol pool contained in the liver of the lal(-/-) mice was 64% vs 6.3% in their lal(+/+) controls. Esterified cholesterol (EC) concentrations in the liver, spleen, small intestine, and lungs of the lal(-/-) mice were elevated 100-, 35-, 15-, and 6-fold, respectively. In the lal(-/-) mice, whole-liver cholesterol synthesis increased 10.2-fold, resulting in a 3.2-fold greater rate of whole-animal sterol synthesis compared to their lal(+/+) controls. The rate of cholesterol synthesis in the lal(-/-) mice exceeded that in the lal(+/+) controls by 3.7 mg/day/animal. Fractional cholesterol absorption and fecal bile acid excretion were unchanged in the lal(-/-) mice, but their rate of neutral sterol excretion was 59% higher than in their lal(+/+) controls. Thus, in this model, the continual expansion of the body sterol pool is driven by the synthesis of excess cholesterol, primarily in the liver. Despite the severity of their disease, the median lifespan of the lal(-/-) mice was 355 days.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Journal of Physiology- Gastrointestinal and Liver Physiology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Aqul</LastName>
                    <ForeName>Amal</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lopez</LastName>
                    <ForeName>Adam M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Posey</LastName>
                    <ForeName>Kenneth S</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Taylor</LastName>
                    <ForeName>Anna M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author>
                    <LastName>Repa</LastName>
                    <ForeName>Joyce J</ForeName>
                    <Initials>JJ</Initials>
                    <Affiliation>UT Southwestern.</Affiliation>
                </Author>
                <Author>
                    <LastName>Burns</LastName>
                    <ForeName>Dennis K</ForeName>
                    <Initials>DK</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Turley</LastName>
                    <ForeName>Stephen D</ForeName>
                    <Initials>SD</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center stephen.turley@utsouthwestern.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Physiol Gastrointest Liver Physiol</MedlineTA>
            <NlmUniqueID>100901227</NlmUniqueID>
            <ISSNLinking>0193-1857</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cholesterol synthesis</Keyword>
            <Keyword MajorTopicYN="N">esterified cholesterol</Keyword>
            <Keyword MajorTopicYN="N">hepatomegaly</Keyword>
            <Keyword MajorTopicYN="N">lysosomal storage disease</Keyword>
            <Keyword MajorTopicYN="N">sterol balance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ajpgi.00243.2014</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpgi.00243.2014</ArticleId>
            <ArticleId IdType="pubmed">25147230</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147209</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1362-4962</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nucleic acids research</Title>
                <ISOAbbreviation>Nucleic Acids Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A 'tool box' for deciphering neuronal circuits in the developing chick spinal cord.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">gku750</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The genetic dissection of spinal circuits is an essential new means for understanding the neural basis of mammalian behavior. Molecular targeting of specific neuronal populations, a key instrument in the genetic dissection of neuronal circuits in the mouse model, is a complex and time-demanding process. Here we present a circuit-deciphering 'tool box' for fast, reliable and cheap genetic targeting of neuronal circuits in the developing spinal cord of the chick. We demonstrate targeting of motoneurons and spinal interneurons, mapping of axonal trajectories and synaptic targeting in both single and populations of spinal interneurons, and viral vector-mediated labeling of pre-motoneurons. We also demonstrate fluorescent imaging of the activity pattern of defined spinal neurons during rhythmic motor behavior, and assess the role of channel rhodopsin-targeted population of interneurons in rhythmic behavior using specific photoactivation.</AbstractText>
                <CopyrightInformation>?? The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hadas</LastName>
                    <ForeName>Yoav</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Medical Neurobiology, IMRIC, Hebrew University Medical School, Jerusalem, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Etlin</LastName>
                    <ForeName>Alex</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medical Neurobiology, IMRIC, Hebrew University Medical School, Jerusalem, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Falk</LastName>
                    <ForeName>Haya</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Medical Neurobiology, IMRIC, Hebrew University Medical School, Jerusalem, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Avraham</LastName>
                    <ForeName>Oshri</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Medical Neurobiology, IMRIC, Hebrew University Medical School, Jerusalem, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kobiler</LastName>
                    <ForeName>Oren</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Panet</LastName>
                    <ForeName>Amos</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Biochemistry, IMRIC, Hebrew University Medical School, Jerusalem, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lev-Tov</LastName>
                    <ForeName>Aharon</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medical Neurobiology, IMRIC, Hebrew University Medical School, Jerusalem, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Klar</LastName>
                    <ForeName>Avihu</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Medical Neurobiology, IMRIC, Hebrew University Medical School, Jerusalem, Israel avihu@cc.huji.ac.il.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nucleic Acids Res</MedlineTA>
            <NlmUniqueID>0411011</NlmUniqueID>
            <ISSNLinking>0305-1048</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">gku750</ArticleId>
            <ArticleId IdType="doi">10.1093/nar/gku750</ArticleId>
            <ArticleId IdType="pubmed">25147209</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147187</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2157-1422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cold Spring Harbor perspectives in medicine</Title>
                <ISOAbbreviation>Cold Spring Harb Perspect Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Curing Color Blindness-Mice and Nonhuman Primates.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">a017418</ELocationID>
            <ELocationID EIdType="doi">10.1101/cshperspect.a017418</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">It has been possible to use viral-mediated gene therapy to transform dichromatic (red-green color-blind) primates to trichromatic. Even though the third cone type was added after the end of developmental critical periods, treated animals acquired red-green color vision. What happened in the treated animals may represent a recapitulation of the evolution of trichromacy, which seems to have evolved with the acquisition of a third cone type without the need for subsequent modification to the circuitry. Some transgenic mice in which a third cone type was added also acquired trichromacy. However, compared with treated primates, red-green color vision in mice is poor, indicating large differences between mice and monkeys in their ability to take advantage of the new input. These results have implications for understanding the limits and opportunities for using gene therapy to treat vision disorders caused by defects in cone function.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Cold Spring Harbor Laboratory Press; all rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Neitz</LastName>
                    <ForeName>Maureen</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Ophthalmology, University of Washington, Seattle, Washington 98109.</Affiliation>
                </Author>
                <Author>
                    <LastName>Neitz</LastName>
                    <ForeName>Jay</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Ophthalmology, University of Washington, Seattle, Washington 98109.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cold Spring Harb Perspect Med</MedlineTA>
            <NlmUniqueID>101571139</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cshperspect.a017418</ArticleId>
            <ArticleId IdType="doi">10.1101/cshperspect.a017418</ArticleId>
            <ArticleId IdType="pubmed">25147187</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147180</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fucosylated chondroitin sulfates from the body wall of the sea cucumber Holothuria forskali. Conformation, selectin binding and biological activity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">jbc.M114.572297</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Fucosylated chondroitin sulfate (fCS) extracted from the sea cucumber Holothuria forskali is composed of the following repeating trisaccharide unit: ???3)GalNAc??4,6S(1???4) [Fuc??X(1???3)]GlcA??(1??? where X stands for different sulfation patterns of fucose (X = 3,4S (46%), 2,4S (39%) and 4S (15%)). As revealed by NMR and MD simulations, the fCS repeating unit adopts a conformation similar to that of the Lex blood group determinant, bringing several sulfate groups into close proximity and creating large negative patches distributed along the helical skeleton of the CS backbone. This may explain the high-affinity of fCS oligosaccharides for L- and P-selectins, as determined by microarray binding of fCS oligosaccharides prepared by Cu2+ catalysed Fenton type and photochemical depolymerization. No binding to E-selectin was observed. fCS poly- and oligosaccharides display low cytotoxicity in vitro, inhibit human neutrophil elastase activity and inhibit the migration of neutrophils through an endothelial cell layer in vitro. While the polysaccharide shows some anti-coagulant activity, small oligosaccharide fCS fragments have much reduced anticoagulant properties, with activity mainly via heparin cofactor II. The fCS polysaccharides showed prekallikrein activation comparable to dextran sulfate, whereas the fCS oligosaccharides caused almost no effect. The H. forskali fCS oligosaccharides were also tested in a mouse peritoneal inflammation model where they caused a reduction in neutrophil infiltration. Overall, the presented data support the action of fCS as an inhibitor of selectin interactions, which play vital roles in inflammation and metastasis progression. Future studies of fCS-selectin interaction may open new avenues for therapeutic intervention using fCS fragments or their mimetics.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, The American Society for Biochemistry and Molecular Biology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Panagos</LastName>
                    <ForeName>Charalambos</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>University of Edinbrugh, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Thomson</LastName>
                    <ForeName>Derek S</ForeName>
                    <Initials>DS</Initials>
                    <Affiliation>GlycoMar, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Moss</LastName>
                    <ForeName>Claire</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>GlycoMar, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Hughes</LastName>
                    <ForeName>Adam D</ForeName>
                    <Initials>AD</Initials>
                    <Affiliation>The Scottish Association for Marine Science, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Kelly</LastName>
                    <ForeName>Maeve S</ForeName>
                    <Initials>MS</Initials>
                    <Affiliation>The Scottish Association for Marine Science, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Imperial College London, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Chai</LastName>
                    <ForeName>Wengang</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Imperial College London, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Venkatasamy</LastName>
                    <ForeName>Radhakrishnan</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Kings College London, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Spina</LastName>
                    <ForeName>Domenico</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Kings College London, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Page</LastName>
                    <ForeName>Clive P</ForeName>
                    <Initials>CP</Initials>
                    <Affiliation>Kings College London, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Hogwood</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>National Institute of Biological Standards and Controls, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Woods</LastName>
                    <ForeName>Robert J</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>University of Georgia, United States;</Affiliation>
                </Author>
                <Author>
                    <LastName>Mulloy</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Imperial College London, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Bavington</LastName>
                    <ForeName>Charlie D</ForeName>
                    <Initials>CD</Initials>
                    <Affiliation>Glycomar, United Kingdom;</Affiliation>
                </Author>
                <Author>
                    <LastName>Uhrin</LastName>
                    <ForeName>Du??an</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>University of Edinburgh, United Kingdom dusan.uhrin@ed.ac.uk.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GAG</Keyword>
            <Keyword MajorTopicYN="N">carbohydrate structure</Keyword>
            <Keyword MajorTopicYN="N">carbohydrate-binding protein</Keyword>
            <Keyword MajorTopicYN="N">glycosaminoglycan</Keyword>
            <Keyword MajorTopicYN="N">inflammation</Keyword>
            <Keyword MajorTopicYN="N">microarray</Keyword>
            <Keyword MajorTopicYN="N">molecular dynamics</Keyword>
            <Keyword MajorTopicYN="N">nuclear magnetic resonance (NMR)</Keyword>
            <Keyword MajorTopicYN="N">selectin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25147180</ArticleId>
            <ArticleId IdType="pii">M114.572297</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M114.572297</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147160</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular human reproduction</Title>
                <ISOAbbreviation>Mol. Hum. Reprod.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Use of DEAD-box polypeptide-4 (Ddx4) gene promoter-driven fluorescent reporter mice to identify mitotically active germ cells in postnatal mouse ovaries.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">gau071</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Several laboratories have independently isolated mitotically active germ cells, termed female germline stem cells (fGSCs) or oogonial stem cells (OSCs), from adult mouse ovaries. However, a recent study from Liu and colleagues using Ddx4-Cre;Rosa26 reporter mice concluded that such germ cells do not exist. Given the disparity in conclusions drawn in this study compared to others, we felt it was important to re-assess the utility of Ddx4-Cre;Rosa26 reporter mice for identification of OSCs in adult mouse ovaries. Transgenic Ddx4-Cre mice were crossed with Rosa26(tdTm/tdTm) mice to drive restricted tomato red (tdTm) gene expression in cells in which the Ddx4 gene promoter has been activated. Crude dispersion of ovaries from recombined offspring generated cell fractions containing tdTm-positive immature oocytes, which are incapable of proliferation and thus probably represent the uncharacterized reporter-positive ovarian cells identified by Liu and colleagues as being mitotically inactive. Dispersed ovaries further subjected to fluorescence-activated cell sorting (FACS) yielded a large population of non-germline tdTm-positive cells, indicative of promoter 'leakiness' in the Ddx4-Cre mouse line. Nonetheless, a small percentage of these tdTm-positive cells exhibited externalized (extracellular, ec) expression of Ddx4 protein (ecDdx4-positive), expressed markers of primitive germ cells but not of oocytes, and actively proliferated in culture, all of which are characteristic features of OSCs. Thus, crude dispersion of ovaries collected from Ddx4 gene promoter-driven reporter mice is not, by itself, a reliable approach to identify OSCs, whereas the same ovarian dispersates further subjected to cell sorting strategies yield purified OSCs that can be expanded in culture.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Eun-Sil</ForeName>
                    <Initials>ES</Initials>
                    <Affiliation>Department of Biology, Laboratory of Aging and Infertility Research, Northeastern University, Boston, Massachusetts 02115, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tilly</LastName>
                    <ForeName>Jonathan L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Department of Biology, Laboratory of Aging and Infertility Research, Northeastern University, Boston, Massachusetts 02115, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Mol Hum Reprod</MedlineTA>
            <NlmUniqueID>9513710</NlmUniqueID>
            <ISSNLinking>1360-9947</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ddx4</Keyword>
            <Keyword MajorTopicYN="N">germline stem cell</Keyword>
            <Keyword MajorTopicYN="N">oocyte</Keyword>
            <Keyword MajorTopicYN="N">oogenesis</Keyword>
            <Keyword MajorTopicYN="N">oogonial stem cell</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">gau071</ArticleId>
            <ArticleId IdType="doi">10.1093/molehr/gau071</ArticleId>
            <ArticleId IdType="pubmed">25147160</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25147152</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1768-3254</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>86C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of medicinal chemistry</Title>
                <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Kaempferol, a potential cytostatic and cure for inflammatory disorders.</ArticleTitle>
            <Pagination>
                <MedlinePgn>103-112</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0223-5234(14)00738-7</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.ejmech.2014.08.011</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a flavonoid found in many edible plants (e.g., tea, broccoli, cabbage, kale, beans, endive, leek, tomato, strawberries, and grapes) and in plants or botanical products commonly used in traditional medicine (e.g., Ginkgo biloba, Tilia spp, Equisetum spp, Moringa oleifera, Sophora japonica and propolis). Its anti-oxidant/anti-inflammatory effects have been demonstrated in various disease models, including those for encephalomyelitis, diabetes, asthma, and carcinogenesis. Moreover, kaempferol act as a scavenger of free radicals and superoxide radicals as well as preserve the activity of various anti-oxidant enzymes such as catalase, glutathione peroxidase, and glutathione-S-transferase. The anticancer effect of this flavonoid is mediated through different modes of action, including anti-proliferation, apoptosis induction, cell-cycle arrest, generation of reactive oxygen species (ROS), and anti-metastasis/anti-angiogenesis activities. In addition, kaempferol was found to exhibit its anticancer activity through the modulation of multiple molecular targets including p53 and STAT3, through the activation of caspases, and through the generation of ROS. The anti-tumor effects of kaempferol have also been investigated in tumor-bearing mice. The combination of kaempferol and conventional chemotherapeutic drugs produces a greater therapeutic effect than the latter, as well as reduces the toxicity of the latter. In this review, we summarize the anti-oxidant/anti-inflammatory and anticancer effects of kaempferol with a focus on its molecular targets and the possible use of this flavonoid for the treatment of inflammatory diseases and cancer.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Masson SAS.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Rajendran</LastName>
                    <ForeName>Peramaiyan</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>NPO-International Laboratory of Biochemistry, 1-166, Uchide, Nakagawa-ku, Nagoya 454-0926, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rengarajan</LastName>
                    <ForeName>Thamaraiselvan</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>NPO-International Laboratory of Biochemistry, 1-166, Uchide, Nakagawa-ku, Nagoya 454-0926, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nandakumar</LastName>
                    <ForeName>Natarajan</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Microbiology, Immunology and Genetics, Ben Gurion University of the Negev, Beer Sheva 84105, P.O.B. 653, Israel.</Affiliation>
                </Author>
                <Author>
                    <LastName>Palaniswami</LastName>
                    <ForeName>Rajendran</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Applied Zoology and Biotechnology, Vivekananda College, Affiliated to Madurai Kamaraj University, Thiruvedakam West, Madurai 625234, India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nishigaki</LastName>
                    <ForeName>Yutaka</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>NPO-International Laboratory of Biochemistry, 1-166, Uchide, Nakagawa-ku, Nagoya 454-0926, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nishigaki</LastName>
                    <ForeName>Ikuo</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>NPO-International Laboratory of Biochemistry, 1-166, Uchide, Nakagawa-ku, Nagoya 454-0926, Japan. Electronic address: nishigaki@se.starcat.ne.jp.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>5</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Med Chem</MedlineTA>
            <NlmUniqueID>0420510</NlmUniqueID>
            <ISSNLinking>0223-5234</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Chemoprevention</Keyword>
            <Keyword MajorTopicYN="N">Flavanoids</Keyword>
            <Keyword MajorTopicYN="N">Inflammatory diseases</Keyword>
            <Keyword MajorTopicYN="N">Kaempferol</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0223-5234(14)00738-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejmech.2014.08.011</ArticleId>
            <ArticleId IdType="pubmed">25147152</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147093</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1741-0134</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>27</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Protein engineering, design &amp; selection : PEDS</Title>
                <ISOAbbreviation>Protein Eng. Des. Sel.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn>289-95</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/protein/gzu034</ELocationID>
            <Abstract>
                <AbstractText>Regulatory T cells (Tregs) are a subpopulation of CD4(+) T cells which suppress immune responses of effector cells and are known to play a very important role in protection against autoimmune disease development, induction of transplantation tolerance and suppression of effective immune response against tumor cells. An effective in vivo Treg depletion agent would facilitate Treg-associated studies across many research areas. In this study, we have developed diphtheria toxin-based monovalent and bivalent murine IL-2 fusion toxins for depleting murine IL-2 receptor positive cells including CD25(+) Treg in vivo. Their potencies were assessed by in vitro protein synthesis inhibition and cell proliferation inhibition assays using a murine CD25(+) CTLL-2 cell line. Surprisingly, in contrast to our previously developed recombinant fusion toxins, the monovalent isoform (DT390-mIL-2) was approximately 4-fold more potent than its bivalent counterpart (DT390-bi-mIL-2). Binding analysis by flow cytometry demonstrated that the monovalent isoform bound stronger than the bivalent version. In vivo Treg depletion with the monovalent murine IL-2 fusion toxin was performed using C57BL/6J (B6) mice. Spleen Treg were significantly depleted with a maximum reduction of ???70% and detectable as early as 12 h after the last injection. The spleen Treg numbers were reduced until Day 3 and returned to control levels by Day 7. We believe that this monovalent murine IL-2 fusion toxin will be an effective in vivo murine Treg depleter.</AbstractText>
                <CopyrightInformation>?? The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA MGH-DF/HCC Recombinant Protein Expression and Purification Core, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marino</LastName>
                    <ForeName>Jose</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Transplant Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trowell</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Transplant Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Huiping</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA MGH-DF/HCC Recombinant Protein Expression and Purification Core, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stromp Peraino</LastName>
                    <ForeName>Jaclyn</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA MGH-DF/HCC Recombinant Protein Expression and Purification Core, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rajasekera</LastName>
                    <ForeName>Priyani V</ForeName>
                    <Initials>PV</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA MGH-DF/HCC Recombinant Protein Expression and Purification Core, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Madsen</LastName>
                    <ForeName>Joren C</ForeName>
                    <Initials>JC</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Transplant Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Division of Cardiac Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sachs</LastName>
                    <ForeName>David H</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA MGH-DF/HCC Recombinant Protein Expression and Purification Core, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Christene A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA MGH-DF/HCC Recombinant Protein Expression and Purification Core, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Benichou</LastName>
                    <ForeName>Gilles</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Transplant Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Zhirui</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA MGH-DF/HCC Recombinant Protein Expression and Purification Core, Boston, MA, USA zhirui.wang@tbrc.mgh.harvard.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Protein Eng Des Sel</MedlineTA>
            <NlmUniqueID>101186484</NlmUniqueID>
            <ISSNLinking>1741-0126</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Pichia Pastoris expression</Keyword>
            <Keyword MajorTopicYN="N">Tregs</Keyword>
            <Keyword MajorTopicYN="N">diphtheria toxin</Keyword>
            <Keyword MajorTopicYN="N">fusion toxin</Keyword>
            <Keyword MajorTopicYN="N">murine IL-2</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">gzu034</ArticleId>
            <ArticleId IdType="doi">10.1093/protein/gzu034</ArticleId>
            <ArticleId IdType="pubmed">25147093</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25147005</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1940-087X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Issue>89</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of visualized experiments : JoVE</Title>
                <ISOAbbreviation>J Vis Exp</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Transplantation of tail skin to study allogeneic CD4 T cell responses in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3791/51724</ELocationID>
            <Abstract>
                <AbstractText>The study of T cell responses and their consequences during allo-antigen recognition requires a model that enables one to distinguish between donor and host T cells, to easily monitor the graft, and to adapt the system in order to answer different immunological questions. Medawar and colleagues established allogeneic tail-skin transplantation in mice in 1955. Since then, the skin transplantation model has been continuously modified and adapted to answer specific questions. The use of tail-skin renders this model easy to score for graft rejection, requires neither extensive preparation nor deep anesthesia, is applicable to animals of all genetic background, discourages ischemic necrosis, and permits chemical and biological intervention. In general, both CD4(+) and CD8(+) allogeneic T cells are responsible for the rejection of allografts since they recognize mismatched major histocompatibility antigens from different mouse strains. Several models have been described for activating allogeneic T cells in skin-transplanted mice. The identification of major histocompatibility complex (MHC) class I and II molecules in different mouse strains including C57BL/6 mice was an important step toward understanding and studying T cell-mediated alloresponses. In the tail-skin transplantation model described here, a three-point mutation (I-A(bm12)) in the antigen-presenting groove of the MHC-class II (I-A(b)) molecule is sufficient to induce strong allogeneic CD4(+) T cell activation in C57BL/6 mice. Skin grafts from I-A(bm12) mice on C57BL/6 mice are rejected within 12-15 days, while syngeneic grafts are accepted for up to 100 days. The absence of T cells (CD3(-/-) and Rag2(-/-) mice) allows skin graft acceptance up to 100 days, which can be overcome by transferring 2 x 10(4) wild type or transgenic T cells. Adoptively transferred T cells proliferate and produce IFN-?? in I-A(bm12)-transplanted Rag2(-/-) mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schmaler</LastName>
                    <ForeName>Mathias</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Biomedicine, Immunoregulation, University of Basel and University Hospital Basel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Broggi</LastName>
                    <ForeName>Maria A S</ForeName>
                    <Initials>MA</Initials>
                    <Affiliation>Department of Biomedicine, Immunoregulation, University of Basel and University Hospital Basel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rossi</LastName>
                    <ForeName>Simona W</ForeName>
                    <Initials>SW</Initials>
                    <Affiliation>Department of Biomedicine, Immunoregulation, University of Basel and University Hospital Basel; simona.rossi@unibas.ch.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Vis Exp</MedlineTA>
            <NlmUniqueID>101313252</NlmUniqueID>
            <ISSNLinking>1940-087X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3791/51724</ArticleId>
            <ArticleId IdType="pubmed">25147005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146993</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-5783</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative ophthalmology &amp; visual science</Title>
                <ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ocular surface injury induces inflammation in the brain: in vivo and ex-vivo evidence of a corneal-trigeminal axis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">IOVS-14-13984</ELocationID>
            <ELocationID EIdType="doi">10.1167/iovs.14-13984</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Purpose. To test whether a corneal injury can stimulate inflammation in the trigeminal ganglion (TG), a structure located in the brain. Methods. After 4 and 8 days from alkali burn induced in the right eye of mice, in vivo MRI of the brain was done before and after USPIO contrast to track macrophages. TGs were stained for Prussian Blue and inflammatory cell markers. IL-1??, TNF?? and VEGF-A transcripts were quantified on day 1, 4 and 8, and 4 days after corneal topical anti-inflammatory treatment with 0.2% dexamethasone. The expression of Substance P and its receptor NK-1R was also measured in the TG on day 4. Results. Corneal alkali burn induced leukocyte infiltration -including T cells- in the right TG at 4 and 8 days. In vivo MRI showed an increased contrast uptake in the right TG, which peaked at day 8. Prussian Blue+ USPIO+ macrophages were observed in the right TG and exhibited a M2-phenotype. The M2-macrophage infiltration was preponderant in the TG after damage. The pro-inflammatory cytokines, Substance P and NK-1R were significantly increased in both the TGs. The expression of IL-1?? and VEGF-A was significantly reduced in the right TG with dexamethasone treatment. Conclusions. We suggest, for the first time, inflammatory involvement of brain structures following ocular surface damage. Our findings support the hypothesis that the neuropeptide Substance P may be involved in the propagation of inflammation from the cornea to the TG through corneal nerves.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by Association for Research in Vision and Ophthalmology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ferrari</LastName>
                    <ForeName>Giulio</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Cornea and Ocular Surface Disease Unit, Eye Repair Lab, San Raffaele Scientific Institute, San Raffaele Hospital, Via Olgettina 60, Milan, 20122, Italy ferrari.giulio@hsr.it.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bignami</LastName>
                    <ForeName>Fabio</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Division of Neuroscience, Eye Repair Lab, San Raffaele Scientific Institute, Via Olgettina 60, Milan, 20132, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Giacomini</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Eye Repair Lab, San Raffaele Scientific Institute, Milan, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Capitolo</LastName>
                    <ForeName>Eleonora</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Division of Neuroscience, San Raffaele Scientific Institute, Institute of Experimental Neurology (INSPE), Via Olgettina 60, Milan, 20122, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Comi</LastName>
                    <ForeName>Giancarlo</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Division of Neuroscience, San Raffaele Scientific Institute, Institute of Experimental Neurology (INSPE), Via Olgettina 60, Milan, 20122, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chaabane</LastName>
                    <ForeName>Linda</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Division of Neuroscience, San Raffaele Scientific Institute, Institute of Experimental Neurology (INSPE), Via Olgettina 60, Milan, 20122, Italy.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rama</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Eye Repair Lab, San Raffaele Scientific Institute, Milano, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
            <NlmUniqueID>7703701</NlmUniqueID>
            <ISSNLinking>0146-0404</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">iovs.14-13984</ArticleId>
            <ArticleId IdType="doi">10.1167/iovs.14-13984</ArticleId>
            <ArticleId IdType="pubmed">25146993</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146988</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-5783</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative ophthalmology &amp; visual science</Title>
                <ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Molecular Mechanism of Formation of Cortical Opacity in CRYAAN101D Transgenic Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">IOVS-14-14623</ELocationID>
            <ELocationID EIdType="doi">10.1167/iovs.14-14623</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Purpose: The CRYAAN101D transgenic mouse model expressing deamidated ??A-crystallin (deamidation at N101 position to D) develops cortical cataract at the age of 7-9 months. The present study was carried out to explore the molecular mechanism that leads to the development of cortical opacity in CRYAAN101D lenses. Methods: RNA seq analysis was carried out on 2- and 4-months old ??A-N101D and WT lenses. To understand the biological relevance and function of significantly altered genes, Ingenuity Pathway Analysis (IPA) was done. To elucidate terminal differentiation defects, immunohistochemical and western-blot analyses were carried out. Results: RNA sequence and IPA data suggested that the genes belonging to gene expression, cellular assembly and organization, and cell cycle and apoptosis networks were altered in N101D lenses. In addition, the tight junction signaling and Rho A signaling were among the top three canonical pathways that were affected in N101D mutant. Immunohistochemical analysis identified a series of terminal differentiation defects in N101D lenses, specifically, increased proliferation and decreased differentiation of lens epithelial cells (LEC) and decreased denucleation of lens fiber cells (LFC). The expression of Rho A was reduced in different-aged N101D lenses, and, conversely, Cdc42 and Rac1 expressions were increased in the N101D mutants. Moreover, earlier in development, the expression of major membrane-bound molecular transporter Na,K-ATPase was drastically reduced in N101D lenses. Conclusions: The results suggest that the terminal differentiation defects, specifically, increased proliferation and decreased denucleation are responsible for the development of lens opacity in N101D lenses.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by Association for Research in Vision and Ophthalmology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hegde</LastName>
                    <ForeName>Shylaja M</ForeName>
                    <Initials>SM</Initials>
                    <Affiliation>Vision Science, UAB, Birmingham, Al, 35205, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Srivastava</LastName>
                    <ForeName>Kiran</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>UAB, birmingham, AL, 35205, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tiwary</LastName>
                    <ForeName>Ekta</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>UAB, Birmingham, AL, 35205, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Srivastava</LastName>
                    <ForeName>Om P</ForeName>
                    <Initials>OP</Initials>
                    <Affiliation>Department of Vision Sciences, University of Alabama at Birmingham, 924 18th Street South, Worrell Building 638, Birmingham, Alabama, 35294-4390, United States srivasta@uab.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
            <NlmUniqueID>7703701</NlmUniqueID>
            <ISSNLinking>0146-0404</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">iovs.14-14623</ArticleId>
            <ArticleId IdType="doi">10.1167/iovs.14-14623</ArticleId>
            <ArticleId IdType="pubmed">25146988</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146987</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-5783</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative ophthalmology &amp; visual science</Title>
                <ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Systemic administration of the antioxidant/iron chelator alpha lipoic acid protects against light-induced photoreceptor degeneration in the mouse retina.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">IOVS-14-15025</ELocationID>
            <ELocationID EIdType="doi">10.1167/iovs.14-15025</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Purpose: Oxidative stress and inflammation play key roles in the light damage (LD) model of retinal degeneration as well as in age-related macular degeneration (AMD). We sought to determine if lipoic acid (LA), an antioxidant and iron chelator, protects the retina against LD. Methods: Balb/c mice were treated with LA or control saline via intraperitoneal injection, and then were placed in constant cool white LED light (10,000 lux) for 4 hours. Retinas were evaluated at several time points after LD. Photoreceptor apoptosis was assessed using the TUNEL assay. Retinal function was analyzed via electroretinography (ERG). Retinal degeneration was assessed after LD by optical coherence tomography (OCT), TUNEL analysis and histology. The mRNAs of several oxidative stress, inflammation and iron related genes were quantified by qPCR. Results: LD resulted in substantial photoreceptor-specific cell death. Dosing with LA protected photoreceptors, decreasing the numbers of TUNEL-positive photoreceptors and increasing the number of surviving photoreceptors. The retinal mRNA levels of genes indicating oxidative stress, inflammation and iron accumulation were lower following LD in mice treated with LA than in control mice. ERG analysis demonstrated functional protection by LA. Conclusions: Systemic LA is protective against light-induced retinal degeneration. Since this agent has already proven protective in other retinal degeneration models and is safe and protective against diabetic neuropathy in patients, it is worthy of consideration for a human clinical trial against retinal degeneration or age-related macular degeneration.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by Association for Research in Vision and Ophthalmology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Liangliang</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Ophthalmology, The Second Hospital of Jilin University, Yatai street, Changchun, 130041, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Chenguang</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, 130041, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Delu</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Scheie Eye Institute, F.M. Kirby Center for Molecular Ophthalmology, 304 Stellar-Chance Labs, 422 Curie Blvd, Philadelphia, PA, 19104, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Yafeng</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Perelman School of Medicine, University of Pennsylvania, F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Philadelphia, PA, 19104, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Perelman School of Medicine, University of Pennsylvania, F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Philadelphia, PA, 19104, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Su</LastName>
                    <ForeName>Guan Fang</ForeName>
                    <Initials>GF</Initials>
                    <Affiliation>Department of Ophthalmology, the Second Hospital of Jilin University, the Department of Ophthalmology, the Second Hospital of Jilin University, 218# Ziqiang Street Changchun, Jilin, 130021, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dunaief</LastName>
                    <ForeName>Joshua L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Perelman School of Medicine, University of Pennsylvania, F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, 305 Stellar Chance Labs, 422 Curie Blvd, Philadelphia, PA, 19104, United States jdunaief@mail.med.upenn.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
            <NlmUniqueID>7703701</NlmUniqueID>
            <ISSNLinking>0146-0404</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">iovs.14-15025</ArticleId>
            <ArticleId IdType="doi">10.1167/iovs.14-15025</ArticleId>
            <ArticleId IdType="pubmed">25146987</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146982</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1552-5783</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative ophthalmology &amp; visual science</Title>
                <ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Resolvin D1 analogue Controls Maturation of Dendritic Cells and Suppresses Alloimmunity in Corneal Transplantation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">IOVS-14-14356</ELocationID>
            <ELocationID EIdType="doi">10.1167/iovs.14-14356</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Purpose:To analyzed the effect of an RvD1 analogue (RvD1a) on dendritic cell maturation, T cell sensitization, and allograft rejection in corneal allotransplantation. Methods:RvD1 receptor expression (ALX/FPR2) on bone marrow-derived dendritic cells (BMDC) was measured using quantitative Real-Time PCR. We determined BMDC maturation after treatment with RvD1a using ELISA to measure IL-12 protein expression and flow cytometry to assess the expression of CD40, MHC II, CD80, and CD86. After corneal transplantation in BALB/c mice we analyzed T cell infiltration in the cornea and the draining lymph nodes using flow cytometry. The ELISPOT assay was used to measure T cell sensitization via the direct and indirect pathway. Angiogenesis and lymphangiogenesis in the cornea after transplantation were measured using immunohistochemistry. Graft opacity and survival were evaluated by slit lamp biomicroscopy. Results:The RvD1 receptor, ALX/FPR2, was expressed at a significantly lower level on immature than mature DCs, and RvD1a reduced DC expression of MHC II, CD40 and IL-12 following LPS stimulation. Using a murine model of corneal transplantation RvD1a-treated hosts exhibited significantly reduced allosensitization as demonstrated by decreased frequencies of IFN-??-secreting T cells in the draining lymph nodes, and reduced T cell infiltration into the grafts. Graft survival was significantly enhanced and angiogenesis at the graft site was suppressed in RvD1a-treated compared to vehicle-treated hosts. Conclusions:These results suggest that RvD1 inhibits DC maturation and reduces alloimmune sensitization following transplantation, thereby establishing a novel connection between resolvin D1 and the regulation of DC-mediated antigen-specific immunity.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 by Association for Research in Vision and Ophthalmology.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hua</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford Street, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jin</LastName>
                    <ForeName>Yiping</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford Street, Boston, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Yihe</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Schepens Eye Research Institute, 20 Staniford St, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Inomata</LastName>
                    <ForeName>Takenori</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford, Boston, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>HyunSoo</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chauhan</LastName>
                    <ForeName>Sunil</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Massachusetts Eye &amp; Ear Infirmary, 20 Staniford Street, Boston, MA, 02114, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Petasis</LastName>
                    <ForeName>Nicos A</ForeName>
                    <Initials>NA</Initials>
                    <Affiliation>Department of Chemistry and Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, CA, 90089, United States.</Affiliation>
                </Author>
                <Author>
                    <LastName>Serhan</LastName>
                    <ForeName>Charles N</ForeName>
                    <Initials>CN</Initials>
                    <Affiliation>Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dana</LastName>
                    <ForeName>Reza</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford Street, Boston, MA, 02114, United States Reza_dana@meei.harvard.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
            <NlmUniqueID>7703701</NlmUniqueID>
            <ISSNLinking>0146-0404</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">iovs.14-14356</ArticleId>
            <ArticleId IdType="doi">10.1167/iovs.14-14356</ArticleId>
            <ArticleId IdType="pubmed">25146982</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146928</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5403</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell death and differentiation</Title>
                <ISOAbbreviation>Cell Death Differ.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/cdd.2014.124</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Bromodomain-containing protein 4 (BRD4) is an important epigenetic reader implicated in the pathogenesis of a number of different cancers and other diseases. Brd4-null mouse embryos die shortly after implantation and are compromised in their ability to maintain the inner cell mass, which gives rise to embryonic stem cells (ESCs). Here we report that BRD4 regulates expression of the pluripotency factor Nanog in mouse ESCs and preimplantation embryos, as well as in human ESCs and embryonic cancer stem cells. Inhibition of BRD4 function using a chemical inhibitor, small interfering RNAs, or a dominant-negative approach suppresses Nanog expression, and abolishes the self-renewal ability of ESCs. We also find that BRD4 associates with BRG1 (brahma-related gene 1, aka Smarca4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4)), a key regulator of ESC self-renewal and pluripotency, in the Nanog regulatory regions to regulate Nanog expression. Our study identifies Nanog as a novel BRD4 target gene, providing new insights for the biological function of BRD4 in stem cells and mouse embryos. Knowledge gained from these non-cancerous systems will facilitate future investigations of how Brd4 dysfunction leads to cancers.Cell Death and Differentiation advance online publication, 22 August 2014; doi:10.1038/cdd.2014.124.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Stein</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cheng</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Shao</LastName>
                    <ForeName>N-Y</ForeName>
                    <Initials>NY</Initials>
                    <Affiliation>Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morrisey</LastName>
                    <ForeName>E E</ForeName>
                    <Initials>EE</Initials>
                    <Affiliation>Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Schultz</LastName>
                    <ForeName>R M</ForeName>
                    <Initials>RM</Initials>
                    <Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>You</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Death Differ</MedlineTA>
            <NlmUniqueID>9437445</NlmUniqueID>
            <ISSNLinking>1350-9047</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cdd2014124</ArticleId>
            <ArticleId IdType="doi">10.1038/cdd.2014.124</ArticleId>
            <ArticleId IdType="pubmed">25146928</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146927</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5403</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell death and differentiation</Title>
                <ISOAbbreviation>Cell Death Differ.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/cdd.2014.121</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Tumor suppressor p53 has a key role in maintaining genomic stability and preventing tumorigenesis through its regulation of cellular stress responses, including apoptosis, cell cycle arrest and senescence. To ensure its proper levels and functions in cells, p53 is tightly regulated mainly through post-translational modifications, such as ubiquitination. Here, we identified E3 ubiquitin ligase TRIM32 as a novel p53 target gene and negative regulator to regulate p53-mediated stress responses. In response to stress, such as DNA damage, p53 binds to the p53 responsive element in the promoter of the TRIM32 gene and transcriptionally induces the expression of TRIM32 in cells. In turn, TRIM32 interacts with p53 and promotes p53 degradation through ubiquitination. Thus, TRIM32 negatively regulates p53-mediated apoptosis, cell cycle arrest and senescence in response to stress. TRIM32 is frequently overexpressed in different types of human tumors. TRIM32 overexpression promotes cell oncogenic transformation and tumorigenesis in mice in a largely p53-dependent manner. Taken together, our results demonstrated that as a novel p53 target and a novel negative regulator for p53, TRIM32 has an important role in regulation of p53 and p53-mediated cellular stress responses. Furthermore, our results also revealed that impairing p53 function is a novel mechanism for TRIM32 in tumorigenesis.Cell Death and Differentiation advance online publication, 22 August 2014; doi:10.1038/cdd.2014.121.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Ju</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>X L</ForeName>
                    <Initials>XL</Initials>
                    <Affiliation>1] Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ, USA [2] Department of Breast Surgery, Qilu Hospital, Shandong University, Ji'nan, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ly</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Belyi</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Center for Systems Biology, Rutgers Cancer Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Xu-Monette</LastName>
                    <ForeName>Z Y</ForeName>
                    <Initials>ZY</Initials>
                    <Affiliation>Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Young</LastName>
                    <ForeName>K H</ForeName>
                    <Initials>KH</Initials>
                    <Affiliation>Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Feng</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, State University of New Jersey, New Brunswick, NJ, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Death Differ</MedlineTA>
            <NlmUniqueID>9437445</NlmUniqueID>
            <ISSNLinking>1350-9047</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cdd2014121</ArticleId>
            <ArticleId IdType="doi">10.1038/cdd.2014.121</ArticleId>
            <ArticleId IdType="pubmed">25146927</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146924</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5403</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell death and differentiation</Title>
                <ISOAbbreviation>Cell Death Differ.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TAK1 control of cell death.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/cdd.2014.123</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Programmed cell death, a physiologic process for removing cells, is critically important in normal development and for elimination of damaged cells. Conversely, unattended cell death contributes to a variety of human disease pathogenesis. Thus, precise understanding of molecular mechanisms underlying control of cell death is important and relevant to public health. Recent studies emphasize that transforming growth factor-??-activated kinase 1 (TAK1) is a central regulator of cell death and is activated through a diverse set of intra- and extracellular stimuli. The physiologic importance of TAK1 and TAK1-binding proteins in cell survival and death has been demonstrated using a number of genetically engineered mice. These studies uncover an indispensable role of TAK1 and its binding proteins for maintenance of cell viability and tissue homeostasis in a variety of organs. TAK1 is known to control cell viability and inflammation through activating downstream effectors such as NF-??B and mitogen-activated protein kinases (MAPKs). It is also emerging that TAK1 regulates cell survival not solely through NF-??B but also through NF-??B-independent pathways such as oxidative stress and receptor-interacting protein kinase 1 (RIPK1) kinase activity-dependent pathway. Moreover, recent studies have identified TAK1's seemingly paradoxical role to induce programmed necrosis, also referred to as necroptosis. This review summarizes the consequences of TAK1 deficiency in different cell and tissue types from the perspective of cell death and also focuses on the mechanism by which TAK1 complex inhibits or promotes programmed cell death. This review serves to synthesize our current understanding of TAK1 in cell survival and death to identify promising directions for future research and TAK1's potential relevance to human disease pathogenesis.Cell Death and Differentiation advance online publication, 22 August 2014; doi:10.1038/cdd.2014.123.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mihaly</LastName>
                    <ForeName>S R</ForeName>
                    <Initials>SR</Initials>
                    <Affiliation>Department of Biological Sciences, North Carolina State University, Environmental and Molecular Toxicology, Raleigh, NC 27695-7633, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ninomiya-Tsuji</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Biological Sciences, North Carolina State University, Environmental and Molecular Toxicology, Raleigh, NC 27695-7633, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morioka</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Biological Sciences, North Carolina State University, Environmental and Molecular Toxicology, Raleigh, NC 27695-7633, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cell Death Differ</MedlineTA>
            <NlmUniqueID>9437445</NlmUniqueID>
            <ISSNLinking>1350-9047</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">cdd2014123</ArticleId>
            <ArticleId IdType="doi">10.1038/cdd.2014.123</ArticleId>
            <ArticleId IdType="pubmed">25146924</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146914</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-1004</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human mutation</Title>
                <ISOAbbreviation>Hum. Mutat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An Efficient Pipeline for the Generation and Functional Analysis of Human BRCA2 Variants of Uncertain Significance.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/humu.22678</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The implementation of next-generation sequence analysis of disease-related genes has resulted in a increasing number of genetic variants with an unknown clinical significance. The functional analysis of these so-called &quot;variants of uncertain significance&quot; (VUS) is hampered by the tedious and time-consuming procedures required to generate and test specific sequence variants in genomic DNA. Here we describe an efficient pipeline for the generation of gene variants in a full-length human gene, BRCA2, using a bacterial artificial chromosome (BAC). This method permits the rapid generation of intronic and exonic variants in a complete gene through the use of an exon-replacement strategy based on simple site-directed mutagenesis and an effective positive-negative selection system in E. coli. The functionality of variants can then be assessed through the use of functional assays, such as complementation of gene-deficient mouse embryonic stem (mES) cells in the case of human BRCA2. Our methodology builds upon an earlier protocol and, through the introduction of a series of major innovations, now represents a practical proposition for the rapid analysis of BRCA2 variants and a blueprint for the analysis of other genes using similar approaches. This method enables rapid generation and reliable classification of VUS in disease-related genes, allowing informed clinical decision-making. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hendriks</LastName>
                    <ForeName>Giel</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Toxicogenetics, Leiden University Medical Center, PO Box 9600, 2300RC, Leiden, the Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morolli</LastName>
                    <ForeName>Bruno</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Call??ja</LastName>
                    <ForeName>Fabienne M G R</ForeName>
                    <Initials>FM</Initials>
                </Author>
                <Author>
                    <LastName>Plomp</LastName>
                    <ForeName>Anouk</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Mesman</LastName>
                    <ForeName>Romy L S</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author>
                    <LastName>Meijers</LastName>
                    <ForeName>Matty</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Sharan</LastName>
                    <ForeName>Shyam K</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author>
                    <LastName>Vreeswijk</LastName>
                    <ForeName>Maaike P G</ForeName>
                    <Initials>MP</Initials>
                </Author>
                <Author>
                    <LastName>Vrieling</LastName>
                    <ForeName>Harry</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hum Mutat</MedlineTA>
            <NlmUniqueID>9215429</NlmUniqueID>
            <ISSNLinking>1059-7794</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BAC recombineering</Keyword>
            <Keyword MajorTopicYN="N">BRCA2</Keyword>
            <Keyword MajorTopicYN="N">VUS</Keyword>
            <Keyword MajorTopicYN="N">functional testing</Keyword>
            <Keyword MajorTopicYN="N">positive-negative selection</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.22678</ArticleId>
            <ArticleId IdType="pubmed">25146914</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146901</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-6903</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurochemical research</Title>
                <ISOAbbreviation>Neurochem. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effective Suppression of Acrylamide Neurotoxicity by Lithium in Mouse.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The primary objective of this investigation was to assess the neuroprotective efficacy of lithium in an acrylamide (ACR)-induced neuropathy model in mice. In this study, Kunming male mice were administered ACR (25??mg/kg bw, i.p. once a day) with or without lithium (25??mg/kg bw, i.p. once a day) for 2??weeks. All ACR-administered mice exhibited severe symptoms of neuropathy. We found that treatment with lithium effectively alleviated behavioral deficits in animals elicited by acrylamide. Interestingly, the reduction of hippocampal neurogenesis resulting from ACR injection was promoted by administration of lithium. Further, lithium treatment significantly offset ACR-induced depletion in p-GSK-3?? (Ser9) levels in hippocampus. Collectively our findings suggest the propensity of lithium to attenuate ACR-induced neuropathy. Further studies are necessary to understand the precise molecular mechanism by which the lithium attenuates neuropathy. Nevertheless, our data clearly demonstrate the beneficial effects of lithium on ACR-induced neuropathy in mice and suggest its possible therapeutic application as an adjuvant in the management of other forms of neuropathy in humans.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Song</LastName>
                    <ForeName>Lingzhen</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>College of Veterinary Medicine, Northwest A&amp;F University, Yangling, 712100, Shaanxi, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jiutao</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Yan</LastName>
                    <ForeName>Runchuan</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Xinde</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Shulin</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Shanting</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Neurochem Res</MedlineTA>
            <NlmUniqueID>7613461</NlmUniqueID>
            <ISSNLinking>0364-3190</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-014-1418-8</ArticleId>
            <ArticleId IdType="pubmed">25146901</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146878</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2682</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>140C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>7</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of photochemistry and photobiology. B, Biology</Title>
                <ISOAbbreviation>J. Photochem. Photobiol. B, Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hemodynamic monitoring of Chlorin e6-mediated photodynamic therapy using diffuse optical measurements.</ArticleTitle>
            <Pagination>
                <MedlinePgn>163-172</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S1011-1344(14)00250-4</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.jphotobiol.2014.07.020</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Tumor response during photodynamic therapy (PDT) is heavily dependent on treatment parameters such as light dose, photosensitizer concentration, and tissue oxygenation. Therefore, it is desirable to have a real-time hemodynamic monitoring device in order to fine-tune the parameters and improve PDT efficacy. In this paper, such a tumor response monitoring system was built incorporating both frequency domain diffuse optical spectroscopy (FD-DOS) and diffuse correlation spectroscopy (DCS), which enables concurrent monitoring of tissue oxygenation (StO2), total hemoglobin concentration (THC) and relative blood flow (rBF). The tumor metabolic rate of oxygen (TMRO2) was calculated by using the hemodynamic parameters. Mouse models bearing xenograft tumors were subjected to chlorin e6 (Ce6)-mediated PDT, and the four parameters were monitored with varying treatment conditions. The results show (1) At 3h post-PDT, rStO2, rBF and rTMRO2 exhibited sharp PDT-induced decreases in responders (&gt;40% reduction in tumor volume). Statistically significant difference between responders and non-responders were observed in rStO2 and rBF, but not in rTMRO2. (2) Non-responders show gradual recovery of rStO2, rBF and rTMRO2 from ???24h post-PDT, while responder group did not show recovery up until 48h post-PDT. Long-term study results up to 2weeks are also shown. It suggests the hybrid diffuse optical system is not only capable of real-time treatment monitoring, but also able to extract tumor metabolic rate of oxygen to provide more insights about therapy mechanism. Translation of this technique to the clinic will make a quick prognosis feasible and help with treatment optimization.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Dong</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 637457, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Toh</LastName>
                    <ForeName>Hui Jin</ForeName>
                    <Initials>HJ</Initials>
                    <Affiliation>Division of Medical Sciences, National Cancer Centre Singapore, 169610, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thong</LastName>
                    <ForeName>Patricia S P</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>Division of Medical Sciences, National Cancer Centre Singapore, 169610, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Tee</LastName>
                    <ForeName>Chuan Sia</ForeName>
                    <Initials>CS</Initials>
                    <Affiliation>Division of Medical Sciences, National Cancer Centre Singapore, 169610, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bi</LastName>
                    <ForeName>Renzhe</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 637457, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Soo</LastName>
                    <ForeName>Khee-Chee</ForeName>
                    <Initials>KC</Initials>
                    <Affiliation>Division of Medical Sciences, National Cancer Centre Singapore, 169610, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Kijoon</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 637457, Singapore; School of Basic Science, Daegu Gyeongbuk Institute of Science &amp; Technology, Daegu 711-873, Republic of Korea. Electronic address: kjlee@dgist.ac.kr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Photochem Photobiol B</MedlineTA>
            <NlmUniqueID>8804966</NlmUniqueID>
            <ISSNLinking>1011-1344</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Diffuse correlation spectroscopy (DCS)</Keyword>
            <Keyword MajorTopicYN="N">Diffuse optical spectroscopy (DOS)</Keyword>
            <Keyword MajorTopicYN="N">Photodynamic therapy (PDT)</Keyword>
            <Keyword MajorTopicYN="N">Relative blood flow (rBF)</Keyword>
            <Keyword MajorTopicYN="N">Tissue oxygenation (StO(2))</Keyword>
            <Keyword MajorTopicYN="N">Tumor metabolic rate of oxygen (TMRO(2))</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1011-1344(14)00250-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jphotobiol.2014.07.020</ArticleId>
            <ArticleId IdType="pubmed">25146878</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146842</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-2568</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Digestive diseases and sciences</Title>
                <ISOAbbreviation>Dig. Dis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fluoxetine Inhibits Hyperresponsive Lamina Propria Mononuclear Cells and Bone Marrow-Derived Dendritic Cells, and Ameliorates Chronic Colitis in IL-10-Deficient Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">We aimed to study the effect of fluoxetine on chronic colitis and its anti-inflammatory mechanism in interleukin-10-deficient (IL-10(-/-)) mice.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">IL-10(-/-) mice were administered with either the vehicle or one of the two dosages of fluoxetine (1 or 5??mg/kg) by oral gavage daily for 2??weeks. Lamina propria mononuclear cells (LPMCs) were isolated from IL-10(-/-) mice treated with or without fluoxetine, and cytokine expression was measured. Bone marrow-derived dendritic cells (BMDCs) isolated from IL-10(-/-), and wild-type mice were pretreated with fluoxetine and then stimulated with lipopolysaccharide. IL-12p40 and tumor necrosis factor (TNF)-?? gene expression was determined by real-time PCR. DNA-binding activity of nuclear factor-??B (NF-??B) was evaluated by electrophoretic mobility shift assay.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Fluoxetine significantly reduced intestinal inflammation as assessed by body weight, colon length, and histopathological grading, and it inhibited the level of TNF-?? gene expression in IL-10(-/-) mice. LPMCs were isolated from IL-10(-/-) mice, and cellular expression of IL-12p40 and interferon-?? was suppressed by fluoxetine treatment. Fluoxetine significantly inhibited IL-12p40 and TNF-?? gene expression and protein secretion in BMDCs from IL-10(-/-) mice. DNA-binding activity of NF-??B was suppressed by fluoxetine pretreatment.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that fluoxetine ameliorates intestinal inflammation in IL-10(-/-) mice and inhibits hyperresponsive LPMCs and BMDCs, which suggests that fluoxetine could be a potential therapeutic agent for inflammatory bowel disease.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Koh</LastName>
                    <ForeName>Seong-Joon</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul National University College of Medicine, 5 Gil 20, Boramae-Road, Dongjak-Gu, Seoul, 156-707, South Korea, jel1206@naver.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Ji Won</ForeName>
                    <Initials>JW</Initials>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Byeong Gwan</ForeName>
                    <Initials>BG</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Kook Lae</ForeName>
                    <Initials>KL</Initials>
                </Author>
                <Author>
                    <LastName>Im</LastName>
                    <ForeName>Jong Pil</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Joo Sung</ForeName>
                    <Initials>JS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Dig Dis Sci</MedlineTA>
            <NlmUniqueID>7902782</NlmUniqueID>
            <ISSNLinking>0163-2116</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-014-3326-9</ArticleId>
            <ArticleId IdType="pubmed">25146842</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146759</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1612-1880</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Chemistry &amp; biodiversity</Title>
                <ISOAbbreviation>Chem. Biodivers.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cytotoxic and Nitric Oxide Production-Inhibitory Activities of Limonoids and Other Compounds from the Leaves and Bark of Melia azedarach.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1121-39</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cbdv.201400190</ELocationID>
            <Abstract>
                <AbstractText>Nine limonoids, 1-9, one apocarotenoid, 11, one alkaloid, 12, and one steroid, 13, from the leaf extract; and one triterpenoid, 10, five steroids, 14-18, and two flavonoids, 19 and 20, from the bark extract of Melia azedarach L. (Chinaberry tree; Meliaceae) were isolated. Among these compounds, three compounds, 4-6, were new, and their structures were established as 3-deacetyl-28-oxosalannolactone, 3-deacetyl-28-oxosalanninolide, and 3-deacetyl-17-defurano-17,28-dioxosalannin, respectively, on the basis of extensive spectroscopic analyses and comparison with literature data. All of the isolated compounds were evaluated for their cytotoxic activities against leukemia (HL60), lung (A549), stomach (AZ521), and breast (SK-BR-3) cancer cell lines. 3-Deacetyl-4'-demethyl-28-oxosalannin (3) against HL60 and AZ521 cells, and methyl kulonate (10) against HL60 cells exhibited potent cytotoxicities with IC50 values in the range of 2.8-5.8?????M. In addition, upon evaluation of compounds 1-13 against production of nitric oxide (NO) in mouse macrophage RAW 264.7 cells induced by lipopolysaccharide (LPS), seven, i.e., trichilinin B (1), 4, ohchinin (7), 23-hydroxyohchininolide (8), 21-hydroxyisoohchininolide (9), 10, and methyl indole 3-carboxylate (12), inhibited production of NO with IC50 values in the range of 4.6-87.3?????M with no, or almost no, toxicity to the cells (IC50 93.2-100?????M). Western blot analysis revealed that compound 7 reduced the expression levels of the inducible NO synthase (iNOS) and COX-2 proteins in a concentration-dependent manner. Furthermore, compounds 5, 6, 13, and 18-20 exhibited potent inhibitory effects (IC50 299-381 molar ratio/32 pmol TPA) against Epstein???Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cell line.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Verlag Helvetica Chimica Acta AG, Z??rich.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>College of Science and Technology, Nihon University, 1-8-14 Kanda Surugadai, Chiyoda-ku, Tokyo 101-8308, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishimoto</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogihara</LastName>
                    <ForeName>Eri</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ukiya</LastName>
                    <ForeName>Motohiko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tokuda</LastName>
                    <ForeName>Harukuni</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koike</LastName>
                    <ForeName>Kazuo</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akihisa</LastName>
                    <ForeName>Momoko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akihisa</LastName>
                    <ForeName>Toshihiro</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Chem Biodivers</MedlineTA>
            <NlmUniqueID>101197449</NlmUniqueID>
            <ISSNLinking>1612-1872</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cytotoxic activity</Keyword>
            <Keyword MajorTopicYN="N">Epstein???Barr virus early antigen</Keyword>
            <Keyword MajorTopicYN="N">Limonoids</Keyword>
            <Keyword MajorTopicYN="N">Melia azedarach</Keyword>
            <Keyword MajorTopicYN="N">NO Production-inhibitory activity</Keyword>
            <Keyword MajorTopicYN="N">Triterpenoids</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbdv.201400190</ArticleId>
            <ArticleId IdType="pubmed">25146759</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146757</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1940-087X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Issue>90</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of visualized experiments : JoVE</Title>
                <ISOAbbreviation>J Vis Exp</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ultrasound-guided Transthoracic Intramyocardial Injection in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3791/51566</ELocationID>
            <Abstract>
                <AbstractText>Murine models of cardiovascular disease are important for investigating pathophysiological mechanisms and exploring potential regenerative therapies. Experiments involving myocardial injection are currently performed by direct surgical access through a thoracotomy. While convenient when performed at the time of another experimental manipulation such as coronary artery ligation, the need for an invasive procedure for intramyocardial delivery limits potential experimental designs. With ever improving ultrasound resolution and advanced noninvasive imaging modalities, it is now feasible to routinely perform ultrasound-guided, percutaneous intramyocardial injection. This modality efficiently and reliably delivers agents to a targeted region of myocardium. Advantages of this technique include the avoidance of surgical morbidity, the facility to target regions of myocardium selectively under ultrasound guidance, and the opportunity to deliver injectate to the myocardium at multiple, predetermined time intervals. With practiced technique, complications from intramyocardial injection are rare, and mice quickly return to normal activity on recovery from anesthetic. Following the steps outlined in this protocol, the operator with basic echocardiography experience can quickly become competent in this versatile, minimally invasive technique.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Prendiville</LastName>
                    <ForeName>Terence W</ForeName>
                    <Initials>TW</Initials>
                    <Affiliation>Department of Cardiology, Boston Children's Hospital.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Department of Cardiology, Boston Children's Hospital.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Zhiqiang</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Cardiology, Boston Children's Hospital.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Pingzhu</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Department of Cardiology, Boston Children's Hospital.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Aibin</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Cardiology, Boston Children's Hospital.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pu</LastName>
                    <ForeName>William T</ForeName>
                    <Initials>WT</Initials>
                    <Affiliation>Department of Cardiology, Boston Children's Hospital; Harvard Stem Cell Institute, Harvard University; wpu@pulab.org.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Vis Exp</MedlineTA>
            <NlmUniqueID>101313252</NlmUniqueID>
            <ISSNLinking>1940-087X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3791/51566</ArticleId>
            <ArticleId IdType="pubmed">25146757</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146751</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0376-2491</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>94</Volume>
                    <Issue>20</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua yi xue za zhi</Title>
                <ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Roles of CXCL9 and CXCL10 in acute rejection after retransplantation in mice].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1584-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effects of chemokines CXCL9 and CXCL10 on cardiac allograft acute rejection mediated by alloreactive memory T cells in a retransplantation model.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Heart transplantation was performed 6 weeks after skin grafting. The mice were divided into 3 groups of control (direct heterotopic heart transplantation without skin grafting); experimental (heart transplantation after skin grafting) and syngraft (C57BL/6???C57BL/6, heterotopic heart transplantation) (n = 12 each). Graft survival and the pathological changes of cardiac graft were observed. And related gene expression in cardiac grafts and serum concentration of CXCL9/CXCL10 were detected.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean survival time of control and experimental groups was 7.75 and 3.25 days respectively (P &lt; 0.01).Serum concentrations of CXCL9 and CXCL10 in recipient mice were higher in the experimental group than those in the control group. Compared with the control group, the relative gene expressions of CXCL9 and CXCL10 were higher in the experimental group. According to pathological examinations, the histological rank of cardiac allograft was Grade 2.27 ?? 0.25 in the control group versus Grade 4.12 ?? 0.03 in the experimental group (P &lt; 0.01).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CXCL9 and CXCL10 play critical roles in retransplantation mediated by alloreactive memory T cells. And acute rejection of cardiac allograft is more extensive in retransplantation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhuang</LastName>
                    <ForeName>Jiawei</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Cardiac Surgery, First Affliated Hospital,Xiamen University, Xiamen 361003, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shan</LastName>
                    <ForeName>Zhonggui</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Cardiac Surgery, First Affliated Hospital,Xiamen University, Xiamen 361003, China. Email: szgdoctor@126.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Teng</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Cardiac Surgery, First Affliated Hospital,Xiamen University, Xiamen 361003, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Xiaobiao</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Cardiac Surgery, First Affliated Hospital,Xiamen University, Xiamen 361003, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Shuiwei</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Cardiac Surgery, First Affliated Hospital,Xiamen University, Xiamen 361003, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType>English Abstract</PublicationType>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA>
            <NlmUniqueID>7511141</NlmUniqueID>
            <ISSNLinking>0376-2491</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25146751</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146733</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0341</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>468-470C</Volume>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Virology</Title>
                <ISOAbbreviation>Virology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A mouse polyomavirus-encoded microRNA targets the cellular apoptosis pathway through Smad2 inhibition.</ArticleTitle>
            <Pagination>
                <MedlinePgn>57-62</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii">S0042-6822(14)00369-9</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.virol.2014.07.052</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Some viruses and most eukaryotic cells have microRNAs that regulate the expression of many genes. Although many viral miRNAs have been identified, only a few have been included in in vivo functional studies. Here we show that a Py-encoded miRNA downregulates the expression of the pro-apoptotic factor Smad2, resulting in the suppression of the apoptosis pathway. To study the Py miRNA in an in vivo context, a miRNA-deficient mutant virus was created on the background of the LID virus strain which establishes a rapid and lethal infection in newborn mice. Apoptosis analysis on kidney tissues indicates that the pro-apoptotic pathway is targeted in the infected host as well. Suppression of apoptosis through targeting of Smad2 by the Py miRNA is expected to synergize with anti-apoptotic effects previously attributed to the polyoma tumor antigens in support of virus replication in the natural host.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sung</LastName>
                    <ForeName>Chang Kyoo</ForeName>
                    <Initials>CK</Initials>
                    <Affiliation>Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA; Department of Biological and Health Sciences, Texas A&amp;M University-Kingsville, Kingsville, TX 78363, USA. Electronic address: chang.sung@tamuk.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yim</LastName>
                    <ForeName>Hyungshin</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Andrews</LastName>
                    <ForeName>Erik</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Benjamin</LastName>
                    <ForeName>Thomas L</ForeName>
                    <Initials>TL</Initials>
                    <Affiliation>Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: thomas_benjamin@hms.harvard.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Virology</MedlineTA>
            <NlmUniqueID>0110674</NlmUniqueID>
            <ISSNLinking>0042-6822</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Animal infection</Keyword>
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">MicroRNA</Keyword>
            <Keyword MajorTopicYN="N">Mouse polyomavirus</Keyword>
            <Keyword MajorTopicYN="N">Smad2 a cellular target</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0042-6822(14)00369-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.virol.2014.07.052</ArticleId>
            <ArticleId IdType="pubmed">25146733</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146644</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1940-087X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Issue>90</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of visualized experiments : JoVE</Title>
                <ISOAbbreviation>J Vis Exp</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Mouse Model for Pathogen-induced Chronic Inflammation at Local and Systemic Sites.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3791/51556</ELocationID>
            <Abstract>
                <AbstractText>Chronic inflammation is a major driver of pathological tissue damage and a unifying characteristic of many chronic diseases in humans including neoplastic, autoimmune, and chronic inflammatory diseases. Emerging evidence implicates pathogen-induced chronic inflammation in the development and progression of chronic diseases with a wide variety of clinical manifestations. Due to the complex and multifactorial etiology of chronic disease, designing experiments for proof of causality and the establishment of mechanistic links is nearly impossible in humans. An advantage of using animal models is that both genetic and environmental factors that may influence the course of a particular disease can be controlled. Thus, designing relevant animal models of infection represents a key step in identifying host and pathogen specific mechanisms that contribute to chronic inflammation. Here we describe a mouse model of pathogen-induced chronic inflammation at local and systemic sites following infection with the oral pathogen Porphyromonas gingivalis, a bacterium closely associated with human periodontal disease. Oral infection of specific-pathogen free mice induces a local inflammatory response resulting in destruction of tooth supporting alveolar bone, a hallmark of periodontal disease. In an established mouse model of atherosclerosis, infection with P. gingivalis accelerates inflammatory plaque deposition within the aortic sinus and innominate artery, accompanied by activation of the vascular endothelium, an increased immune cell infiltrate, and elevated expression of inflammatory mediators within lesions. We detail methodologies for the assessment of inflammation at local and systemic sites. The use of transgenic mice and defined bacterial mutants makes this model particularly suitable for identifying both host and microbial factors involved in the initiation, progression, and outcome of disease. Additionally, the model can be used to screen for novel therapeutic strategies, including vaccination and pharmacological intervention.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Papadopoulos</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Medicine, Section of Infectious Disease, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kramer</LastName>
                    <ForeName>Carolyn D</ForeName>
                    <Initials>CD</Initials>
                    <Affiliation>Department of Medicine, Section of Infectious Disease, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slocum</LastName>
                    <ForeName>Connie S</ForeName>
                    <Initials>CS</Initials>
                    <Affiliation>Department of Medicine, Section of Infectious Disease, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weinberg</LastName>
                    <ForeName>Ellen O</ForeName>
                    <Initials>EO</Initials>
                    <Affiliation>Department of Medicine, Section of Infectious Disease, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hua</LastName>
                    <ForeName>Ning</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Biophysics, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gudino</LastName>
                    <ForeName>Cynthia V</ForeName>
                    <Initials>CV</Initials>
                    <Affiliation>Department of Medicine, Section of Infectious Disease, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamilton</LastName>
                    <ForeName>James A</ForeName>
                    <Initials>JA</Initials>
                    <Affiliation>Department of Medicine, Section of Infectious Disease, Boston University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Genco</LastName>
                    <ForeName>Caroline A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Department of Medicine, Section of Infectious Disease, Boston University School of Medicine; cgenco@bu.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Vis Exp</MedlineTA>
            <NlmUniqueID>101313252</NlmUniqueID>
            <ISSNLinking>1940-087X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3791/51556</ArticleId>
            <ArticleId IdType="pubmed">25146644</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146643</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1940-087X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Issue>90</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of visualized experiments : JoVE</Title>
                <ISOAbbreviation>J Vis Exp</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3791/51763</ELocationID>
            <Abstract>
                <AbstractText>Current astrocytoma models are limited in their ability to define the roles of oncogenic mutations in specific brain cell types during disease pathogenesis and their utility for preclinical drug development. In order to design a better model system for these applications, phenotypically wild-type cortical astrocytes and neural stem cells (NSC) from conditional, genetically engineered mice (GEM) that harbor various combinations of floxed oncogenic alleles were harvested and grown in culture. Genetic recombination was induced in vitro using adenoviral Cre-mediated recombination, resulting in expression of mutated oncogenes and deletion of tumor suppressor genes. The phenotypic consequences of these mutations were defined by measuring proliferation, transformation, and drug response in vitro. Orthotopic allograft models, whereby transformed cells are stereotactically injected into the brains of immune-competent, syngeneic littermates, were developed to define the role of oncogenic mutations and cell type on tumorigenesis in vivo. Unlike most established human glioblastoma cell line xenografts, injection of transformed GEM-derived cortical astrocytes into the brains of immune-competent littermates produced astrocytomas, including the most aggressive subtype, glioblastoma, that recapitulated the histopathological hallmarks of human astrocytomas, including diffuse invasion of normal brain parenchyma. Bioluminescence imaging of orthotopic allografts from transformed astrocytes engineered to express luciferase was utilized to monitor in vivo tumor growth over time. Thus, astrocytoma models using astrocytes and NSC harvested from GEM with conditional oncogenic alleles provide an integrated system to study the genetics and cell biology of astrocytoma pathogenesis in vitro and in vivo and may be useful in preclinical drug development for these devastating diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>McNeill</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                    <Affiliation>Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmid</LastName>
                    <ForeName>Ralf S</ForeName>
                    <Initials>RS</Initials>
                    <Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bash</LastName>
                    <ForeName>Ryan E</ForeName>
                    <Initials>RE</Initials>
                    <Affiliation>Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vitucci</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Curriculum in Genetics and Molecular Biology, University of North Carolina School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>White</LastName>
                    <ForeName>Kristen K</ForeName>
                    <Initials>KK</Initials>
                    <Affiliation>Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Werneke</LastName>
                    <ForeName>Andrea M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Constance</LastName>
                    <ForeName>Brian H</ForeName>
                    <Initials>BH</Initials>
                    <Affiliation>Biological and Biomedical Sciences Program, University of North Carolina School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huff</LastName>
                    <ForeName>Byron</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Radiation Oncology, Emory University School of Medicine.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>C Ryan</ForeName>
                    <Initials>CR</Initials>
                    <Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine; Division of Neuropathology, Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine; Department of Neurology, Neurosciences Center, University of North Carolina School of Medicine; rmiller@med.unc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Vis Exp</MedlineTA>
            <NlmUniqueID>101313252</NlmUniqueID>
            <ISSNLinking>1940-087X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3791/51763</ArticleId>
            <ArticleId IdType="pubmed">25146643</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146620</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0366-6999</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>127</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Chinese medical journal</Title>
                <ISOAbbreviation>Chin. Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adverse factors increase preeclampsia-like changes in pregnant mice with abnormal lipid metabolism.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2814-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Preeclampsia (PE) is a multifactorial pregnancy complication. Maternal underlying condition and adverse factors both influence the pathogenesis of PE. Abnormal lipid metabolism as a maternal underlying disease may participate in the occurrence and development of PE. This study aimed to observe the effects of adverse factors on PE-like symptoms of pregnant mice with genetic abnormal lipid metabolism.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Apolipoprotein C-III (ApoC3) transgenic mice with abnormal lipid metabolism were subcutaneously injected with L-arginine methyl ester (L-NAME) or normal saline (NS) daily starting at Day 7 or 16 of pregnancy (ApoC3+L-NA and ApoC3+NS groups), and wild-type (WT) mice served as a control (WT+L-NA and WT+NS groups). All mice were subdivided into early and late subgroups by injection time. The mean arterial pressure (MAP) and urinary protein were measured. Pregnancy outcomes, including fetal weight, placental weight, live birth rate, and fetal absorption rate, were analyzed. Pathologic changes in the placenta were observed by hematoxylin-eosin staining. One-way analysis of variance, t-test, and ??(2) test were used for statistical analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">MAP significantly increased for ApoC3+NS groups compared with WT+NS groups (P &lt; 0.05), without significant difference in urine protein. Following L-NAME injection, MAP and urinary protein significantly increased for ApoC3+L-NA and WT+L-NA compared with the corresponding NS groups (P &lt; 0.05), and the increase for ApoC3+L-NA was more obvious. Urinary protein levels in early ApoC3+L-NA and WT+L-NA significantly increased compared with the corresponding late groups (P &lt; 0.05). Fetal absorption rate significantly increased and fetal and placental weights significantly decreased in early ApoC3+L-NA and WT+L-NA compared with the corresponding NS groups (P &lt; 0.05), without significant difference in late ApoC3+L-NA and WT+L-NA groups. Fetal weight in early ApoC3+L-NA was significantly lower than in early WT+L-NA group (P &lt; 0.05). Morphologic examination of placentas from early ApoC3+L-NA and WT+L-NA groups showed varying degrees of fibrinoid necrosis.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ApoC3 transgenic mice with abnormal lipid metabolism showed gestational hypertension. Adverse factors and early effect time could aggravate the PE-like symptoms for ApoC3 transgenic mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Xiaoyan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Zi</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China. Email: zi_yang@email.com.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Yiwei</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Huan</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Chin Med J (Engl)</MedlineTA>
            <NlmUniqueID>7513795</NlmUniqueID>
            <ISSNLinking>0366-6999</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25146620</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146619</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0366-6999</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>127</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Chinese medical journal</Title>
                <ISOAbbreviation>Chin. Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Microvascular protective role of pericytes in melatonin-treated spinal cord injury in the C57BL/6 mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2808-13</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pericytes, located on microvessels, help to maintain vascular stability and blood-brain barrier integrity. The influence of pericytes on microvessels after spinal cord injury (SCI) is less clear. Therefore, the aim of this study was to investigate whether pericytes took a protective effect on microvessels in melatonin-treated SCI.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">C57BL/6 mice were randomly divided into three groups: sham group, SCI group, and melatonin group (n = 27 per group). Functional recovery was evaluated using the Basso Mouse Scale. Motor neurons were observed using hematoxylin and eosin staining. Pericyte coverage was analyzed using immunofluorescence. Permeability of blood-spinal cord barrier (BSCB) was assessed by administration of Evan's Blue. Protein levels of occludin, aquaporin-4 (AQP4), angiopoietin-1 (Ang1), intercellular cell adhesion molecule-1 (ICAM-1), Bcl-2, and Bax were determined using Western blotting. Mimicking the pathological conditions of SCI, melatonin-treated primary pericytes were subjected to oxygen-glucose deprivation/reperfusion (OGD/R). Secretion of Ang1 was analyzed using an enzyme-linked immunosorbent assay, and the expression of ICAM-1 was detected by immunofluorescence.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Melatonin treatment improved locomotor functional outcome and rescued motor neurons. Pericyte coverage was significantly reduced after SCI; melatonin treatment alleviated the loss of pericyte coverage and rescued perfused microvessels 7 days after injury. The permeability of BSCB and loss of occludin were attenuated, and edema formation and upregulation of AQP4 were inhibited, after melatonin treatment. The expression of Ang1 and Bcl-2 was improved, while the expression of ICAM-1 and Bax was inhibited, in melatonin-treated SCI mice. Furthermore, the secretion of Ang1 was increased and the expression of ICAM-1 was inhibited in melatonin-treated pericytes after OGD/R.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Melatonin ameliorated the loss of blood vessels and disruption of BSCB to exert a protective effect on SCI, which might be mediated by increased pericyte coverage. The upregulation of Ang1 in pericytes could inhibit inflammation and apoptosis to protect the microvessels.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jing</LastName>
                    <ForeName>Yingli</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Qingbin</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Xiaochen</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Bingwei</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Mingming</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaoyan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Shuying</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hongwei</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiu</LastName>
                    <ForeName>Ruijuan</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Institute of Microcirculation, Key Laboratory of Microcirculation, Ministry of Health, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100005, China. Email: xiurj@aliyun.com; xiurj@imc.pumc.edu.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Chin Med J (Engl)</MedlineTA>
            <NlmUniqueID>7513795</NlmUniqueID>
            <ISSNLinking>0366-6999</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25146619</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25146585</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2222</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
                <ISOAbbreviation>Clin. Exp. Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>???? T cells regulate chronic airway inflammation and development of airway remodelling.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/cea.12395</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">????T cells play a crucial immunoregulatory role in the lung, maintaining normal airway tone and preventing hyperresponsiveness to innocuous allergen. During acute inflammatory episodes, ????T cells promote resolution of acute inflammation. However their contribution to inflammation associated airway remodelling remains unexplored. Here we investigate the effects of ????T cell blockade on established allergic airway inflammation and development of remodelling METHODS: Sensitised mice were exposed to prolonged ovalbumin challenge or continuous house dust mite exposure to induce chronic inflammation and remodelling. Functional blocking anti-TCR?? antibody was administered therapeutically and parameters of airway inflammation and remodelling were examined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Therapeutic blockade of ????T cells prevented the typical resolution of acute airway inflammation characterised by elevated eosinophil and Th2 cell numbers. Moreover, the lung displayed exacerbated airway remodelling, typified by excess peribronchiolar collagen deposition CONCLUSIONS: These results demonstrate a unique role for ????T cells in constraining allergen induced airway remodelling. Manipulating the ????T cell compartment may therefore contribute to strategies to prevent and treat remodelling. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Murdoch</LastName>
                    <ForeName>Jenna R</ForeName>
                    <Initials>JR</Initials>
                    <Affiliation>Leukocyte Biology Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, UK, SW7 2AZ.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gregory</LastName>
                    <ForeName>Lisa G</ForeName>
                    <Initials>LG</Initials>
                </Author>
                <Author>
                    <LastName>Lloyd</LastName>
                    <ForeName>Clare M</ForeName>
                    <Initials>CM</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Exp Allergy</MedlineTA>
            <NlmUniqueID>8906443</NlmUniqueID>
            <ISSNLinking>0954-7894</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Th2 cells</Keyword>
            <Keyword MajorTopicYN="N">airway remodelling</Keyword>
            <Keyword MajorTopicYN="N">allergic inflammation</Keyword>
            <Keyword MajorTopicYN="N">????T cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cea.12395</ArticleId>
            <ArticleId IdType="pubmed">25146585</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25146474</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1939-327X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>63</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetes</Title>
                <ISOAbbreviation>Diabetes</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Combined Therapy With GABA and Proinsulin/Alum Acts Synergistically to Restore Long-term Normoglycemia by Modulating T-Cell Autoimmunity and Promoting ??-Cell Replication in Newly Diabetic NOD Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3128-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2337/db13-1385</ELocationID>
            <Abstract>
                <AbstractText>Antigen-based therapies (ABTs) fail to restore normoglycemia in newly diabetic NOD mice, perhaps because too few ??-cells remain by the time that ABT-induced regulatory responses arise and spread. We hypothesized that combining a fast-acting anti-inflammatory agent with an ABT could limit pathogenic responses while ABT-induced regulatory responses arose and spread. ??-Aminobutyric acid (GABA) administration can inhibit inflammation, enhance regulatory T-cell (Treg) responses, and promote ??-cell replication in mice. We examined the effect of combining a prototypic ABT, proinsulin/alum, with GABA treatment in newly diabetic NOD mice. Proinsulin/alum monotherapy failed to correct hyperglycemia, while GABA monotherapy restored normoglycemia for a short period. Combined treatment restored normoglycemia in the long term with apparent permanent remission in some mice. Proinsulin/alum monotherapy induced interleukin (IL)-4- and IL-10-secreting T-cell responses that spread to other ??-cell autoantigens. GABA monotherapy induced moderate IL-10 (but not IL-4) responses to ??-cell autoantigens. Combined treatment synergistically reduced spontaneous type 1 T-helper cell responses to autoantigens, ABT-induced IL-4 and humoral responses, and insulitis, but enhanced IL-10 and Treg responses and promoted ??-cell replication in the islets. Thus, combining ABT with GABA can inhibit pathogenic T-cell responses, induce Treg responses, promote ??-cell replication, and effectively restore normoglycemia in newly diabetic NOD mice. Since these treatments appear safe for humans, they hold promise for type 1 diabetes intervention.</AbstractText>
                <CopyrightInformation>?? 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tian</LastName>
                    <ForeName>Jide</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA dkaufman@mednet.ucla.edu jtian@mednet.ucla.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dang</LastName>
                    <ForeName>Hoa</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>An Viet</ForeName>
                    <Initials>AV</Initials>
                    <Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Zheying</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaufman</LastName>
                    <ForeName>Daniel L</ForeName>
                    <Initials>DL</Initials>
                    <Affiliation>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA dkaufman@mednet.ucla.edu jtian@mednet.ucla.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Diabetes</MedlineTA>
            <NlmUniqueID>0372763</NlmUniqueID>
            <ISSNLinking>0012-1797</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">db13-1385</ArticleId>
            <ArticleId IdType="doi">10.2337/db13-1385</ArticleId>
            <ArticleId IdType="pubmed">25146474</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
